AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies by Thangaratinam, Shakila et al.
HEALTH TECHNOLOGY ASSESSMENT
VOLUME 22 ISSUE 23 MAY 2018
ISSN 1366-5278
DOI 10.3310/hta22230
AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): 
a double-blind randomised trial on effectiveness and 
acceptability of monitoring strategies
Shakila Thangaratinam, Nadine Marlin, Sian Newton, Annalise Weckesser, 
Manny Bagary, Lynette Greenhill, Rachel Rikunenko, Maria D’Amico, 
Ewelina Rogozin´ska, Andrew Kelso, Kelly Hard, Jamie Coleman,  
Ngawai Moss, Tracy Roberts, Lee Middleton, Julie Dodds, Angela Pullen, 
Sandra Eldridge, Alexander Pirie, Elaine Denny, Doug McCorry and  
Khalid S Khan on behalf of the EMPiRE Collaborative Network

AntiEpileptic drug Monitoring in
PREgnancy (EMPiRE): a double-blind
randomised trial on effectiveness and
acceptability of monitoring strategies
Shakila Thangaratinam,1,2,3* Nadine Marlin,3
Sian Newton,1,3 Annalise Weckesser,4 Manny Bagary,5
Lynette Greenhill,5 Rachel Rikunenko,6
Maria D’Amico,1,3 Ewelina Rogozin´ska,1,2
Andrew Kelso,7 Kelly Hard,8 Jamie Coleman,9
Ngawai Moss,10 Tracy Roberts,11 Lee Middleton,12
Julie Dodds,1,2,3 Angela Pullen,13 Sandra Eldridge,3
Alexander Pirie,8 Elaine Denny,4 Doug McCorry5
and Khalid S Khan1,2,3 on behalf of the EMPiRE
Collaborative Network
1Women’s Health Research Unit, Blizard Institute, Barts and the London School
of Medicine and Dentistry, Queen Mary University of London, London, UK
2Multidisciplinary Evidence Synthesis Hub (mEsh), Blizard Institute, Barts and the
London School of Medicine and Dentistry, Queen Mary University of London,
London, UK
3Pragmatic Clinical Trials Unit, Blizard Institute, Barts and the London School of
Medicine and Dentistry, Queen Mary University of London, London, UK
4Centre for Health and Social Care Research, Birmingham City University,
Birmingham, UK
5Neuropsychiatry Department, The Barberry, Birmingham, UK
6Research and Development, Birmingham Children’s Hospital, Birmingham, UK
7Department of Neurology, Royal London Hospital, London, UK
8Research and Development, Birmingham Women’s Hospital, Birmingham, UK
9School of Clinical and Experimental Medicine, University of Birmingham,
Birmingham, UK
10Patient and Public Involvement group member, Katie’s Team,
Katherine Twining Network, Queen Mary University of London, London, UK
11Health Economics Unit, University of Birmingham, Birmingham, UK
12Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
13Epilepsy Action, Leeds, UK
*Corresponding author

Declared competing interests of authors: Manny Bagary reports personal fees from Eisai Co., Ltd,
and personal fees from UCB Pharma outside the submitted work. Angela Pullen reports grants from
GlaxoSmithKline plc., Cyberonics, Inc., Sanofi S.A., Desitin Pharma Ltd and UCB Pharma Ltd outside the
submitted work. Sandra Eldridge is a member of the Health Technology Assessment Clinical Trials Board
and National Institute for Health Research Clinical Trials Unit Support Funding.
Disclaimer: This report contains transcripts of interviews conducted in the course of the research and
contains language that may offend some readers.
Published May 2018
DOI: 10.3310/hta22230
This report should be referenced as follows:
Thangaratinam S, Marlin N, Newton S, Weckesser A, Bagary M, Greenhill L, et al. AntiEpileptic drug
Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and
acceptability of monitoring strategies. Health Technol Assess 2018;22(23).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment HTA/HTA TAR
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 4.236
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science
Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: journals.library@nihr.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they
are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to
minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research
information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation
and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 09/55/38. The contractual start date
was in September 2011. The draft report began editorial review in June 2016 and was accepted for publication in March 2017. The authors
have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher
have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft
document. However, they do not accept liability for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme
or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by
the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the
HTA programme or the Department of Health and Social Care.
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Thangaratinam et al. under the terms of a
commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the
purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided
that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials
and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief
Health Technology Assessment 
NIHR Journals Library
Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK
NIHR Journals Library Editors
Editor-in-Chief
Professor Hywel Williams Director, HTA Programme, UK and Foundation Professor and Co-Director of the
Centre of Evidence-Based Dermatology, University of Nottingham, UK
Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, 
University of Exeter Medical School, UK
Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)
Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK
Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management 
and Marketing, University College Cork, Ireland
Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK
Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK
Dr Peter Davidson  Director of the NIHR Dissemination Centre, University of Southampton, UK
Ms Tara Lamont  Scientific Advisor, NETSCC, UK
Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, 
University of York, UK 
Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK
Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK
Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK
Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK
Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences,  
University of Nottingham, UK
Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School,
University of Warwick, UK
Please visit the website for a list of members of the NIHR Journals Library Board: 
www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact:  journals.library@nihr.ac.uk
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
AntiEpileptic drug Monitoring in PREgnancy (EMPiRE):
a double-blind randomised trial on effectiveness and
acceptability of monitoring strategies
Shakila Thangaratinam,1,2,3* Nadine Marlin,3 Sian Newton,1,3
Annalise Weckesser,4 Manny Bagary,5 Lynette Greenhill,5
Rachel Rikunenko,6 Maria D’Amico,1,3 Ewelina Rogozin´ska,1,2
Andrew Kelso,7 Kelly Hard,8 Jamie Coleman,9 Ngawai Moss,10
Tracy Roberts,11 Lee Middleton,12 Julie Dodds,1,2,3 Angela Pullen,13
Sandra Eldridge,3 Alexander Pirie,8 Elaine Denny,4 Doug McCorry5
and Khalid S Khan1,2,3 on behalf of the EMPiRE Collaborative Network
1Women’s Health Research Unit, Blizard Institute, Barts and the London School of Medicine and
Dentistry, Queen Mary University of London, London, UK
2Multidisciplinary Evidence Synthesis Hub (mEsh), Blizard Institute, Barts and the London School
of Medicine and Dentistry, Queen Mary University of London, London, UK
3Pragmatic Clinical Trials Unit, Blizard Institute, Barts and the London School of Medicine and
Dentistry, Queen Mary University of London, London, UK
4Centre for Health and Social Care Research, Birmingham City University, Birmingham, UK
5Neuropsychiatry Department, The Barberry, Birmingham, UK
6Research and Development, Birmingham Children’s Hospital, Birmingham, UK
7Department of Neurology, Royal London Hospital, London, UK
8Research and Development, Birmingham Women’s Hospital, Birmingham, UK
9School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK
10Patient and Public Involvement group member, Katie’s Team, Katherine Twining Network,
Queen Mary University of London, London, UK
11Health Economics Unit, University of Birmingham, Birmingham, UK
12Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
13Epilepsy Action, Leeds, UK
*Corresponding author s.thangaratinam@qmul.ac.uk
Background: Pregnant women with epilepsy on antiepileptic drugs (AEDs) may experience a reduction in
serum AED levels. This has the potential to worsen seizure control.
Objective: To determine if, in pregnant women with epilepsy on AEDs, additional therapeutic drug
monitoring reduces seizure deterioration compared with clinical features monitoring after a reduction in
serum AED levels.
Design: A double-blind, randomised trial nested within a cohort study was conducted and a qualitative
study of acceptability of the two strategies was undertaken. Stratified block randomisation with a 1 : 1
allocation method was carried out.
Setting: Fifty obstetric and epilepsy clinics in secondary and tertiary care units in the UK.
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Participants: Pregnant women with epilepsy on one or more of the following AEDs: lamotrigine,
carbamazepine, phenytoin or levetiracetam. Women with a ≥ 25% decrease in serum AED level from
baseline were randomised to therapeutic drug monitoring or clinical features monitoring strategies.
Interventions: In the therapeutic drug monitoring group, clinicians had access to clinical findings and
monthly serum AED levels to guide AED dosage adjustment for seizure control. In the clinical features
monitoring group, AED dosage adjustment was based only on clinical features.
Main outcome measures: Primary outcome – seizure deterioration, defined as time to first seizure and to
all seizures after randomisation per woman until 6 weeks post partum. Secondary outcomes – pregnancy
complications in mother and offspring, maternal quality of life, seizure rates in cohorts with stable serum
AED level, AED dose exposure and adverse events related to AEDs.
Analysis: Analysis of time to first and to all seizures after randomisation was performed using a Cox
proportional hazards model, and multivariate failure time analysis by the Andersen–Gill model. The effects
were reported as hazard ratios (HRs) with 95% confidence intervals (CIs). Secondary outcomes were
reported as mean differences (MDs) or odds ratios.
Results: A total of 130 women were randomised to the therapeutic drug monitoring group and 133 to
the clinical features monitoring group; 294 women did not have a reduction in serum AED level. A total of
127 women in the therapeutic drug monitoring group and 130 women in the clinical features monitoring
group (98% of complete data) were included in the primary analysis. There were no significant differences
in the time to first seizure (HR 0.82, 95% CI 0.55 to 1.2) or timing of all seizures after randomisation
(HR 1.3, 95% CI 0.7 to 2.5) between both trial groups. In comparison with the group with stable serum
AED levels, there were no significant increases in seizures in the clinical features monitoring (odds ratio
0.93, 95% CI 0.56 to 1.5) or therapeutic drug monitoring group (odds ratio 0.93, 95% CI 0.56 to 1.5)
associated with a reduction in serum AED levels. Maternal and neonatal outcomes were similar in both
groups, except for higher cord blood levels of lamotrigine (MD 0.55 mg/l, 95% CI 0.11 to 1 mg/l) or
levetiracetam (MD 7.8 mg/l, 95% CI 0.86 to 14.8 mg/l) in the therapeutic drug monitoring group than
in the clinical features monitoring group. There were no differences between the groups on daily AED
exposure or quality of life. An increase in exposure to lamotrigine, levetiracetam and carbamazepine
significantly increased the cord blood levels of the AEDs, but not maternal or fetal complications. Women
with epilepsy perceived the need for weighing up their increased vulnerability to seizures during pregnancy
against the side effects of AEDs.
Limitations: Fewer women than the original target were recruited.
Conclusion: There is no evidence to suggest that regular monitoring of serum AED levels in pregnancy
improves seizure control or affects maternal or fetal outcomes.
Future work recommendations: Further evaluation of the risks of seizure deterioration for various
threshold levels of reduction in AEDs and the long-term neurodevelopment of infants born to mothers in
both randomised groups is needed. An individualised prediction model will help to identify those women
who need close monitoring in pregnancy.
Trial registration: Current Controlled Trials ISRCTN01253916.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 23.
See the NIHR Journals Library website for further project information.
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Plain English summary
P regnant women with epilepsy who take medication for their seizures may have a decrease in the druglevels in their blood. This may worsen seizures. Some hospitals in the UK use regular blood tests to
check the amount of drug in the mother’s blood and offer to increase the dose of the medication if the
levels reduce. Most hospitals in the UK do not monitor drug levels because existing National Institute for
Health and Care Excellence and Scottish Intercollegiate Guidelines Network guidelines recommend a
strategy based on monitoring clinical features. There is a lack of evidence to support either management.
The AntiEpileptic drug Monitoring in PREgnancy (EMPiRE) study aimed to find out if routine blood tests to
monitor drug levels in pregnancy is better than management based on only clinical findings in preventing
seizures and avoiding complications in pregnancy. We obtained women’s views on the two strategies.
Of the 560 mothers with epilepsy on medication, the drug levels fell in 267 women. The risk of seizures
and pregnancy complications as well as infants’ birthweight and mothers’ quality of life were similar in the
group managed by monitoring drug levels regularly and in the group managed based on only clinical
findings. We did not identify a link between an increase in seizures and a decrease in drug levels. Babies
born to mothers whose drug levels were monitored regularly were exposed to a higher dose of the drug at
birth. Women reported that the decisions that they make regarding epilepsy medication intake and dose
are influenced by their feelings of responsibility for the health of their babies.
Our findings do not support regular blood monitoring of antiepileptic drug levels in pregnancy.
DOI: 10.3310/hta22230 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 23
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Thangaratinam et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of
Southampton Science Park, Southampton SO16 7NS, UK.
xix

Scientific summary
Background
Management of women with epilepsy on antiepileptic drugs (AEDs) is aimed at achieving seizure control on
the lowest possible dose and number of AEDs. A reduction in serum AED levels in pregnancy is believed to be
associated with seizure deterioration. A strategy of therapeutic drug monitoring of AED in pregnancy is
considered to have the potential to minimise seizures.
Objectives
Primary
To determine, in pregnant women with epilepsy on AEDs who experience a 25% decrease in serum AED
levels, if additional therapeutic drug monitoring reduces the risk of seizure deterioration in comparison to
clinical features monitoring alone.
Secondary
l To determine if there is a relationship between the level of reduction in serum AED levels and seizures.
l To evaluate the effects of the two strategies on pregnancy complications.
l To determine the effect of two monitoring strategies on quality of life.
l To assess if there is a difference in the total AED exposure between the two randomised groups.
l To assess the adverse effects of AED in all women exposed to the drugs.
l To obtain women’s views by a qualitative study.
Methods
Design
A double-blind, randomised trial nested within a cohort study was conducted and a qualitative study of
acceptability of the two strategies was undertaken.
Setting
Fifty obstetric and/or epilepsy clinics in the UK between November 2011 and May 2015.
Participants
Inclusion criteria
l Pregnant women on AED with a viable pregnancy (< 24 weeks’ gestation).
l Confirmed diagnosis of epilepsy.
l Women on AED monotherapy (lamotrigine, carbamazepine, phenytoin or carbamazepine) or
polytherapy (lamotrigine with either carbamazepine, phenytoin or levetiracetam).
l Capable of understanding English.
Exclusion criteria
l Women aged < 16 years.
l A diagnosis of status epilepticus or non-epileptic seizures.
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l On non-lamotrigine polytherapy, sodium valproate monotherapy or polytherapy.
l Significant learning disability.
l Alcohol or substance abuse.
l Unable to complete seizure diaries or take AED in pregnancy.
l Participation in a blinded, placebo-controlled trial of an investigational medicinal product in pregnancy.
Outcome measures
Primary
Seizure deterioration defined as timing of all seizures after randomisation until 6 weeks after delivery.
Secondary
l Maternal: neurological, obstetric and quality of life.
l Fetal and neonatal: mortality and morbidity, birthweight, head circumference and cord blood serum
AED levels.
Study conduct
Women with epilepsy on AED recruited in the study cohort were randomised to either therapeutic drug
monitoring or clinical features monitoring if there was a ≥ 25% decrease in serum AED levels at any time
in pregnancy, compared with baseline or pre-pregnancy levels. Women and clinicians in the clinical
features monitoring arm and non-randomised cohort were blinded to the serum AED levels. The seizure
status was elicited from seizure diaries and complications from hospital records.
Sample size
We estimated that 660 randomised women are required to demonstrate a 25% seizure hazard decrease
[hazard ratio (HR) ≈0.75] with therapeutic drug monitoring, providing 80% power (at a p-value of 0.05)
and assuming an outcome-free survival rate of 60% in the clinical features monitoring group and 10%
loss to follow-up.
Analysis
All analyses were on an intention-to-treat basis, and estimates of effect size (e.g. hazard or risk ratio) were
presented as point estimates, with corresponding 95% confidence intervals (CIs). A multivariate failure
time analysis of time to first seizure, and subsequent seizures, was performed using a generalisation of Cox
proportional hazard model, taking into account the correlation of observations within each subject by
incorporating robust standard errors for parameter estimates with the Andersen–Gill model.
Results
We recruited 560 mothers from 50 hospitals, randomised 267 women to either the therapeutic drug
monitoring or clinical features monitoring group and included data from 257 women for primary analysis.
There were no significant differences between the two groups for the time to first seizure (HR 0.82, 95% CI
0.55 to 1.2) or time to multiple seizures (HR 1.34, 95% CI 0.70 to 2.6). There were no differences between
the arms in maternal and fetal complications, breastfeeding, birthweight, cord pH and quality of life. Cord
blood levels of lamotrigine and levetiracetam were higher in the therapeutic drug monitoring group than in
the clinical features monitoring group with adjusted mean differences (MDs) of 0.55 mg/l (95% CI 0.11 to
1.0 mg/l) and 7.8 mg/l (95% CI 0.86 to 14.8 mg/l), respectively, with similar levels of carbamazepine in
both groups.
SCIENTIFIC SUMMARY
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In comparison with the non-randomised group with stable serum AED levels, there were no significant
increases in seizures in the clinical features monitoring (odds ratio 0.93, 95% CI 0.56 to 1.5) or therapeutic
drug monitoring group (odds ratio 0.93, 95% CI 0.56 to 1.5). Increase in exposure to AED dose in women
on monotherapy and polytherapy had no significant effect on maternal and neonatal outcomes, except for
an increase in cord blood levels of lamotrigine (MD 0.55 mg/l, 95% CI 0.11 to 1.0 mg/l) and levetiracetam
(MD 7.8 mg/l, 95% CI 0.86 to 14.8 mg/l) in the therapeutic drug monitoring group than in the clinical features
monitoring group. There were no differences for cord blood levels of carbamazepine (MD –0.47 mg/l, 95% CI
–1.5 to 0.6 mg/l) between the two groups.
Mothers with epilepsy on medication felt that they should weigh up their increased vulnerability to seizures
during pregnancy against teratogenic effects of AEDs. We identified possible tension between health
professionals’ focus on drug adherence and the women’s desire for their babies to be born without any
health problems.
Conclusions
There is no evidence to support the theory that regular monitoring of AED drug levels in pregnancy offers
additional benefit in seizure control than management based on only clinical features. Although there are
no increases in short-term maternal or fetal complications with the drug monitoring strategy compared
with a clinical-based strategy, the long-term neurodevelopment of babies exposed to higher serum AED
levels in this group needs further evaluation.
Trial registration
This trial is registered as ISRCTN01253916.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Burden of the problem
Epilepsy complicates 0.6% of all pregnancies in the UK, affecting 0.5–1.0% of the general population.1
Approximately one-third of people receiving antiepileptic drugs (AEDs) are of reproductive age,2 and there
has been a rise in the number of pregnancies exposed to AEDs in the past few decades.3 Maternal mortality
is 10-fold higher among pregnant women with epilepsy than among those without epilepsy.1 In 2009–12,
14 maternal deaths in the UK were attributed to epilepsy4 and sudden unexpected death in epilepsy,
accounting for about 80% of deaths in women with epilepsy.1,4 These were invariably a direct consequence
of seizures. The numbers of maternal deaths related to epilepsy in the UK have been stagnant over the last
15 years. Confidential enquiries into maternal deaths have repeatedly highlighted concerns about epilepsy
management during pregnancy.4,5
In addition to major risks to the mother, uncontrolled epilepsy with generalised tonic–clonic convulsions
carries risk of harm to the fetus including miscarriage, fetal hypoxia and acidosis, and fetal loss.6–8
The effect of epilepsy can impact daily living, resulting in loss of driving licence, negative impact on
employment and relationships and reduced quality of life (QoL). Seizure control is central to the
management of pregnant women with epilepsy, and mothers are often advised to continue the AED
in pregnancy.
Antiepileptic drug exposure in utero is associated with congenital malformation,9 with fetal risk related to
the number of AEDs, AED type and, probably, AED dose.10 Furthermore, the magnitude of AED dose
exposure to the fetus in utero and the effect of continued AED intake in pregnancy on the long-term
neurological development of children is not known. There is a consensus that the risks of uncontrolled
convulsive seizures in the mother outweigh the potential teratogenic risk and any other adverse effect
on offspring.11,12
Antiepileptic drug levels decrease in pregnancy in a proportion of women with epilepsy and are
hypothesised to aggravate seizures.13–15 Monitoring of serum AED levels in each trimester, and after
delivery, has been recommended by the American Academy of Neurology based on consensus as a good
practice.16 In the UK, however, the National Institute for Health and Care Excellence and Scottish
Intercollegiate Guidelines Network guidelines do not recommend regular AED monitoring in pregnancy
because of a paucity of evidence.12
There are no randomised trials evaluating the effects of additional therapeutic drug monitoring (TDM) over
clinical features monitoring (CFM) in determining the optimal management of women with epilepsy on
AEDs in pregnancy. Furthermore, the acceptability of the two strategies, their impact on the QoL of the
mother and pregnancy outcomes is not known.
Objectives
Primary objective
To determine, in pregnant women with epilepsy on AEDs who experience a 25% decrease from baseline
in serum AED levels, if a strategy of additional therapeutic drug monitoring compared with clinical features
monitoring alone to determine the optimal dose of AED reduces the risk of seizures.
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Secondary objectives
1. To determine if there is a relationship between the level of reduction in serum AED levels and seizures,
by comparing women in a non-randomised cohort with stable levels with those in randomised cohorts
with a decrease in levels.
2. To evaluate the effect of the two monitoring strategies on maternal and fetal outcomes in women with
a decrease in serum AED levels.
3. To assess the effect of therapeutic drug monitoring versus clinical features monitoring on QoL in
pregnant women with epilepsy on AEDs.
4. To identify any differences in total AED dose exposure between therapeutic drug monitoring and
clinical features monitoring strategies.
5. To assess the adverse effects of AEDs in all women exposed to the drugs.
6. To gain insight into the way pregnant women with epilepsy rationalise and make sense of the
management of AEDs in the context of their lives through a qualitative study.
7. To evaluate the cost-effectiveness of the two strategies.
INTRODUCTION
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Chapter 2 Methods
Study design
A double-blind, randomised trial nested within a cohort study was conducted and a qualitative study
of acceptability of the two strategies was undertaken. The study received ethics approval from the
National Research Ethics Service Committee West Midlands (reference number 11/WM/0164, trial
registration 01253916).
Setting
The trial was conducted across 50 obstetric and/or epilepsy clinics in secondary and tertiary care units in
the UK between November 2011 and May 2015.
Patient and public involvement
The Epilepsy Action charity assisted with the trial design and promotion. A member of the charity (APU)
contributed in Trial Steering Committee (TSC) meetings to the general management of the project.
A patient representative (NMo) sat on the Trial Management Group and TSC panels and provided input
towards the overall supervision of the trial.
Eligibility criteria
For inclusion in the trial, participants had to fulfil the following eligibility criteria.
Inclusion criteria
l Viable pregnancy of < 24 weeks’ gestation.
l Confirmed diagnosis of epilepsy including primary, localised or unclassified.
l Lamotrigine monotherapy/polytherapy (with carbamazepine, phenytoin or levetiracetam) or
carbamazepine monotherapy or phenytoin monotherapy or levetiracetam monotherapy.
l Capable of understanding the information provided.
Exclusion criteria
l Aged < 16 years.
l Documented status epilepticus in the last year or non-epileptic seizures in the last 2 years.
l Non-lamotrigine polytherapy or sodium valproate monotherapy or polytherapy.
l Participation in any blinded, placebo-controlled trials of investigational medicinal products
in pregnancy.
l Significant learning disability.
l Unable to complete seizure diaries or recall frequency of seizures accurately.
l History of alcohol or substance abuse or dependence in the last 2 years.
l Expressed an intention not to take AEDs in pregnancy.
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Health technologies assessed
Women with a decrease in serum AED levels in pregnancy compared with baseline levels at booking or
pre-pregnancy were randomised to management based on serum AED levels or to management based on
clinical factors only.
Therapeutic drug monitoring group
The monthly levels of serum AED were communicated to the responsible clinicians. Clinicians managed
women based on knowledge of serum AED levels in addition to clinical factors. The management involved
discussion with the patient of potential risks of reduced serum levels, and the risks and benefits of an
increase in AED dose to mother and baby. Women were provided treatment options including more
frequent monitoring, increase in dosage of the AED immediately or delayed increase pending early testing.
Clinical features monitoring group
The clinician and mother were not informed of the serum AED levels, unless requested as part of an
unblinding procedure. The decision to change the dose of AED was made by a responsible clinician based
on clinical features alone.
Randomisation
Participants were allocated in 1 : 1 ratio to therapeutic drug monitoring or clinical features monitoring
using a stratified block randomisation, with random block size of two, four or six to reduce predictability.
Stratification variables were:
l baseline AED therapy: (1) lamotrigine monotherapy, (2) carbamazepine, phenytoin or levetiracetam
monotherapy, or (3) lamotrigine polytherapy
l presence or absence of seizures 3 months prior to pregnancy.
Randomisation was carried out online using computer-generated randomisation sequences provided by the
Nottingham Clinical Trials Unit.
Outcome
Primary outcome
The primary outcome was seizure deterioration, which was defined as time to first seizure, including first
and subsequent seizures after randomisation, over the whole period of monitoring including 6 weeks
post delivery.
Secondary outcomes
Maternal
l Neurological: the proportion of women experiencing seizures who were seizure free in the 3 months
prior to consent, number of seizures per week and number of seizure-free days per week, mean daily
AED dose exposure and adverse events as measured by the Liverpool Adverse Events Profile (LAEP).
l Obstetric: maternal death, mode of delivery, pre-term labour, induction of labour, pre-eclampsia,
ante- and postpartum haemorrhage, admission to high-dependency/intensive care unit, breastfeeding,
infection and gestational diabetes mellitus.
l QoL: epilepsy-specific QoL [as measured by the Quality Of Life In Epilepsy – 31-item questionnaire
(QOLIE-31)] and a generic QoL [as measured by the EuroQol-5 Dimensions (EQ-5D)].
METHODS
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Fetal and neonatal
l Stillbirth, neonatal death, major congenital malformations (defined as structural abnormalities with
surgical, medical or cosmetic importance diagnosed either antenatally or postnatally17), minor
abnormalities, Apgar scores at 1 minute and 5 minutes, admission to neonatal unit, birthweight,
head circumference, fetal growth and cord blood levels of AED.
Study conduct
Relevant neurological and obstetric histories were obtained from pregnant women with epilepsy at their
booking/antenatal visit. Baseline data were collected on age, ethnicity, age at first seizure (excluding febrile
seizures), seizure frequency over the previous 6 months, seizure types, epilepsy syndrome, aetiology of
epilepsy, duration of epilepsy, current AED and dose, baseline serum AED level, indications of depression
[as measured via the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E)], learning difficulty,
school leaving age, educational performance, current employment, previous AED pregnancy exposure,
previous pregnancy complications, perinatal outcome, number of children, health of children and
educational status of children at the first visit. Indications of depression at baseline were scored by
participant responses to the NDDI-E. A score of > 15 out of 24 on the NDDI-E was considered to be
indicative of depression and clinicians were requested to refer in accordance with local practice.
Participants were regularly monitored for serum AED levels from baseline at monthly intervals until
6–8 weeks post partum. Women were asked to record seizure activity in diaries specially developed for
collecting trial data throughout the course of their participation. Women completed the EQ-5D (maximum
score of 1), LAEP (maximum score of 76) and a Patient Costs Questionnaire at baseline, and all follow-up
and postnatal visits. Responses to the QOLIE-31 (maximum score of 100 or QOLIE-31 overall health,
maximum score of 10) were collected at baseline and in late pregnancy (i.e. 32–36 weeks’ gestation).
A higher score indicates a better health state.
Women with a ≥ 25% reduction in serum AED levels at any time in pregnancy, compared with baseline
or pre-pregnancy levels, were randomised to therapeutic drug monitoring or clinical features monitoring.
Women without a reduction in serum AED levels continued to be monitored in the non-randomised arm,
and were randomised if their serum AED levels fell below 25% at any time until delivery. Women and
clinicians in the clinical features monitoring arm and non-randomised cohort were blinded to the results.
If randomised to the therapeutic drug monitoring arm, the serum levels were communicated to the
participating centre within 1 working day of receipt of the test result from the laboratory. If appropriate, the
clinician or the research midwife/nurse (on the advice of the clinician) contacted the participant to advise on
a course of action within 7 working days of receipt of information from the trial unit. The current daily dose
of AED and any adjustment was recorded. In exceptional circumstances, additional serum AED levels were
requested from the central laboratory outside the trial visit plan, if deemed appropriate by the treating
clinician (e.g. clinical suspicion of toxicity or non-adherence).
We obtained information on seizure status from the seizure diaries, and all maternal and fetal outcomes
from clinical records. When women were admitted in labour, blood samples for serum AED levels were
obtained alongside routine blood tests at any point from admission in labour up until discharge. After
delivery, cord bloods were obtained for serum AED levels and cord pH. Details of the qualitative study are
provided in Chapter 4, and details of amendments to study conduct and criteria are provided in Appendix 1.
The study has been reported in line with recommended guidelines.18,19
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Criteria for unblinding of serum levels in the control and
non-randomised groups
The serum AED levels were revealed to the clinicians and women in the blinded groups (control and
non-randomised) in the following circumstances:
l deterioration of seizures despite treatment – the serum AED level was revealed in these cases at the
request of the clinician, similar to standard clinical practice
l clinical suspicion of toxicity
l if levels of AED were found to be above the therapeutic range with risks of toxicity
l results were requested by the clinician or patient for any other reason.
Withdrawal criteria
If a patient withdrew consent for the study, all data collected up to the point of withdrawal were retained
unless the patient requested otherwise. If, for whatever reason, the patient discontinued monitoring, the
participant was not withdrawn from the study and data collection continued to allow intention-to-treat
analysis, unless consent to do this was withdrawn. Rates were monitored to detect differential dropout,
which can bias clinical trial results and reduce the power of the study.
Sample size estimation
A large, prospective registry of pregnant women with epilepsy suggested that around 40% of women
experience seizures during pregnancy.20 We set the outcome-free survival rate under clinical features
monitoring at 60% and estimated sample sizes for various effect sizes smaller than what was observed in
our systematic review. Table 1 gives a range of estimates of sample sizes for different powers and effect
sizes for the primary outcome of time to first seizure.
We aimed to collect data from at least 594 randomised women, giving 80% power (at p = 0.05) to
detect a 25% seizure hazard decrease [hazard ratio (HR) ≈0.75]. We considered 25% to be the minimally
important difference in seizure deterioration to be achieved, given the potential drawbacks of increasing
AED dose exposure. We assumed a loss to follow-up of 10%, and estimated the need to randomise
660 women with a reduction in serum AED level.
TABLE 1 Sample size estimates for different powers and effect sizes
Control survival rate (60%)
Total sample size
80% power 90% power
Increased to 78% (hazard ratio ≈0.60) 182 244
Increased to 76% (hazard ratio ≈0.65) 258 344
Increased to 73% (hazard ratio ≈0.70) 380 508
Increased to 71% (hazard ratio ≈0.75) 594 794
METHODS
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Analysis
Participants were analysed belonging to the group to which they were randomised, unless they were
randomised in error. All estimates of effect size (e.g. hazard or risk ratio) were presented as point
estimates, with corresponding 95% confidence intervals (CIs) and p-values. All analyses were carried out
using Stata® version 12.0 (StataCorp LP, College Station, TX, USA).
The primary analysis of time to first seizure was performed using a Cox proportional hazards model.
The primary multivariate failure time analysis of time to first seizure was performed using a generalisation
of the Cox proportional hazards model, taking into account the correlation of observations within each
subject by incorporating robust standard errors for parameter estimates, the Andersen–Gill model.21 For
both models, survival analysis was performed on a daily scale. Multiple seizures of the same or different
types on the same day were not considered separately. An event was defined as at least one seizure of
any type on a calendar day. Censoring occurred at the first date with missing information on seizure
occurrence, or at end of follow-up if no event was recorded and follow-up was complete without
missing records.
In addition to the treatment allocation, all primary and secondary models included the randomisation
factors of AED type (lamotrigine monotherapy/carbamazepine, phenytoin or levetiracetam monotherapy/
lamotrigine polytherapy) and seizures 3 months prior to consent (yes/no) as covariates in the model. To
increase the precision of the treatment effect estimate, we also adjusted for the following baseline values
that were determined a priori: maternal age, age at first seizure (excluding febrile seizures) and general
seizure classification at baseline (tonic–clonic seizure/non-tonic–clonic seizure/unclassified).
Secondary analyses of differences between the two randomised arms for pregnancy outcomes, cord blood
serum AED levels and QoL were performed using analysis of covariance. We used Poisson models for
analyses of the LAEP, logistic models for binary outcomes, ordered logistic regression for the categorical
outcome ‘breastfeeding’ and linear regression for continuous outcomes.
We analysed the association between the reduction in serum AED levels and seizure status using logistic
regression models for the binary outcome of seizure-free status by the end of follow-up, and Poisson
regression models for weekly seizure rate and number of seizure days per week. Seizure-free status was
analysed including randomised and non-randomised participants. Rates were compared between clinical
features monitoring and the non-randomised cohort. AED dose exposure was compared between therapeutic
drug monitoring, clinical features monitoring and the non-randomised cohort using linear regression. For
analysis of participants on multiple AEDs, we used multivariate multiple regression to analyse the two
drugs together.
Fetal outcomes were analysed using mixed models to account for clustering of twins by mother (2.7% of
pregnancies in study population). Convergence issues were dealt with by using a simpler analysis of
covariance model ignoring clustering. We compared these results against a model including only one twin
per pair, and in all cases the model results were very similar. The number of twins included in any analysis
was very small and the impact of ignoring the clustering in these situations was deemed sufficiently low.
Assumption checks and sensitivity analysis
Extreme values were checked as part of the data cleaning procedure. Any remaining outliers were
considered to be true data values and therefore analysed as reported. However, using box plots we
identified one participant with extremely large numbers of seizures. We assessed the robustness of the
secondary analysis of seizure rates by excluding this value and interpreted the results accordingly. For
survival models, the proportional hazards assumption was checked using Schoenfeld residuals, log–log
plots and through inclusion of time-dependent effects; subgroup effects were presented to investigate
violations and compared using the Wald test for treatment–covariate interactions. We investigated
whether or not any treatment effect differed by seizure type by only considering tonic–clonic seizures
as outcomes.
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Missing values
Withdrawals and those lost to follow-up were included in the analysis up to the last point that data are
available. If the number of seizures was unknown for a date or a date range, we contacted the mothers by
telephone or in person to obtain missing details. When this was not possible, records were reviewed by
two independent neurologists (DM and AK), who commented on the likelihood of seizure and type of
seizure in the missing slot. When the neurologists were not able to provide this opinion, or there was a
discrepancy in their opinion, the opinion of a third neurologist (Shanika Samarasekera) was sought. When
all neurologists were unable to provide estimation on likelihood of seizure, the average seizure rate for
tonic–clonic seizures and the rate for non-tonic–clonic seizures over the period of the participant’s
completed diary were applied.
When the seizure type was missing or no other data for the seizure type were available, the average rate
over any seizure type was used. If multiple seizures occurred during a time frame, they were equally
spaced out over the time frame. If the number of seizures was larger than the number of days, the
seizures were equally spaced out over each day in the time frame. A sensitivity analysis was conducted for
the analysis of time to first seizure to investigate if an interval censoring approach showed a different
result. When there were missing data on seizure occurrence, participants were censored at the first date
on which seizure occurrence was known. A sensitivity analysis will be performed for the analysis of
multiple events ignoring any dates or date ranges in which seizure occurrence is unknown.
Sensitivity analysis for interval analysis for time to first seizure
This sensitivity analysis was planned a priori but not conducted. The reasons are as follows.
The exact date of the first seizure was uncertain in eight women. Three women had substantially more
seizures than the number of days in the period of uncertainty. For these women we assumed daily
seizures, as the actual number of seizures occurring on a single day is irrelevant for the primary analysis.
Three women reported more than one seizure occurring during a period of 3–6 weeks. Interval censoring
approaches standardly available in the statistical packages allow only one event to occur during the period
of uncertainty. Allowing for multiple events during the period of uncertainty would require the application
of multistate models, which would probably introduce other issues, such as convergence problems. Two
women had a single seizure during 1 month. Here, the interval censoring approach standardly available
could have been applied. However, as a result of the small number and the issues arising for other women
(as described in the previous paragraph), it was decided not to perform this analysis.
Oversight of the trial
The management of our study included an element of expert advice that was entirely independent from
the investigators and their host institution(s). The trial was overseen by a 15-member TSC, which included
three independent members and a consumer representative from Epilepsy Action. There were three
independent members in the five-member Data Monitoring Committee (DMC). The terms of reference and
charter for the DMC were determined at the outset, taking into account issues relevant to the monitoring
of this study.22
Health economics analysis
The original sample size for the study was 660 randomised women. In 2014, given the slow rate of
recruitment of the trial, the funder, after discussion with the DMC and TSC, decided not to extend the
recruitment period of the trial, prior to achievement of the planned sample size. The economic analysis
was integral to the initial study design, but given that the planned sample size was not recruited, it was
postponed pending results to see if it was justified. Given that the study ultimately found no evidence
to support that regular monitoring of AED drug levels in pregnancy offers additional benefit in seizure
control than management based only on clinical features, any justification for an economic evaluation has
not materialised.
METHODS
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Chapter 3 Results
Flow of women recruited in the study
We recruited 593 women: 580 for the cohort and 13 for the qualitative study. The median number of
women recruited per centre was nine [interquartile range (IQR) 6–13]. Of the 580 women recruited into the
cohort, 20 were recruited but subsequently found to fail the inclusion criteria, resulting in 560 women who
were monitored for a reduction in serum AED levels. Less than 1% of participants (n = 6) were recruited
twice into the study because they became pregnant again during the trial period. Overall, 263 women had a
reduction in serum AED level at some point in their pregnancy and were randomised to therapeutic drug
monitoring (n = 130) or clinical features monitoring (n = 133) groups, and the remaining 293 had stable
serum AED levels until delivery. Four women who were randomised in error after the end of pregnancy
were analysed with the non-randomised group. Complete outcome data for the primary analysis were
available from 127 women (98%) in the therapeutic drug monitoring group, 130 (98%) in the clinical
features monitoring group and 294 (99%) in the non-randomised group (Figure 1).
Characteristics of women included
A total of 85% of recruited women in the therapeutic drug monitoring, clinical features monitoring and
non-randomised groups were white. Around 60% in each of the groups had been educated to Advanced
level (A level) or higher. Half of all women in the non-randomised cohort (50%) were nulliparous, and the
corresponding figures were 58% and 54% in therapeutic drug monitoring and clinical features monitoring
groups, respectively. The rates of congenital abnormalities in previous pregnancies were between 5% and
8% of women in the therapeutic drug monitoring, clinical features monitoring and non-randomised
groups. There was a history of mental illness in about one-tenth of the women (Table 2).
Tonic–clonic seizure was the most common type of seizure, being diagnosed in 80% (100/130) of women
in the therapeutic drug monitoring group, 82% (109/133) in the clinical features monitoring group and
81% (237/294) in the non-randomised cohort. One-quarter of women in each of the randomised groups
(therapeutic drug monitoring: 26%, 34/130; clinical features monitoring: 24%, 32/133) and one-third in
the non-randomised group (29%, 84/294) were seizure free for 3 months before pregnancy. Lamotrigine
monotherapy was the most common AED medication taken by around half of the women at baseline.
Lamotrigine polytherapy was taken by one-tenth in the therapeutic drug monitoring (11%, 14/130) and
clinical features monitoring (9%, 12/133) groups, and by 5% in the non-randomised cohort (15/294). The
doses of individual AEDs taken at the time of randomisation in the therapeutic drug monitoring and clinical
features monitoring groups are provided in Table 3.
Baseline QoL measurements are provided in Table 4. Scores for the NDDI-E, QoL (EQ-5D), LAEP and
QOLIE-31 were balanced across the therapeutic drug monitoring and clinical features monitoring groups.
Time to randomisation from consent
Figure 2 shows the time from baseline to randomisation for randomised participants. Randomisation was
performed, on average, 68 days [standard deviation (SD) 43 days] from baseline (median 59 days, IQR
40–96 days).
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Excluded
• Did not meet inclusion 
   criteria, n = 1516
• Refused to participate, n = 311
• Missed appointment, n = 88
• Detected prior to 
   randomisation, n = 17
Consented but ineligible
(n = 20)
• Missing adjustment 
   factor, n = 1
• Insufficient diary
   data, n = 2
Stable serum AED levels
(n = 293)
• Trial team missed
   a 25% fall, n = 2
• Lost to follow-up
   before baseline, 
   n = 1
• Insufficient diary 
   data, n = 33
Non-randomised cohort
(n = 293)
Included in analysis
(n = 261)
Non-randomised cohort
(n = 294)
Screened for eligibility
(n = 2495)
Consented and monitored for 25% fall in AED blood level
(n = 580)
Monitored according to change in serum AED level
(n = 560)
• Randomised after 
   miscarriage, n = 1
• Randomised after
   delivery, n = 1
TDM
(n = 132)
• Insufficient diary 
   data, n = 3
TDM followed up
(n = 130)
• Randomised after
   delivery, n = 2
CFM
(n = 135)
CFM followed up
(n = 133)
Fall in serum AED levels
(n = 267)
Included in primary analysis 
(n = 127) (TDM), (n = 130) (CFM)
Randomised
FIGURE 1 Consolidated Standards of Reporting Trials flow chart. CFM, clinical features monitoring;
TDM, therapeutic drug monitoring.
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TABLE 2 Baseline demographic and obstetric details of women included in the study
Variable
Trial group, n (%)
Randomised
Non-randomised
(N= 294)TDM (N= 130) CFM (N= 133)
Ethnic group n= 130 n= 133 n= 294
White 113 (87) 118 (89) 253 (86)
Black 2 (2) 3 (2) 6 (2)
Asian 13 (10) 7 (5) 25 (9)
Mixed 0 (0) 2 (2) 8 (3)
Other 2 (2) 3 (2) 2 (1)
Highest qualification n= 127 n= 133 n= 292
Degree level 50 (39) 49 (37) 114 (39)
A level 29 (23) 33 (25) 68 (23)
GCSE 44 (35) 48 (36) 87 (30)
Below GCSE 4 (3) 3 (2) 23 (8)
Smoking status n= 130 n= 133 n= 294
Smoker 17 (13) 14 (11) 34 (12)
Ex-smoker 30 (23) 31 (23) 90 (31)
Non-smoker 83 (64) 88 (66) 170 (58)
Alcohol units per week n= 130 n= 133 n= 294
0 122 (94) 117 (88) 266 (91)
1–9 8 (6) 16 (12) 25 (9)
≥ 10 0 (0) 0 (0) 3 (1)
Parity n= 130 n= 133 n= 294
0 75 (58) 72 (54) 147 (50)
1–4 55 (42) 59 (44) 144 (49)
≥ 5 0 (0) 2 (2) 3 (1)
Previous children n= 76 n= 100 n= 225
Neonatal deaths 1 (1) 1 (1) 2 (1)
Stillbirths 0 (0) 0 (0) 3 (1)a
At least one congenital abnormality in previous children 7 (7) 4 (5) 17 (8)
Medical history n = 130 n = 133 n = 293
Maternal congenital abnormalities 5 (4) 5 (4) 5 (2)
Diabetes 3 (2) 1 (1) 9 (3)
Chronic hypertension 2 (2) 2 (2) 7 (2)
Renal disease 3 (2) 2 (2) 5 (2)
HIV infection 0 (0) 0 (0) 1 (0)
Learning difficulties 3 (2)b 1 (1) 11 (4)c
Mental illness 19 (15) 15 (11) 33 (11)
A level, Advanced level; CFM, clinical features monitoring; GCSE, General Certificate of Secondary Education; HIV, human
immunodeficiency virus; TDM, therapeutic drug monitoring.
a There were 226 participants analysed in this group.
b There were 129 participants analysed in this group.
c There were 292 participants analysed in this group.
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TABLE 3 Baseline neurological characteristics of women in the study
Variable
Trial group
Randomised
Non-randomised
cohortTDM CFM
Age at first seizure (years), mean (SD) [n] 16.8 (8) [130] 17.0 (7) [132] 16.1 (7) [290]
Years since first seizure, mean (SD) [n] 12.2 (8) [121] 12.1 (7) [124] 16.1 (8) [261]
Seizures 3 months prior to pregnancy [N] 34.0 (26) [130] 32.0 (24) [133] 84.0 (29) [294]
Seizure classification,a n (%) N = 130 N= 133 N= 294
TCS 100 (80) 109 (82) 237 (81)
Absence 29 (22) 35 (26) 85 (29)
Myoclonus 13 (10) 20 (15) 33 (11)
Simple 19 (15) 20 (15) 30 (10)
Complex 36 (28) 19 (14) 57 (19)
Unclassified/other 6 (5) 7 (5) 14 (5)
AED intake at baseline, n (%) N = 130 N= 133 N= 294
LTG monotherapy 68 (52) 70 (53) 148 (50)
CBZ, PHT or LEV monotherapy 48 (37) 51 (38) 131 (45)
LTG polytherapy 14 (11) 12 (9) 15 (5)
Type of AED intake at baseline, n (%) N = 130 N= 133 N= 294
CBZ 16 (12) 20 (15) 54 (18)
LTG 68 (52) 70 (53) 148 (50)
LEV 31 (24) 31 (23) 77 (26)
PHT 1 (1) 0 (0) 0 (0)
LTG and LEV 14 (11) 11 (8) 15 (5)
LTG and CBZ 0 (0) 1 (1) 0 (0)
Dose of AED at randomisation (mg), mean (SD) [n]
CBZ only 581.3 (339.1) [16] 695.0 (336.4) [20]
LTG only 246.3 (124.4) [68] 242.9 (148.5) [70]
LEV only 1500.0 (724.6) [31] 1572.6 (880.8) [31]
PHT only [0] 200.0 [1]
LTG and LEV, LTG dose 448.2 (215.8) [14] 379.6 (92.8) [11]
LTG and LEV, LEV dose 1767.9 (846.2) [14] 2100.0 (1119.3) [10]
LTG and CBZ, LTG dose [0] 200.0 [1]
LTG and CBZ, CBZ dose [0] 300.0 [1]
CBZ, carbamazepine; CFM, clinical features monitoring; LEV, levetiracetam; LTG, lamotrigine; PHT, phenytoin; SD, standard
deviation; TCS, tonic–clonic seizure; TDM, therapeutic drug monitoring.
a Some women experience more than one seizure type.
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TABLE 4 Baseline scores for questionnaires
Variable
Trial group, mean (SD) [n]
Randomised
Non-randomised (N= 294)TDM (N= 130) CFM (N= 133)
NDDI-Ea 9.7 (3.3) [130] 9.9 (3.6) [133] 10.1 (3.5) [284]
EQ-5Db 0.90 (0.17) [126] 0.90 (0.16) [127] 0.89 (0.18) [267]
LAEPc 34.3 (8.9) [124] 34.9 (10.4) [121] 35.3 (9.2) [259]
QOLIE-31 scored (UK) 73.7 (14.6) [128] 72.8 (15.5) [128] 71.0 (16.8) [274]
QOLIE-31 overall healthe (UK) 7.0 (1.8) [127] 7.0 (1.9) [128] 7.1 (1.8) [273]
CFM, clinical features monitoring; SD, standard deviation; TDM, therapeutic drug monitoring.
a Maximum score of 24.
b Maximum score of 1.
c Maximum score of 76.
d Maximum score of 100.
e Maximum score of 10.
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FIGURE 2 Time from baseline to randomisation in days. (a) Clinical features monitoring; and (b) therapeutic
drug monitoring.
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Effects of therapeutic drug monitoring and clinical features monitoring
strategies for antiepileptic drug dosing on maternal seizures
A total of 257 women provided a cumulative analysis time of 35,859 days from randomisation to
censoring, with 25,001 days from randomisation to first seizure. The median time of follow-up from
randomisation to censoring was 153 (IQR 115–179) and 134 (IQR 84–169) days for the therapeutic drug
monitoring and clinical features monitoring groups, respectively. The number of days with seizure and
actual number of seizures that occurred in both groups are provided in Table 5.
Seizure data were captured from randomisation to the first day of missing data. One-quarter of women in
the clinical features monitoring group had a total observation period of < 12 weeks in comparison to 8%
of the therapeutic drug monitoring group. A total observation period of 12–24 weeks was seen in half
of each randomised group, and one-quarter of the clinical features monitoring and one-third of the
therapeutic drug monitoring participants had a total observation period of 24–36 weeks. One woman in
each group had seizure data captured for > 36 weeks. The mean number of days with captured seizure
data was higher for the therapeutic drug monitoring group by 19 days.
TABLE 5 Seizure data from randomisation to censoring (as defined by the first date of missing diary data)
Variable
Randomised group, n (%)
TDM (N= 127) CFM (N= 130)
Total observation period (weeks)
< 12 11 (8) 32 (25)
12 to < 24 69 (54) 65 (50)
24 to < 36 46 (36) 32 (25)
≥ 36 1 (1) 1 (1)
Median (IQR) (days) 153 (115–179) 134 (84–169)
Number of days with any seizures
0 79 (66) 80 (63)
1–29 36 (30) 43 (34)
30–59 5 (4) 2 (2)
60–89 0 (0) 2 (2)
≥ 90 7 (6) 3 (2)
Median (IQR) 0 (0–3) 0 (0–4)
Total number of seizures
0 79 (64) 80 (62)
1–9 29 (24) 26 (20)
10–99 10 (8) 20 (16)
100–499 6 (5) 3 (2)
≥ 500 3 (2) 1 (1)
Median (IQR) 0 (0–4) 0 (0–5)
CFM, clinical features monitoring; TDM, therapeutic drug monitoring.
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Two-thirds of each randomised group did not experience any seizures after randomisation, whereas
approximately one-third of both groups experienced 1–29 days with seizures. Number of days with seizures
was similar in both groups (Figure 3). Less than one-quarter of women in both groups had up to nine
seizures post randomisation. The proportion of women who experienced 10–99 seizures was twice as high
in the clinical features monitoring group (16%) as in the therapeutic drug monitoring group (8%). Small
numbers of women in each group experienced > 100 seizures after randomisation and ≥ 30 days of seizures.
There were no differences in the proportion of women who experienced at least one seizure in the
therapeutic drug monitoring (48/127, 38%) and clinical features monitoring (50/130, 38%) groups, with a
mean observed time to first seizure of 28 days (SD 42 days) in the therapeutic drug monitoring group and
27 days (SD 36 days) in clinical features monitoring group. There was a 20% reduction in the time to first
seizure with therapeutic drug monitoring compared with clinical features monitoring, a difference that was
not significant (HR 0.8, 95% CI 0.55 to 1.2). The CI suggests a possible effect of between a 45% decrease
and a 20% increase in seizure rate with therapeutic drug monitoring and includes a HR of 0.75; therefore,
the possibility of a clinically relevant difference between therapeutic drug monitoring and clinical features
monitoring cannot be rejected. Figure 4 shows the results of the Cox regression of time to first seizure
and the corresponding Kaplan–Meier curve. Assumption checks indicated no violation of the proportional
hazards assumption globally (p = 0.17). However, some violation was detected for adjustment factor
maternal age (p = 0.003), indicating that the influence of age on seizure occurrence changes over time.
After including a time-dependent effect for age, the proportional hazards assumption was satisfied for all
covariates. Including the time-dependent effect resulted in a minor change to the CI, but not the effect
size or statistical significance (HR 0.8, 95% CI 0.54 to 1.3). These investigations supported the use of the
Cox model for our analysis.
Maternal age at baseline slightly increased with date of randomisation over the 3-year study period
(p = 0.11), which may explain some of the time-dependent effect. The effect of age as a risk factor may
also have varied over time, indicating that higher maternal age at baseline might have carried a larger risk
later in the study period than at the start of the study period.
Ninety-eight (38%) women experienced only one seizure, 75 (29%) experienced two or more seizures
and 72 (28%) experienced three or more seizures. Of the 98 women who had suffered a first seizure,
75 women experienced a second seizure, 35 in the therapeutic drug monitoring group and 40 in the
clinical features monitoring group, with a mean duration to second seizure of 12.1 and 11.6 days,
respectively. Subsequently, 72 women with a second seizure had a third seizure, 33 in the therapeutic
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FIGURE 3 Seizure diaries: total number of days with any seizures from randomisation to the end of follow-up by
allocation group, excluding women with no seizures. CFM, clinical features monitoring; TDM, therapeutic
drug monitoring.
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FIGURE 4 Survival graphs for time to first seizure and subsequent seizures. (a) Event 1; (b) event 2; (c) event 3; and
(d) event 4. CFM, clinical features monitoring; TDM, therapeutic drug monitoring; trt, treatment allocation.
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drug monitoring group (median 3 days, IQR 1–17 days) and 39 in the clinical features monitoring group
(median 3 days, IQR 1–13 days).
The analysis of overall time to first seizure and subsequent seizures showed a larger increase with
therapeutic drug monitoring than clinical features monitoring, but this was not significant (HR 1.3, 95% CI
0.7 to 2.6). Figure 5 shows the Kaplan–Meier curve of the multiple failure time analysis of time to first
seizure and subsequent seizures.
Assumption checks indicated violations of the proportional hazards assumption globally and for all
covariates. To investigate the source of the violations we performed the Cox regression model including
time-dependent effects for all covariates. Only maternal age showed a significant time-dependent effect,
which was subsequently included in the Cox regression. The resulting model showed no indication of
proportional hazards assumption violation for any covariates. Including the time-dependent effect resulted
in a minor change to the effect size and CI, with no changes to statistical significance (HR 1.4, 95% CI
0.73 to 2.6).
Additionally, we investigated treat–covariate interactions by estimating effects within subgroups of each
covariate. The subgroup effect sizes were mostly similar and are shown in Table 6. No statistically
significant effect modification was detected for any covariate.
These investigations supported the use of the Cox model for our analysis.
Proportional hazards assumption checks
For time to first seizure, and time to multiple seizures, we did not find any differences between the
subgroups based on seizure status 3 months before pregnancy, type of AED intake at baseline and the
type of seizure (see Table 6).
Sensitivity analysis
We undertook a sensitivity analysis by including only women with tonic–clonic seizures. For the analysis
of time to first tonic–clonic seizure, 257 women provided a total analysis time of 31,572 days from
randomisation to first seizure or censoring. Table 7 shows that the risk of time to first seizure was lower in
the therapeutic drug monitoring group than in the clinical features monitoring group, but this difference
was not statistically significant (HR 0.80, 95% CI 0.43 to 1.5). Figure 6 shows the results of the Cox
regression of time to first tonic–clonic seizure and the corresponding Kaplan-Meier curve.
Figure 7 shows the Kaplan–Meier curve of the multiple failure time analysis of time to first tonic–clonic
seizure and subsequent seizures.
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FIGURE 5 Survival graphs for time to first seizure and time to subsequent seizures after randomisation. Time to
(a) event 1; (b) event 2; (c) event 3; and (d) event 4. CFM, clinical features monitoring; TDM, therapeutic drug
monitoring; trt, treatment allocation.
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TABLE 6 Assumption check: primary analysis within subgroups of covariates
Covariate Subgroup n Subgroup TDM effect, HR (95% CI)
Seizures 3 months prior to pregnancy No 192 1.0 (0.35 to 2.8)
Yes 65 1.4 (0.68 to 2.8)
Baseline AED group LTG monotherapy 133 1.1 (0.41 to 3.0)
CBZ, PHT or LEV monotherapy 99 1.5 (0.56 to 4.1)
LTG polytherapy 25 1.3 (0.27 to 6.3)
Maternal age (years)a < 25 50 1.0 (0.35 to 2.9)
25 to < 35 166 1.8 (0.68 to 4.6)
≥ 35 41 1.1 (0.21 to 5.5)
Age at first seizure (years)a < 10 37 0.28 (0.07 to 1.1)
10 to < 20 138 1.9 (0.90 to 4.2)
≥ 20 82 3.3 (0.91 to 12.1)
Baseline broad seizure classification TCS 96 0.40 (0.11 to 1.4)
Non-TCS 154 1.4 (0.71 to 2.8)
Unspecified only 7 0.7 (NA)
CBZ, carbamazepine; LEV, levetiracetam; LTG, lamotrigine; NA, not available; PHT, phenytoin; TCS, tonic–clonic seizure;
TDM, therapeutic drug monitoring.
a Maternal age and age at first seizure were grouped into clinically meaningful categories for presenting subgroup effects.
However, tests for interaction were performed on the continuous covariate.
TABLE 7 Sensitivity analysis: first event for tonic–clonic seizure only
Model n
Analysis time (days),
mean (SD)
Proportion of women
with any seizures
TDM effect, HR (95% CI)TDM CFM TDM CFM
Time to first TCS 257 132 (63) 114 (65) 0.16 0.17 0.80 (0.43 to 1.50)
CFM, clinical features monitoring; TCS, tonic–clonic seizure; TDM, therapeutic drug monitoring.
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FIGURE 6 Survival graph for time to first event analysis on tonic–clonic seizure only. CFM, clinical features
monitoring; TDM, therapeutic drug monitoring.
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FIGURE 7 Survival graphs for time to first tonic–clonic seizure and time to subsequent tonic–clonic seizures. Time to
(a) event 1; (b) event 2; (c) event 3; and (d) event 4. CFM, clinical features monitoring; TCS, tonic–clonic seizure;
TDM, therapeutic drug monitoring; trt, treatment allocation.
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The analysis of time to first and subsequent tonic–clonic seizures showed a decrease with therapeutic drug
monitoring compared with clinical features monitoring, which was not significant (Table 8; HR 0.62, 95% CI
0.28 to 1.4).
Effects of monitoring strategies on maternal and fetal outcomes
Maternal outcomes
Pregnancy outcomes
There were no differences between the therapeutic drug monitoring or clinical features monitoring groups
in mean gestational age at delivery, pre-term birth rate, mode of delivery, rates of ante- or postpartum
haemorrhage or admission to a neonatal unit or rate of breastfeeding (Table 9).
TABLE 9 Effect of AED monitoring strategies on maternal outcomes
Maternal outcome
Randomised group, n (%) [N] TDM effect
TDM CFM OR (95% CI) MD (95% CI)
Maternal death 0 (0) [130] 0 (0) [133] –
Gestational age at delivery (weeks),
mean (SD) [n]
39.2 (2.1) [126] 39.1 (2.4) [130] 0.84 (–3.0 to 4.7)
Mode of delivery (effect of CS or
instrumental)
1.3 (0.78 to 2.1)
Pre-term delivery at < 37 weeks 8 (6) [127] 15 (12) [130] 0.50 (0.20 to 1.2)
Induction of labour 46 (37) [126] 39 (30) [130] 1.4 (0.79 to 2.3)
Pre-eclampsia 5 (4) [126] 4 (3) [130] 1.4 (0.36 to 5.7)
Gestational diabetes mellitus 9 (7) [126] 3 (2) [130] 3.2 (0.85 to 12.5)
Antepartum haemorrhage 2 (2) [127] 2 (2) [129] 1.1 (0.14 to 8.7)
Postpartum haemorrhage 19 (15) [127] 18 (14) [130] 1.1 (0.55 to 2.3)
Admission to HDU or ICU 5 (4) [127] 3 (2) [130] 1.8 (0.41 to 7.8)
Breastfeeding [127] [126] 0.82 (0.50 to 1.4)
Breast 75 (58) 69 (52)
Mixed 15 (12) 20 (15)
Bottle 36 (28) 38 (29)
CFM, clinical features monitoring; CS, caesarean section; HDU, high-dependency unit; ICU, intensive care unit; MD, mean
difference; OR, odds ratio; TDM, therapeutic drug monitoring.
TABLE 8 Sensitivity analysis: multiple failure times on tonic–clonic seizure only
Model n
Analysis time (days),
mean (SD)
Number of seizure days,
mean (SD)
TDM effect, HR (95% CI)TDM CFM TDM CFM
Multiple seizure rate 257 149 (50) 130 (55) 0.54 (1.9) 0.84 (3.2) 0.621 (0.28 to 1.4)
CFM, clinical features monitoring; TCS, tonic–clonic seizure; TDM, therapeutic drug monitoring.
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Maternal exposure to antiepileptic drugs and rates of seizures
One woman received phenytoin monotherapy and one woman received lamotrigine polytherapy with
carbamazepine. There were no differences between the therapeutic drug monitoring and clinical features
monitoring groups in the mean daily dose of AEDs prescribed (monotherapy or polytherapy) (Table 10).
Appendix 2 shows the effect of increasing the dose of AEDs in women taking monotherapy and
polytherapy, and found no significant effect on maternal pregnancy outcomes.
Fetal outcomes
There were no neonatal deaths in any of the randomised women and two stillbirths in the clinical features
monitoring group. The odds of major congenital malformations, small for gestational age fetuses and
admission to the neonatal unit did not differ between the two groups (Table 11). We did not observe any
differences in birthweight, head circumference, Apgar scores at 1 and 5 minutes, and cord arterial and venous
pH of infants born to mothers exposed to therapeutic drug monitoring or clinical features monitoring
strategies. The cord blood levels of the AEDs were available for babies born to women taking lamotrigine
(n= 131), carbamazepine (n= 26) and levetiracetam (n= 66). We observed a significant increase in the cord
blood levels of lamotrigine [mean difference (MD) 0.55 mg/l, 95% CI 0.11 to 1.0mg/l) and levetiracetam (MD
7.8mg/l, 95% CI 0.86 to 14.8 mg/l) in infants born to mothers managed in the therapeutic drug monitoring
group compared with in the clinical features monitoring group. There were no differences in cord blood levels
of carbamazepine (MD –0.47 mg/l, 95% CI 1.5 to 0.60 mg/l) between the two groups. We quantify the effect
of an increase in AED dose on fetal outcomes in Appendix 3. An increase in exposure to AED dose by 1 mg
significantly increased the cord blood levels of lamotrigine, by 0.007 mg/l (see Appendix 3), levetiracetam, by
0.008mg/l, and carbamazepine, by 0.003 mg/l, in women on AED monotherapy. The cord blood levels of
lamotrigine and levetiracetam were increased by 0.009 and 0.008mg/l, respectively, for every 1-mg increase
in dose of AED in women on polytherapy. The cord blood venous pH was significantly reduced by –0.0002
per 1-unit increase in dose of carbamazepine, but there were no effects on other fetal outcomes with
increasing doses of AED (see Appendix 3).
Maternal quality of life
Table 12 compares the QoL measurements in mothers exposed to the two AED monitoring strategies.
There were no differences in the EQ-5D postnatal scores between the two groups (MD 0.002, 95% CI
–0.05 to 0.05). The scores for the QOLIE-31 and the overall health score were similar in both groups
(see Table 12).
Effect of a reduction in serum antiepileptic drug levels on maternal seizures
Table 13 compares the seizure status between women in the non-randomised group with stable serum
AED levels and women in the clinical features monitoring and therapeutic drug monitoring groups with a
decrease in serum AED levels of > 25%. There were no significant differences between the groups in
seizure status, which was adjusted for baseline seizures in the 3 months prior to pregnancy.
TABLE 10 Differences in dose of AED exposure between the therapeutic drug monitoring and clinical features
monitoring strategies
AED
Daily AED exposure (mg), mean (SD) [n]
TDM effect, mean difference
(95% CI)TDM CFM
CBZ only 616.7 (355.8) [16] 695.0 (336.4) [20] –12.1 (–226.7 to 202.4)
LTG only 290.9 (137.5) [68] 252.6 (148.0) [70] 32.3 (–14.4 to 79.0)
LEV only 1735.6 (701.9) [31] 1628.5 (926.5) [31] 166.5 (–229.8 to 562.7)
LTG and LEV LTG: 487.5 (206.7);
LEV: 1920.1 (858.9) [11]
LTG: 413.8 (91.1);
LEV: 2122.2 (1077.5) [14]
LTG: 97.4 (–28.7 to 223.4);
LEV: –137.3 (–945.9 to 671.4)
CBZ, carbamazepine; CFM, clinical features monitoring; LEV, levetiracetam; LTG, lamotrigine; TDM, therapeutic
drug monitoring.
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TABLE 11 Effect of AED monitoring strategies on fetal outcomes
Fetal outcomes
Randomised group, n (%) [N] TDM effect
TDM CFM OR (95% CI) MD (95% CI)
Stillbirths 0 (0) [125] 2 (2) [134] – –
Neonatal deaths 0 (0) [126] 0 (0) [134] –
Major congenital malformations 7.0 (6) [125] 10.0 (8) [134] 0.66 (0.23 to 1.8)
Admission to neonatal unit 16.0 (13) [125] 18.0 (13) [134] 1.6 (0.29 to 9.5)
Apgar score at 1 minute, mean
(SD) [n]
8.5 (1.4) [123] 8.5 (1.5) [127] – –0.11 (–0.47 to 0.25)
Apgar score at 5 minutes, mean
(SD) [n]
9.4 (0.87) [124] 9.3 (0.84) [128] – 0.03 (–0.18 to 0.23)
Birthweight (kg), mean (SD) [n] 3.3 (0.60) [124] 3.3 (0.68) [134] – 0.02 (–0.13 to 0.17)
Small for gestational age fetus
(birthweight < 10th centile)
13.0 (11) [124] 22 (16) [134] 0.43 (0.08 to 2.3)
Head circumference (cm), mean
(SD) [n]
34.2 (1.8) [104] 34.2 (1.7) [108] –0.16 (–0.60 to 0.27)
Cord arterial pH, mean (SD) [n] 7.3 (0.09) [55] 7.2 (0.07) [46] 0.01 (–0.02 to 0.04)
Cord venous pH, mean (SD) [n] 7.3 (0.08) [59] 7.3 (0.07) [54] 0.001 (–0.030 to 0.031)
Cord blood levels CBZ (mg/l),
mean (SD) [n]
3.3 (1.5) [13] 4.3 (1.3) [13] –0.47 (–1.5 to 0.6)
Cord blood levels LTG (mg/l),
mean (SD) [n]
2.5 (1.6) [63] 1.9 (1.3) [68] 0.55 (0.11 to 1.0)
Cord blood levels LEV (mg/l),
mean (SD) [n]
22.5 (17.0) [30] 13.9 (10.5) [36] 7.8 (0.86 to 14.8)
CBZ, carbamazepine; CFM, clinical features monitoring; LEV, levetiracetam; LTG, lamotrigine; MD, mean difference;
OR, odds ratio; TDM, therapeutic drug monitoring.
TABLE 12 Effects of therapeutic drug monitoring and clinical features monitoring strategies on maternal QoL
Outcome
Randomised group, mean (SD) [n]
MDa (95% CI)TDM CFM
EQ-5D score 0.90 (0.20) [99] 0.90 (0.18) [102] 0.00 (–0.05 to 0.05)
QOLIE-31 score (UK) 71.0 (16.0) [114] 73.7 (13.5) [110] –2.5 (–5.1 to 0.0)
QOLIE-31 overall health (UK) 6.9 (1.8) [115] 7.3 (1.6) [110] –0.35 (–0.72 to 0.02)
CFM, clinical features monitoring; TDM, therapeutic drug monitoring.
a Models are adjusted for baseline values in addition to adjustment factors included in all models.
TABLE 13 Seizure status by end of follow-up compared with baseline
Group N
Seizure status at end of
follow-up, n (%)
OR (95% CI)No seizures Any seizures
Non-randomised cohort (decrease in serum AED
level never exceeding 25%)
263 140 (53) 123 (47) Reference group
CFM (decrease in serum AED level exceeding 25%) 130 71 (55) 59 (45) 0.93 (0.56 to 1.5)
TDM (decrease in serum AED level exceeding 25%) 132 74 (56) 58 (44) 0.93 (0.56 to 1.5)
CFM, clinical features monitoring; OR, odds ratio; TDM, therapeutic drug monitoring.
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Table 14 shows that there were no differences in the average number of seizures per week and the
average number of days with seizures per week, analysed using Poisson models. We removed an extreme
outlier who had an average of 256 seizures per week.
Serious adverse outcomes
Sixty-one women experienced one or more serious adverse outcomes between the time of consent and
6 weeks postnatally (Table 15).
The most frequent serious adverse event was admission to hospital for seizures, which contributed to 37%
of serious adverse events in the therapeutic drug monitoring group, 40% of the serious adverse events
in the non-randomised group and almost half of the serious adverse events in the clinical features
monitoring group.
Other maternal adverse outcomes made up approximately one-quarter of serious adverse outcomes in
each group. Similarly, congenital malformation contributed almost one-quarter to each group, although
this was less frequent in the clinical features monitoring group at 18%.
The distribution of serious adverse events did not considerably differ between each group. No serious
adverse events were related to the trial.
TABLE 15 Serious adverse outcomes
SAE description
Trial group, n (%)
Randomised group
Non-randomised (N= 25)TDM (N= 19) CFM (N= 17)
Admission to HDU/ICU 1 (5) 2 (12) 2 (8)
Admission to hospital for seizures 7 (37) 8 (47) 10 (40)
Admission to neonatal unit 1 (5) 0 (0) 0 (0)
Congenital malformation 5 (26) 3 (18) 6 (24)
Miscarriage 0 (0) 0 (0) 1 (4)
Other fetal adverse outcomea 1 (5) 1 (6) 1 (4)
Other maternal adverse outcomeb 5 (26) 4 (24) 6 (24)
CFM, clinical features monitoring; HDU, high-dependency unit; ITU, intensive care unit; SAE, serious adverse event;
TDM, therapeutic drug monitoring.
a Suspected fetal anaemia, spontaneous pneumothorax or infection.
b Postoperative wound infection, suspected cholestasis, bipolar condition, postpartum haemorrhage per vaginal bleed,
ankle/fibula injury, intrauterine growth restriction, twins, urinary tract and chest infection, antepartum haemorrhage,
minor road traffic accident, slurred speech/facial weakness, stress/psychological evaluation, pulmonary embolism, post
epidural head, back, neck and perineal pain, recurrent perianal Crohn’s disease, cervical suture or high blood pressure.
Note
Percentages do not add up to 100 as some women may contribute to more than one SAE category.
No SAE was related to the trial.
TABLE 14 Comparison of average seizure frequency between clinical features monitoring and non-randomised
participants
Outcome n
Group, median (IQR) Effect of non-randomised
cohort, incident rate ratio
(95% CI)CFM Non-randomised
Seizure rate per week 392 0 (0–0.26) 0 (0–0.26) 1.0 (0.84 to 1.4)
Days with seizures per week 393 0 (0–0.23) 0 (0–0.19) 0.88 (0.62 to 1.2)
CFM, clinical features monitoring.
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Chapter 4 Qualitative study
Introduction
Women with epilepsy who become pregnant possess an expertise on which to base their expectations of
pregnancy and childbirth. Their experience of living with epilepsy influences the ways in which they make
sense of their pregnancy, as well as their views on the management of the condition. Thus, women’s
position as ‘expert patients’ enables them to balance the risks and benefits to themselves and their baby of
AEDs within the context of their lives. This chapter reports on the qualitative study undertaken to capture
this expertise and to explore in some depth women’s lived experiences and perspectives of pregnancy
while managing their epilepsy. Qualitative data provide an additional dimension to quantitative results,
allowing participants to focus on the issues of importance to them and to explain how they make sense of
events within the context of their everyday lives. The growth of qualitative studies within a quantitative
randomised controlled trial (RCT) framework is important, especially in trials, such as AntiEpileptic drug
Monitoring in PREgnancy (EMPiRE), which are conducted within sensitive settings of maternal and fetal
medicine, in which participants may be considered ‘vulnerable’.23 The purpose of this qualitative study is to
understand women’s lived experiences and perspectives on managing their epilepsy during pregnancy
through interviews with both women who choose to accept participation in the RCT as well as those
who declined.
Background
To date, research on epilepsy and pregnancy has been largely investigated using quantitative methods, and
this is reflected in evidence-based reviews covering the area.24,25 Expert reviews26,27 and guidelines28 on the
management of epilepsy in pregnancy focus on aspects of care important to health professionals. However,
there is a stark absence of research concerning the priorities and perspectives of patients themselves.
A review of qualitative literature29 in this area was conducted in 2013 and found only one study30 that
directly investigated women’s experiences of epilepsy during pregnancy. This ‘exploratory qualitative’ study,
carried out by Thompson et al.,30 investigated the experiences of women living with epilepsy of health-care
services at key phases of reproduction, including contraception, pre-conceptual care, pregnancy, birth and
breastfeeding, and parenting and child safety. Women reported mixed experiences of health care during
these stages: some felt that they had received good care, but others were given inadequate information and
offered advice from practitioners only after an event, and, thus, they could not take appropriate preventative
action. Thompson et al.30 argue that the management of a chronic illness and reproductive health involves
work of a ‘moral dimension’. For example, in relation to their pregnancy, the concern with the effects of
AEDs on their unborn babies created a conflict for women between being a ‘good mother’ and being a
‘good patient’. Thompson et al.’s study30 provides a much needed contribution to understandings of how
epilepsy influences women’s experiences of the various stages of pregnancy and reproduction. However, as
it is an exploratory study with a small sample size of 15 women, findings remain limited in scope.
The 2013 literature review29 included studies exploring not only women’s experiences of pregnancy,
but also their experiences of reproductive health while managing epilepsy. This expansion of the review
resulted in 16 additional publications, which were limited in their generalisability because of the small
sample sizes and/or poor quality of data. Since the publication of this review, one additional study has
been published in this area: Qiang et al.’s 201631 small qualitative study on the support networks of
12 pregnant women living with epilepsy. There is, therefore, a dearth of high-quality research on the
experiences of pregnant women living with epilepsy.
Study aim
To investigate the perspectives and experiences of pregnant women living with, and managing, epilepsy.
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Objectives
To gain insight into the way pregnant women with epilepsy rationalise and make sense of the
management of AEDs in the context of their lives by addressing the following research questions:
l How do women experience living with epilepsy before becoming pregnant?
l What do women perceive as issues of concern for them and their baby in terms of epilepsy
management during pregnancy and childbirth?
l How do women construct and make sense of the risks, and benefits, for themselves and for their baby
in terms of medication?
l How do women perceive maternal responsibility in the context of having epilepsy?
l What and who influences women’s decision-making in the management of their condition
during pregnancy?
l How do women view their experience of pregnancy and childbirth and the management of their
medication during this time?
Methodology
The above research questions were explored empirically through semistructured interviews using participant
narratives.32 This approach allowed research participants some control in the research agenda as they could
focus on issues that were of concern to them and elaborate in order to provide context and rationales for
the ways in which they make sense of managing their epilepsy over the course of a pregnancy. Reporting
was undertaken in line with recommended guidelines.33
Sample
Theoretical sampling was employed to purposely include women from different geographical regions, with
a diversity of sociocultural backgrounds, and who had varied histories with epilepsy and had experienced a
range of neurological symptoms. A total of 32 women participated in interviews, of whom 21 had enrolled
in the RCT and 11 had declined the trial but agreed to take part in the qualitative study. Recruitment
and sampling continued until data saturation was reached and no further analytical categories emerged
from ongoing analysis of interview data.34 Saturation was determined independently by the EMPiRE trial
qualitative lead, Elaine Denny, and research fellow, Annalise Weckesser. Women were first approached
face to face by research nurses and midwives and given informed consent forms for the qualitative study.
Annalise Weckesser then telephoned women who had agreed to take part in the qualitative study and
who had signed informed consent forms.
Method
The aim of this research was to gain insight into the way women make sense of living with epilepsy
during pregnancy and, thus, a qualitative approach was appropriate. All women were requested to take
part in two or three interviews, which were audio-recorded with their permission and transcribed verbatim.
Annalise Weckesser or Elaine Denny interviewed the women twice. Annalise Weckesser and Elaine Denny
are both women with experience conducting qualitative research. The interviewers did not establish
relationships with participants prior to the commencement of the study. Participants knew that Annalise
Weckesser and Elaine Denny were non-clinical members of the EMPiRE trial research team, and that both
have research interests in gender, reproductive health and chronic illness.
The first interviews took place when women were pregnant and had either entered the trial or refused to
enter the trial. The second interviews took place approximately 6 weeks after participants had given birth.
First interviews lasted approximately 1 hour and second interviews lasted approximately half an hour.
Eight women did not participate in follow-up postnatal interviews: one returned to her country of origin,
two withdrew from the RCT and five were unable to be contacted.
QUALITATIVE STUDY
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Interviews were conducted at places and times convenient to participants. The majority of women were
interviewed in their own homes; however, some preferred to be interviewed at hospitals after their
antenatal clinic appointments and some interviews took place over the telephone. Most women were
interviewed on their own; however, some women asked for their partner (n = 4) or mother (n = 2) to be
present to help them remember details of their seizures and medication. Most postnatal interviews were
conducted over the telephone as this was most convenient for women with the time constraints of caring
for their newborn. In appreciation for their time and participation, women were given a £20 gift voucher
following completion of their first interview.
First interviews took place on the women’s entry to or refusal of the randomised trial, and these interviews
focused on the six research questions (see Objectives). Additional interviews were originally proposed with
women in the qualitative study who had experienced a reduction in serum AED level or who experienced a
seizure during pregnancy to explore if these events altered patients’ perspectives on epilepsy and pregnancy
and raised new concerns. However, this was not possible as research nurses and midwives did not inform
Annalise Weckesser and Elaine Denny when a patient had a seizure during pregnancy. However, in
postnatal interviews, Annalise Weckesser and Elaine Denny learned that some participants did have seizures
during their pregnancy and we were able to capture these experiences retrospectively. Postnatal interviews
concentrated on women’s reflections on the research questions on the presumption that pregnancy
experiences can only be fully reflected on once the outcome of the pregnancy is known. Short field notes
were taken immediately after the first and second interviews to make note of, and describe, where
interviews took place.
Elaine Denny and Annalise Weckesser developed interview guides to ensure data collection on relevant
topics (see Appendix 4), but participants were also free to raise issues of importance to them. The
interview guide was developed based on themes identified in a review of qualitative literature on the
experiences of pregnancy and reproductive health of women living with epilepsy, which was published by
Elaine Denny and Annalise Weckesser in 2013.29 Basic demographic data including current age, parity and
years living with epilepsy were collected from participants at the beginning of the first interview.
Ethical considerations
As epilepsy is considered to be a stigmatising condition,35 the researchers avoided stereotyping and
discriminatory use of language. Each woman’s guidance was sought at the beginning of interviews
concerning acceptable use of terminology. The researchers complied with the British Sociological
Association’s statement of ethical practice.36 Pseudonyms have been used to protect the anonymity
of participants.
Analysis
A narrative analysis was adopted as this method has much to contribute to studies of chronic illness.
As Riessman notes, ‘[t]elling narratives is a major way that individuals make sense of disruptive events [such
as illness] in their lives’.37 Within this narrative mode of analysis, a thematic approach was undertaken –
a method that allowed for the identification of common themes across cases while enabling individual
women’s stories to remain intact.38 To ensure rigour in the analysis process and to establish trustworthiness
in the findings, Elaine Denny, Annalise Weckesser and a member of the EMPiRE trial team read all interview
transcriptions. Annalise Weckesser took the lead in developing the analysis to increase internal consistency,
but all members agreed on coding frames and analytical themes for internal validity. Annalise Weckesser
created a coding frame for categorisation of data using NVivo 10 (QSR International, Warrington, UK).
Analytical themes and concepts were developed and explored using the constant comparison method.39
An additional strand of narrative analysis was also conducted, allowing for the integrity of each woman’s
interview to be maintained.38 This analysis of narratives allowed for an understanding of the inter-
relatedness of a person’s life story that can be lost and fragmented in the constant comparison method.38
These two methods of analysis provided insights into how women experience pregnancy and epilepsy, and
how they make sense of these events within the context of their lives.
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Findings
Sample results
Participants came from urban areas, including London, Birmingham, Cardiff and Liverpool, as well as
more rural areas such as Shrewsbury, Gwent and Worcestershire. Table 16 provides the sociodemographic
details of participating women. At the time women were first interviewed, over half were becoming
mothers for the first time (n = 18) and the rest had at least one child. The youngest participant was aged
TABLE 16 Sociodemographic background of the study sample (N = 32)
Demographic Number of participants
Age (years)
Range 19–42
Mean 31
Marital status
Married 18
Cohabiting 10
Non-cohabiting/with partner 2
Single 2
Parity
Primigravida 18
Gravida 2, parity 1 10
Gravida 3, parity 2 4
Employment
Professional 17
Retail 2
Student 1
Unemployed/full-time mother 12
Ethnicity
White British 21
British Asian 4
White European 1
White American 1
Black African 1
Chinese 1
British black Caribbean 1
Years with epilepsy
Range 1–29
Mean 11.2
Types of seizuresa
One-off seizure 1
Absence seizures 9
Myoclonic 9
TCS (self-defined) 17
TCS, tonic–clonic seizure.
a Some women report more than one type.
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19 years and the oldest was aged 42 years (mean age 31 years). More than half of participants were
married (n = 18) and others lived with partners (n = 10), lived separate from partners (n = 2) or were single
(n = 2). Women worked in professional occupations (n = 17) and in retail (n = 2), or were unemployed
and/or full-time mothers (n = 12); one was a full-time student. The majority of participants had been born
in the UK and self-identified as white British (n = 21); others identified as British Asian (n = 4) and British
black Caribbean (n = 1). A number of women had immigrated to the UK, including three participants who
identified as white European and one each as Chinese, black African and white American. One NHS
Mandarin interpreter was required to provide an interview translation.
Participants had varied histories with epilepsy. One mother was diagnosed only within the past year and,
at the other end of the spectrum, a participant had lived with the condition for 29 years. On average,
women had lived with their condition for 11 years. Women also experienced a wide range of neurological
symptoms. Participants self-identified their seizure types, ranging from tonic–clonic seizures (which
constitute the more popular images of epileptic convulsive seizures with a person losing consciousness,
their muscles stiffening and jerking), myoclonic seizures (involving the brief, shock-like jerking of muscles)
and absence seizures (which are absences in awareness and women often described these experiences like
‘déjà vu’ or an ‘aura’). Some women experienced more than one type of seizure at different stages in their
life, and the frequency of seizures also differed between women and among individual women over time.
Interview findings
The following findings are based on ante- and postnatal interviews. For the purposes of this chapter,
findings are presented thematically rather than as narrative case studies to facilitate the reporting of
findings related to the qualitative study’s research objectives of understanding:
l women’s experiences of living with epilepsy before becoming pregnant
l women’s concerns in relation to epilepsy management in pregnancy
l women’s strategies for balancing risks and benefits to themselves and their babies in relation to medication
l women’s perceptions of maternal responsibility in the context of having epilepsy
l the influences on women’s decision-making in the management of epilepsy and pregnancy
l women’s postnatal reflections on the experience of pregnancy and childbirth, and the management
of epilepsy
l women’s reasons for declining trial participation (for participants who declined participation in the
randomised trial).
Although reporting findings through this separation of strands of experiences brings clarity, it must be
noted that it creates a false distinction; in reality, people’s experiences, feelings and actions are interlinked
and, thus, cannot be easily reduced to simple, segregated categories.
Experiences of living with epilepsy before becoming pregnant
Women’s histories of living with epilepsy before becoming pregnant are highly diverse. This diversity is
reflected in the spectrum of seizure types and frequencies experienced by participants, and the number of
years they have lived with the condition (see Table 16). Although some women had been diagnosed in
childhood, others did not receive a diagnosis until more recently and/or after a first pregnancy.
With regard to how the management of their condition impacted on day-to-day life, women’s responses
ranged and were shaped by this diversity of seizure types and frequencies. For some, the fear of having a
seizure was a daily occurrence:
[I] feel quite nervous and self-conscious all the time because I don’t know when I’m going to have my
next seizure.
Cecilia
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For some, epilepsy impacted on their work and chosen career paths. For example, one participant reported
losing her job in a factory after her diagnosis as she was not allowed to work near the machinery in case
she should have a seizure. Another participant had been training as a beautician but was told she could
not continue with the course after disclosing her diagnosis, as she would not be allowed to use some of
the electrolysis machines.
The majority of participants, however, reported that on a day-to-day basis their condition did not impact on
them greatly. Some made modifications to their lifestyle (ensuring that they get enough sleep, refraining
from excessive alcohol consumption, not bathing alone, etc.) but saw these as minor adjustments. Riva is
one such woman; despite these adjustments, she states that she leads a ‘normal life’:
[Prior to becoming pregnant] I could get up every day, I would have my medication, I could go to work
and have a normal life and go back home. And you know, it wasn’t something that would impact me
greatly . . . I had a gap of several years between my seizures. So for me the seizures, like it didn’t feel
like it had a particularly detrimental impact on my life.
Other participants had such infrequent seizures, some having ever experienced only one seizure, that they
reported not feeling they had ‘real epilepsy’ and that they were ‘lucky’ as they believed they faced less
hardship and stigma than those with less controlled and more ‘severe’ seizures.
In addition to the diversity of epilepsy experiences, some participants faced additional pregnancy and/or
concurrent health concerns that took primacy over their epilepsy. Some women reported fertility issues,
challenges having a baby in their forties, undergoing in vitro fertilisation treatments and/or having past
experiences of miscarriage. Becoming pregnant was reported, by some, to be more of a challenge and
concern than managing their epilepsy:
I thought, ‘OK, I just need to manage my medication and then I’ll get pregnant’ . . . I think more than
anything to do with my medication that was the biggest shock for me, that actually it isn’t that easy to
get pregnant. Like it’s easy to manage what dosage you take and to keep tabs on what you’re taking,
making sure you go and see the specialist and [your epilepsy is] managed. But I think the biggest
shock to me was just the process of actually getting pregnant in the first place.
Sonia
Other participants reported additional health concerns that impacted on their day-to-day life, including
Tourette syndrome, congenital talipes equinovarus, overactive thyroid and high blood pressure, as well as
other related health issues that arose during pregnancy, such as pre-eclampsia and gestational diabetes.
One participant felt that managing her Tourette’s affected her more than her epilepsy:
The epilepsy I don’t notice, because if I have a fit, it’s always at night time. So I’ve never had one in
the day, I’ve always been fine. Because in the day, I kind of control the Tourette’s.
Tanya
Women’s experiences of epilepsy were also influenced by their different sociocultural and religious
backgrounds. One participant believed that her epilepsy had been caused by a curse and attended
evangelical faith healing sessions. Another participant, Amina (aged 31 years), after being diagnosed
with the condition reported becoming a more ‘devout’ practising Muslim, signified by adopting a hijab.
Amina believes that her faith helps her manage her condition; however, she continues to take her AEDs:
I’ve got my religion, but I’ve also got the doctors. This medication’s there for a reason. It’s helped me
not have a seizure all this time so I’ll just continue.
Women’s experiences of living with epilepsy prior to becoming pregnant are highly diverse and are shaped
by their particular seizure type(s) and history, whether or not they have additional health and fertility
concerns and their sociocultural backgrounds.
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Concerns in relation to epilepsy management and pregnancy
As discussed in the previous section, for many participants the everyday management of epilepsy prior to
becoming pregnant had become routine and normalised. However, pregnancy often becomes a stage at
which women have to reflect on their condition and how it impacts on their health and that of their baby.
This is illustrated by the case of Philomena (aged 31 years), who states that before becoming pregnant she
‘wasn’t thinking about [her epilepsy] from one day to the next . . .’. After first being diagnosed, she initially
took on ‘all the good habits’. She continues:
I never used to drink . . . [I] only took a bath when people were there. So you kind of start with really
good practices . . . [A]nd then as the years go by you just stop thinking about it completely and you
just take your tablets every night and you’re fine . . . But then as soon as you became pregnant
you need to get back into good habits . . . [W]hen you have the baby you need to change [them]
on the floor, you shouldn’t do this, you shouldn’t do that, and you were just a bit like, ‘Oh yeah,
I completely forgot!’.
Thus, pregnancy is a time that raises many concerns for women living with epilepsy, concerns about things
that some may have previously taken for granted.
Participants reported that their primary concern was to give birth to a healthy baby, with no abnormalities:
I think really you worry about everything, you could worry about anything, but I think the main thing
is I just want to have a happy and healthy baby at the end of it.
Simone
At the moment I get concerned about whether [the baby’s] going to be normal or not. Otherwise,
I haven’t got any concerns.
Mary
The first question I’m asked is, ‘Do you want a girl or a boy?’. And I just say, ‘I want a normal baby’.
A healthy, normal baby . . . I don’t care whether it’s a girl or a boy . . . I hope it’s a healthy, fat baby.
Samina
Women also expressed concerns about the effects of their AEDs on their unborn babies. Although
participants often reported feeling some reassurance from health practitioners who advised them that the
medication they were on were newer AEDs believed to be safer during pregnancy, some still had concerns
about possible teratogenic effects, including spina bifida and learning disabilities. This is illustrated in the
following extract:
The doctors are like ‘Oh this is a great drug, it’s much better than the one you were on before’.
And I’m thinking, ‘Yes, but the one I was on before it’s been around 20, 30 years’. So you know
that there’s defects, but you know at what levels those defects occur and how likely it is to happen.
Whereas you put me on this new medication, which actually has been around maybe 4 or 5 years so
you have a little bit of experience . . . Even though [the doctors’] experience and knowledge is quite
valid, but at the same time they don’t have to live with the consequences of it.
Riva
Some women were concerned that they could pass their condition on to their babies, despite the
knowledge that genetic inheritance of epilepsy is very rare:
The other thing that you worry about is sometimes it’s like I hope [epilepsy’s] not something I can pass
on to my baby because I really wouldn’t want that . . . Even though they say it’s not inherited you just
don’t know because they say some forms can be.
Fatimah
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Women also expressed concerns about having a seizure during their pregnancy, labour and/or in the early
postnatal period. During pregnancy, women were especially concerned about having a seizure in their final
trimester, when the baby is seen to be more ‘fully formed’. As Li Min stated:
[I’m] worried that [I’m] going to have a seizure towards the end, when the baby’s like mature . . .
[I’m] really scared that it’s going to happen and it’s going to affect the baby and me as well.
Participants worried that a seizure could cause a decrease in the amount of oxygen that gets to the fetus.
Tiredness and stress during pregnancy and from the strains of giving birth were also seen as possible
seizure triggers. For example, one participant, Laura, feared that she was more likely to have a seizure in
her current pregnancy than in her former, as she was now experiencing more sleeplessness as a result of
taking care of her firstborn, who was still a baby:
I think I’m probably more concerned this time round because I have it in the back of my mind that I’ll
probably have more seizures during this pregnancy because of having [my son] and the sort of stress
of looking after him really, as well as the tiredness . . . [T]he end of the day comes and you think
‘I don’t think I’ve even brushed my teeth today to start off with’ . . . So I’m more concerned that I’m
going to be more tired, which will lead to me having more seizures, which will lead to me being
more tired.
Finally, women were very concerned about having a seizure because this could result in losing driving
privileges until they have been seizure free for 1 year:
The main hope is not to have any déjà vu. Because even the slightest déjà vu I need to inform
[my medical team] . . . So that is a worry, but mainly for the selfish reasons of driving.
Laura
[If I have a seizure] then I wouldn’t be able to drive, which I think would be a massive issue . . .
[T]hat would make everything like a million per cent more difficult.
Philomena
Women in rural areas with little public transport and those who required a vehicle for work were especially
concerned about the isolation and inconveniences caused by losing their driver’s licence in the event of
a seizure.
Strategies for balancing risks and benefits to themselves and their babies in relation
to medication
Many of the participants reported thinking about whether or not they should have children in view of
having epilepsy. Most women had planned their pregnancies (n = 22) and two women had been advised
against having children because of their condition (one by a doctor and one by their partner). Philomena
reflects on her decision to have a baby, stating:
You think about what effects the drugs have on the baby, what if I had a fit . . . There are all of those
considerations, but for me none of them outweighs actually having a baby.
In relation to taking AEDs, women made their medication management decisions by weighing up the risks
to the health of their baby, their own health and other aspects of their life. Some women felt it was
particularly important to keep taking their medication during their pregnancy to minimise the risk
of seizures:
I can’t help but think I’m so scared that I’ll have a seizure and somehow or another I will end up
hurting either the baby or myself . . . And I think your priorities completely change, you do want to do
what is best for your baby, but at the same time if you’re harming yourself you can’t be doing what’s
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right for your baby. If I fall and if I have a seizure, then I’m risking both anyway. I think you’ve just got
to look at it practically.
Fatimah
The risk of me being on the medication is minimal [to the baby] . . . But the risk of me falling down a
flight of stairs could kill her really.
Shelly
Thus, although participants saw continuing their AEDs during pregnancy as potentially harmful to the
health of their babies, such risks had to be balanced with what some saw as a more likely and harmful risk
of having a seizure that could occur if they stopped or reduced their medication. Some women did choose
to stop or reduce their medication in the first trimester because of the perception that the fetus was at
heightened risk of malformations at this time:
When I found out I was pregnant with [my first child], I did stop taking [the medication] ‘til after my
3-month scan, and I did do this time as well for the current pregnancy . . . I went to the [clinic] at
about 10 weeks’ pregnant and [the epilepsy nurse] said, ‘Have you had any seizures?’. I said, ‘No’. She
said, ‘You know you’re more susceptible, etc., etc.?’. And I said, ‘Yes’. And she said, ‘Well I’m going
to leave you to it’. And then 10 days later I had a bout of seizures, so that just brought me up to my
12-week scan, so I’m back on my medication now, properly.
Laura
Women’s decisions about taking medication in pregnancy to prevent seizures had to be balanced with
other aspects of their lives, such as the need to keep their driving licence. One participant, Sandra, had a
seizure during her first pregnancy, and during her second pregnancy she stated:
[The seizure] cost me my driving licence. I was a community midwife [in a rural area] . . . It was the
most depressing time without a driving licence. I didn’t really know how much it meant to me, and it
put me off getting pregnant again because the thought of losing my driving licence again, it was too
much of a risk.
Sandra
Sandra believed she had the seizure because her epilepsy specialist midwife had failed to increase her
AED dosage during the first pregnancy. She reported that for this current pregnancy her epilepsy
specialist midwife had agreed to increase her medication, but if the midwife had not, Sandra would have
self-managed her medication and increased her dosage to prevent a seizure.
Perceptions of maternal responsibility in the context of having epilepsy
Although women’s decisions ranged from stopping, reducing, maintaining and increasing their AEDs over
the course of their pregnancies, overwhelmingly the rationale for such decisions was based on a feeling of
maternal responsibility towards their babies. This is illustrated in the following two contrasting extracts,
one from a woman discussing her decision not to take her AEDs in the first trimester, and one woman on
why she continues to take her medication during her pregnancy:
If I took the tablets all the time and something happened and [the baby] comes out deformed in some
way or had something wrong with it, then I would think that I’ve been a selfish person and feel
terrible for doing that when I know I can cope for so long without them.
Mary, on not taking AEDs
[T]here is the odd night I’ll get into bed and every night [think] ’have you taken your tablets? Yes’.
But I will remember if I lay there long enough. I’m like, ‘Oh, I didn’t take them’. But it’s not just me I’m
thinking about now. So yes, it is a little bit more important. Because I’m not just taking them for me.
Veronica, on taking AEDs
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Both women made decisions regarding their medication based on feelings of maternal responsibilities
towards their unborn children. The types of seizures that the women experienced also informed their
choices. Prior to having full tonic–clonic seizures, Mary would often experience symptoms including auras.
Thus, if she had any of these early warning signs she would take her medication. In contrast, Veronica did
not have such warning symptoms prior to having a seizure.
Women continuing or increasing their medication to prevent seizures in pregnancy still had concerns about
the chance AEDs could affect their baby’s health. These concerns derived from their role as mothers and
carers, now looking after the health of their unborn child as well their own. Clara stated, regarding the
possible teratogenic effects, that:
[C]hances are very, very low, but then there’s always still that chance. And it’s not just you that you’re
talking about any more, it’s an extra person, which took me by surprise at how differently I probably
feel about that because, you’re like, it’s not just me any more, it’s another little person.
Participants’ feelings of maternal responsibility were also evident in the form of guilt associated with the
possibility of having a baby born with health problems, as illustrated in the following extract:
I worried a lot that if there were problems with the baby that it would be my fault. It wouldn’t
necessarily be my fault, but it kind of is if you know what I mean. I worried that the drugs that I took
. . . I did have quite sleepless nights thinking, ‘Oh God, what if something happens to the baby and
they’re born with defects that I’m going to have to explain to it’. That worries me.
Nicole
Influences on decision-making in the management of epilepsy and pregnancy
Women had a range of influences on their decision-making in the management of epilepsy and
pregnancy. In relation to their medication, many made decisions regarding their dosage in consultation
with their neurologist, epilepsy nurse or epilepsy midwife, but were also informed by knowledge of their
own body, history with the condition and seizure warning symptoms. Women’s decisions, as discussed in
Perceptions of maternal responsibility in the context of having epilepsy, were also shaped by considerations
for the well-being of their baby. Many participants had partners and key family members (such as mothers)
who provided them with care and support in the management of their condition. However, partners and
family members did not play key roles in influencing women’s AED management choices. As Fiona replied,
in relation to her medication, ‘At the end of the day I make the decisions for what I want and what’s best
for me and the child’.
Some women reported using the internet to research the teratogenic effects of the particular AEDs they
took, but viewed such information as supplementary to the professional advice of their medical team.
Postnatal reflections on the experience of pregnancy and childbirth, and the
management of epilepsy
Women’s perspectives on pregnancy and managing epilepsy were shaped by labour and pregnancy
outcomes. The majority of women reported giving birth to babies who, from birth to the point of the
postnatal interview, did not have any apparent health problems linked to taking AEDs. For such women,
their views on having a pregnancy while managing epilepsy were largely positive. This is reflected by
Jeannette, who stated, 6 weeks after giving birth to a healthy baby:
I just don’t think if a woman has epilepsy [that she] should be scared to have a baby because [she]
could be like me, everything is fine, no worries at all. So I wouldn’t even worry about thinking,
‘Oh I can’t have a baby because I’ve got epilepsy’. Because it’s twaddle really.
One participant reported early health problems with her baby that she was concerned could be linked to
AEDs. Amy had a son ‘born with shaky arms and legs’ and some possible visual impairment. She stated
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that ‘[At] first, I thought, “Oh was that to do with the medication?” Could that have had an influence
because I take these tablets?’. She consulted paediatricians who attributed these complications to an
‘immature neurological system’ and assured her that her son would ‘grow out’ of the ‘shakes’. Amy stated
that she now felt ‘pretty reassured’ as the doctors did not believe the medication caused her son’s health
impairments and because she is prescribed ‘one of the safest drugs and take[s] quite a relatively low dose’.
Although seizure during labour had been a concern for some women while they were pregnant, only one
participant experienced a seizure during childbirth. Many women reported negative experiences in postnatal
wards as a result of a lack of sleep and staff shortages. Some women reported feeling ‘abandoned’ and
‘vulnerable’ to seizure in the postnatal ward. They expressed a desire for a partner or family member to
remain on the ward to help care for them and their newborn infant. Although a few wards allowed
partners/family members to remain outside of visiting hours, this was not universally practised across all
wards. One woman reported that she felt that she would not have another baby because of her poor
postnatal care experience.
In relation to caring for their newborns, many women reported having to make accommodations as a
result of their epilepsy. This was evident in sleeping patterns, breastfeeding strategies and day-to-day care
practices for infants. For some participants, sleep deprivation was a seizure trigger. Thus, to ensure they
had enough sleep, some had partners, family members or night nannies take the lead in baby care and
feeding overnight. Some of these women expressed feelings of guilt that they were not ‘proper’ mothers
because they were not doing night feeds.
Many women found mixed feeding (combining breastfeeding and bottle feeding) an effective way to
ensure that their babies got the health benefits of breast milk while also being able to ‘top up’ with
formula milk. Women felt that this feeding strategy helped babies sleep for longer periods in the night,
allowing women to get more sleep. Bottle feeding also allowed partners and family members to share in
the feeding duties. A few women reported receiving conflicting advice from health professionals regarding
the safety of breastfeeding while taking AEDs.
Precautionary practices in the day-to-day care of newborns, such as breastfeeding or nappy changing while
sitting on the floor, refraining from bathing a baby alone and using a car seat when carrying a baby on
stairs, were less likely to be taken up by women with a history of well-controlled seizures.
Reasons for declining participation in the randomised trial
Eleven women declined to participate in the RCT. About half (n = 6) of this group chose not to take part
in the RCT because the randomisation process was not acceptable to them. They were concerned that
they may be streamed into the clinical features monitoring strategy of the trial, and would have their
medication dosage increased only after a seizure and not when their blood levels decreased, with negative
consequences for them and/or their baby. Such women reported that they felt they would lose control
over the management of their epilepsy:
I thought it would be easier to control my seizures if I didn’t go into the study.
Clara
For me it would be quite a bizarre choice not to know what was happening to the levels of
lamotrigine in my blood, and not to intervene.
Sandra
These six women also expressed concern that they would be at more risk of a seizure if they were randomised:
Should I require additional medication, that wouldn’t necessarily be prescribed if I was part of the
wrong part of the trial.
Nicole
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If I could choose which group I was going into that would be fantastic, but I was told I couldn’t
choose which group I was going into. So it wasn’t worth the risk [of having a seizure].
Sandra
The five other non-randomised women chose to decline trial participation for the following reasons:
1. work and time commitments (n = 1)
2. lived too far from hospital for required monthly antenatal visits (n = 1)
3. fear of needles (n = 1)
4. stopped taking AEDs prior to pregnancy and did not want to resume (n = 1)
5. believed she did not have epilepsy (n = 1).
Discussion
Women sit on a wide spectrum of seizure types and frequencies, and this makes it difficult to categorise
women by epilepsy type. The ways in which women made sense of their pregnancy and epilepsy experiences
were shaped by both biography and social context. These varied experiences informed the way participants
perceived their condition and how they managed their condition before, during and post pregnancy.
Women who experienced relatively few seizures or who had well-controlled seizures often stated that they
felt ‘lucky’ and believed that they faced fewer hardships and stigma than those with more ‘severe’ or ‘real’
epilepsy. Overall, participants did not view their epilepsy as a ‘disability,’ but instead as a chronic health
condition that they could manage by taking medication and/or avoiding seizure triggers, including
tiredness, excessive alcohol consumption and stress.
For many women, prior to becoming pregnant, the day-to-day management of their condition had become
routine and normalised. Pregnancy marked a time when these management routines came to be disrupted.
Women had to re-evaluate their drug regime as they now had to consider their increased vulnerability to
seizure during pregnancy as well as the risk of teratogenic effects of the AEDs. Women had to weigh up
these risks to themselves and to their babies in a context of uncertainty. Risks of seizures and teratogenic
effects of medication were possibilities, but not certainties. Participants reported adopting a variety of
strategies to mitigate and balance these risks, including reducing, stopping, continuing and increasing their
medication during pregnancy. Underlying most of these management strategies was a desire to safeguard
the health of their baby.
The findings suggest that a tension may exist between the health professional’s focus on drug adherence
and the patient’s experience of doubt. Women may feel that health professionals have different priorities
from them, as it is women who will live with the consequences of drug regimens and any teratogenic effects
on their babies. As the findings above show, women experience feelings of maternal guilt and responsibility
for their babies being born with any health problems or abnormalities. These findings resonate with those of
Thompson et al.’s 30 study, which found that women living with epilepsy undertake ‘moral work’ in relation
to their pregnancies and that their concerns with the effects of AEDs on their unborn babies create a conflict
between being a ‘good mother’ and being a ‘good patient’.
Strengths and limitations of the qualitative study
As this study was carried out alongside the EMPiRE trial, including only women who chose to have
children, there is a risk of bias as those having children may have more well-managed seizures and fewer
negative symptoms and side effects associated with their medication. Approximately one-third of women
of childbearing age living with epilepsy in the UK consider not having children, or having fewer children,
because of their condition.40
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Additional limitations of this qualitative study include the use of a self-selected sample and an inability to
capture participants’ experiences of seizure during pregnancy. These seizure experiences were captured
only retrospectively through postnatal interviews.
Despite these limitations, the study’s strength lies in the original contribution it makes to further
understanding women’s experiences of epilepsy, pregnancy and reproductive health, in which there has
previously been a dearth of robust, in-depth qualitative research.29 To our knowledge, this constitutes one
of only two studies to directly examine women’s experiences of pregnancy while managing epilepsy.30
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Chapter 5 Discussion
In pregnant women with epilepsy on AEDs, a strategy of additional therapeutic drug monitoring did notsignificantly reduce the risk of time to first or to multiple seizures compared with management based on
clinical features alone. Babies born to mothers who received therapeutic drug monitoring in pregnancy were
exposed to significantly high levels of the AEDs lamotrigine and levetiracetam at birth. The average doses
of AEDs prescribed in both groups were similar. There were no differences in pregnancy complications,
maternal quality-of-life measure, birthweight and breastfeeding rates between the two strategies. The risk
of seizure was not greater in the groups whose serum AED levels were reduced than the stable group
when the clinical features monitoring and therapeutic drug monitoring groups were compared with the
non-randomised cohort. Women’s decisions on AED intake and increasing the dose of medication were
influenced by concerns for the baby.
The EMPiRE study is the largest randomised trial to date on pregnant women with epilepsy. We recruited
women across all four nations in the UK, involving centres that had access to joint obstetric epilepsy care.
Our findings are generalisable across the UK for the care of women in the NHS.
Strengths and limitations
We included women on AEDs that are commonly prescribed in pregnancy, with evidence of a reduction
in levels in pregnancy, and availability of serum level measurements in the NHS. We excluded women on
sodium valproate, as sodium valproate levels in pregnancy are considered to be unreliable, and it is not
standard practice in the UK to test sodium valproate levels in (or out of) pregnancy. Our chosen design
of early consent, and randomisation only when the serum levels fell, ensured that the data on all the
randomised patients contributed to an estimation of the effect, enhancing the statistical power to detect
a difference. Follow-up of the non-randomised cohort made it possible for us to blind the control group.
Our choice of primary outcome, loss of seizure control, could be defined and analysed in various ways, with
no consensus on the best approach.40 The standard approaches to analysis assume a normal distribution.
We expected our data to be highly skewed, with a large proportion (50–60%) of women remaining seizure
free throughout pregnancy,41 and chose time-to-event analysis incorporating estimation of robust standard
errors. Since tonic–clonic seizures are considered to be the most severe, we undertook a sensitivity analysis
of the primary outcome when limited to only tonic–clonic seizures. By not prespecifying the level of AED
in the therapeutic drug monitoring group at which the dose should be increased, we gave clinicians the
flexibility to exercise judgement about whether to adjust the AED dose, and to what extent, taking into
account patient preferences and factors other than serum AED level that impinge on the decision. The
EMPiRE study assessed the effect of two strategies on pregnancy outcomes and is the first trial to assess
QoL in mothers with epilepsy on AEDs.
We randomised fewer women than the required target (n = 660) to provide definitive evidence on the
decrease in time to first seizure by at least 25%. An important clinical effect cannot be ruled out, as indicated
by the inclusion of target HR in the confidence limits. We involved units that were able to recruit at least one
woman per month and took initiatives to set up joint obstetric epilepsy clinics where none existed before.
Owing to our inclusion criteria for recruitment being extended until 24 weeks of pregnancy, it is likely that
we may have missed randomising women at an earlier gestation when the levels of AEDs had decreased.
Although we preferred to use pre-pregnancy levels of AED as the baseline measure against which to
compare future levels to detect any decrease, in practice pre-pregnancy levels of AEDs were rarely available.
We accepted serum AED levels at baseline in pregnancy as the alternative, but it is likely that we may have
missed the decrease in AEDs in these cases. However, our approach was pragmatic, reflecting current clinical
practice, in which clinicians have to rely on first levels in pregnancy as the baseline. Given the small numbers
of women on individual AEDs, we refrained from providing separate seizure risks that depended on AED
intake. We prespecified a 25% reduction in serum AED level as the threshold for randomising women,
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determined by consensus involving neurologists. It is possible that the effect size would be different for other
cut-off points. Although we recruited women from a large number of centres, some centres in the UK
refused to participate, as the neurologists from these sites were convinced of the superiority of one strategy
over the other. This could be one of the reasons for slow recruitment.
Women’s views for declining participation in the randomised trial
Findings from the qualitative study regarding women’s rationale for declining the trial may also help
understand reasons for slow recruitment. Eleven women who participated in the qualitative study declined
the RCT; of these, approximately half reported that they found the process of randomisation unacceptable.
They expressed concern that randomisation would lead to a ‘loss of control’ over the management of their
epilepsy as they could potentially be streamed into the clinical features monitoring strategy of the trial, and
would have their medication dosage increased only after a seizure and not when their blood levels fell.
They believed that not increasing their medication when their blood levels dropped could potentially lead
to a seizure and they or their baby could be harmed. Thus, women’s concerns regarding preventing
seizures in pregnancy and maintaining control over their medication regime could also underpin slow
recruitment to the trial.
Reductions in serum antiepileptic drug level in pregnancy and seizure deterioration
Serum AED concentrations often decrease during pregnancy. Physiological changes in pregnancy alter AED
pharmacokinetics and AED concentrations. There is reduced gastric tone and motility, and increased
plasma volume, renal clearance, albumin levels and protein binding.9,14,42,43 The reductions in serum AED
levels are considered to aggravate seizures.44 Monitoring of serum AED levels in each trimester and after
delivery has been recommended by the American Academy of Neurology based on consensus as a good
practice.44 In the UK, however, the Scottish Intercollegiate Guidelines Network’s guideline does not
recommend regular AED monitoring in pregnancy because of a paucity of evidence.12 Our systematic
review on the effect of AED monitoring strategies in pregnant women with epilepsy on AED showed lower
rates of seizures with therapeutic drug monitoring than clinical features monitoring strategies.45 The studies
were not randomised, or controlled, results were heterogeneous and there was imprecision, with small
numbers of women making findings unreliable.
In our trial, we did not observe any differences in seizure rates and time to first and to multiple seizures
with the two strategies. Although the point estimates of hazard to time to first seizure and first
tonic–clonic seizure, and to multiple tonic–clonic seizures, showed a trend towards favouring therapeutic
drug monitoring, the findings were not significant.
Antiepileptic drug exposure in pregnancy to mother and fetus
The measurement of total AED exposure enabled us to delineate the likelihood of excess exposure
under therapeutic drug monitoring, in which dose escalation is expected in response to a known decrease
in serum AED levels. However, no differences were observed between the groups. It is likely that, when
serum AED levels fell, the intervention in the therapeutic drug monitoring group comprised either close
monitoring or dose escalation, whereas, without information on serum AED level, clinicians escalated drug
doses in response to their clinical monitoring. Despite similar average AED dose exposure in both groups, the
cord blood levels of the commonly prescribed AEDs lamotrigine and levetiracetam were higher in newborns
in the therapeutic drug monitoring group. The developmental quotient of infants of mothers exposed to
lamotrigine in pregnancy compared with women without epilepsy and women not on AEDs appeared to be
similar in a small study.46 There is limited evidence to assess the effect of levetiracetam or AED polytherapy
on long-term neurodevelopment.47
Quality of life in women using antiepileptic drugs
The effects of seizures extend into daily living, resulting in a loss of driving licence, and are known to
have a negative impact on employment and relationships, and reduced QoL.48 We found no differences
in the scores for QoL between the two groups. The additional information on serum AED levels in
pregnancy, and the subsequent management based on it, did not appear to adversely affect women’s QoL.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
Recommendations for clinical practice
Women with epilepsy on AEDs require management in a multidisciplinary setting, with a team involved in
both care of their pregnancy and their seizures. The standards of care for individuals with epilepsy vary
widely across the UK.49 This is particularly relevant for pregnant women with epilepsy. Our survey of epilepsy
specialists (n = 29) in the UK showed that one-third of participants managed women with epilepsy on AED
with regular therapeutic monitoring of drug levels, one-third adjusted doses based on clinical features only
and the rest used therapeutic drug monitoring occasionally.50 Given the wide CIs, reflecting the imprecision,
the absence of differences between the two strategies and similar rates of seizures in women with stable
and reduced serum AED levels, we are not able to advocate routine therapeutic drug monitoring monitoring
in pregnancy.
Although we randomised only half the number of women required to provide the definitive answer, given
the wide imprecision in the CIs, we do not expect one strategy to be shown to be significantly effective
compared with the other, even if we had managed to recruit to target. We calculated the fragility index,
which is the number of currently randomised women who should have been seizure free, to show a 25%
decrease in seizures, as postulated in our sample size calculation. Only 36 women should have suffered
seizures, compared with the observed number of 48 women, a significant number that should have been
reduced. We also calculated the additional number of women needed to show statistical significance for
the effect size as observed. Assuming that the observed effect size and SD holds, we estimate that the
number of women that would need to be recruited to demonstrate a significant effect of therapeutic drug
monitoring and clinical features monitoring on time to first seizure and time to any seizure was 1038 and
1302, respectively.
The risk of seizure deterioration was not significantly different in the non-randomised group with stable
serum AED levels and those with a decrease of ≥ 25%, reinforcing the lack of benefit of routine drug
monitoring. Furthermore, we observed a significant increase in the cord blood levels of lamotrigine and
levetiracetam in women whose AED doses were managed based on therapeutic drug monitoring. Given
the above findings, in the absence of firm evidence on long-term neurodevelopmental outcomes in infants
exposed to AEDs, particularly the newer AEDs such as levetiracetam, caution is required prior to routine
dose escalation based on serum AED levels alone.
Our qualitative study findings have led to the following recommendations on care for pregnant women
living with epilepsy.
l Pre-conception information: pre-conception counselling interventions need to continue to work
towards better identifying, and reaching out to, women who are not accessing this information, and to
provide consistent information on whether or not they should start a family.
l Antenatal care and medication management: women’s varied positions on the spectrum of seizure
types need be more fully recognised by health professionals, as this informs how women understand
and manage their condition. It should also be recognised that women’s decisions to stop, reduce,
maintain or increase their AEDs over the course of their pregnancies are based on a rationale of
maternal responsibility towards their babies.
l Postnatal care: ward practices need to facilitate appropriate access for partners and families of women
with epilepsy in order to manage their condition following delivery.
l Supporting mothers with epilepsy: women would benefit from more advice and information
concerning modifying their caregiving practices (changing nappies on the floor, never bathing babies
alone, etc.), as these practices were often not considered fully until after the babies were born.
Recommendations for future research
Given the difficulties in achieving the target sample size, despite recruitment in more than 50 centres,
conducting future randomised trials with a large sample size will be challenging. Any such trials will need
to take into account the core outcomes needed for minimal reporting to enable meaningful evidence
synthesis. The risks of seizure deterioration for various threshold levels of decrease in AEDs need further
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evaluation. A robust risk assessment method, using an individualised prediction model by taking into
account mothers’ clinical characteristics including type and duration of seizure, type of AED and change in
serum AED levels, will help to identify those women who need close monitoring in pregnancy. Importantly,
the long-term neurodevelopment of the infants born to mothers in both randomised groups, and any
impact on health-care costs, need further evaluation.
In relation to the qualitative research on pregnant women’s experiences of managing epilepsy, additional
research is needed with women with less controlled and/or more frequent seizures. As the qualitative study
was carried out alongside the EMPiRE trial, which included only women who had chosen to have children,
there is a risk of bias as those women having children may have better-managed seizures and fewer
negative symptoms and side effects associated with their medication. Furthermore, there is a need for a
more integrated approach in future research in this area to provide a more comprehensive picture of the
clinical and experiential aspects of taking AEDs.
DISCUSSION
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Chapter 6 Conclusion
In pregnant women with epilepsy on AEDs such as lamotrigine, carbamazepine, levetiracetam andphenytoin as mono- or polytherapy, regular monitoring of drug levels to inform dosage of AED does not
significantly reduce the risk of seizure deterioration or lower maternal and fetal complications compared
with management based on clinical features alone. Infants born to women in the therapeutic drug
monitoring group were exposed to higher levels of AEDs than those in the clinical features monitoring arm.
The qualitative study sought to address the dearth of research on women’s experiences of pregnancy while
managing their epilepsy and, to date, is one of only two studies in this area.30 Findings suggested that a
tension exists between the professional’s focus on drug adherence and the patient’s experience of doubt,
as she must live with the consequences of drug regimens. Furthermore, women’s varied positions on the
spectrum of seizure types must be more fully recognised, as this informs how they understand and
manage their condition. In relation to the trial, qualitative findings on women’s rationales for declining the
trial highlight that the randomisation process was not acceptable to some women as they felt they could
potentially lose control over the management of their medication, which, in turn, could lead to a seizure
during pregnancy.
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Appendix 1 Amendments to protocol
The trial protocol is available online.51
TABLE 17 Amendments to the protocol
What was proposed in original grant application What was done in the EMPiRE study
1. The original target sample size was 1000 women with
epilepsy on AEDs
There were difficulties meeting this target. An extension
was requested in order to meet the recruitment target,
which was rejected and recruitment stopped at 557
2. Data were collected for a health economic evaluation It was decided that the analysis of these data will be parked
until further funding is available
3. The BSID was being used to assess mental and motor
development of the infant at the 6-week postnatal visit
It was agreed by the TSC that the BSID would not collect
valuable data at such an early stage in a child’s
development and was removed from the protocol
4. Serum albumin levels were to be checked on visits 1, 3
and 5
Serum albumin levels are not routinely checked, and
committee members felt that the logistics and cost of the
test outweighed the research benefits
5. Cord blood was not initially being taken at delivery Committee members felt strongly that it was important to
obtain data on the levels of AED transferred from the
mother to baby
6. Suspected non-adherence to AED was not initially being
documented
Further clarification of action to be taken regarding
suspected non-adherence was necessary. Clinicians of
group Ba non-adherent patients were to be unblinded
7. Participants were sent the patient information sheet
7 days before their booking visit to allow time to consider
consenting to the trial
Patients were sent the patient information sheet 24 hours
before the booking visit in an attempt to increase
recruitment
8. There was no option for clinicians to request additional
serum levels to be taken
This was added as an option for circumstances in which
there is a clinical suspicion of toxicity or non-adherence
9. The NDDI-E tool was not originally being used The NDDI-E questionnaire was included as part of baseline
data collection
10. Serum AED samples for participants in group B were
not frozen until the end of the trial
Freezing blood samples in group B was introduced to mirror
existing clinical practice, as many units do not routinely
check serum AED levels
11. The QOLIE-31 tool was filled out at each monthly visit The QOLIE-31 questionnaire was lengthy and only
necessary to be conducted at baseline and then once
between 32 and 36 weeks’ gestation
12. Only clinicians were consenting women in to the trial Specialist midwives and suitably qualified members of staff
at a site were able to consent participants into the trial
13. The original inclusion criteria stated that women who
have a confirmed viable pregnancy of < 16 weeks’
gestation can be recruited
This was amended to include women who have a
confirmed viable pregnancy of < 24 weeks’ gestation
(23 weeks and 6 days) in order to increase recruitment
14. Exclusion criteria included women who have a history
of poor adherence
The exclusion criteria were amended to include women who
clearly expressed an intention not to take AEDs in pregnancy
or come to the clinic regularly. It allowed clinicians not to
recruit someone who had a chaotic follow-up and planned
to do that for the rest of the pregnancy
continued
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TABLE 17 Amendments to the protocol (continued )
What was proposed in original grant application What was done in the EMPiRE study
15. Clarification was required for unblinding to serum AED
levels
Clinicians and participants will automatically be unblinded if
there is an undetectable serum AED level at any time for
participants in groups Ab and Cc. Clinicians and participants
will not be automatically unblinded to undetectable serum
AED levels for participants randomised to group B
16. Maternal bloods were to be collected at delivery, and
the postnatal visit will be conducted at 6 weeks post
delivery
It was clarified that maternal delivery bloods could be
collected at any point between labour admission up to
discharge. The postnatal visit could be conducted at any
point between 6 and 8 weeks post delivery
BSID, Bayley Scales of Infant Development.
a Group B, clinical features monitoring.
b Group A, therapeutic drug monitoring.
c Group C, not randomised.
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Appendix 2 Maternal outcomes
TABLE 18 Maternal adverse effects of AED exposure: lamotrigine alone
Outcome Number of mothers
Mean lamotrigine
exposure in mg (SD)
Measure
Effect of increasing
exposure (95% CI)No outcome Outcome
LAEP score 178 N/A N/A IRR 1.0 (1.0 to 1.0)
Gestational age at delivery 257 N/A N/A MD 0.00 (–0.00 to 0.02)
CS or instrumental delivery 255 273 (153) 287 (156) OR 1.0 (1.0 to 1.0)
Pre-term labour 249 281 (155) 253 (149) OR 1.0 (1.0 to 1.0)
Induction of labour 254 273 (151) 301 (165) OR 1.0 (1.0 to 1.0)
Pre-eclampsia 248 279 (154) 293 (165) OR 1.0 (1.0 to 1.0)
Gestational diabetes mellitus 248 276 (150) 374 (234) OR 1.0 (1.0 to 1.0)
Antepartum haemorrhage 187 277 (154) 351 (172) OR 1.0 (1.0 to 1.0)
Postpartum haemorrhage 254 272 (152) 312 (159) OR 1.0 (1.0 to 1.0)
Admission to HDU or ICU 249 277 (154) 310 (160) OR 1.0 (1.0 to 1.0)
Feeding 253 OR 1.0 (1.0 to 1.0)
Breast 264 (132)
Mixed 300 (177)
Bottle 309 (186)
CS, caesarean section; HDU, high-dependency unit; ICU, intensive care unit; IRR, incidence rate ratio; N/A, not applicable;
OR, odds ratio.
Note
Clustering of multiple fetuses by mother ignored as a result of convergence issues.
TABLE 19 Mean difference AED exposure by occurrence of maternal adverse events: lamotrigine alone
Adverse events Number of mothers MD in lamotrigine exposure (95% CI)
CS or instrumental delivery 255 24.1 (–12.5 to 60.8)
Pre-term labour 256 –11.2 (–85.3 to 62.9)
Induction of labour 254 22.2 (–20.0 to 64.4)
Pre-eclampsia 255 14.8 (–89.4 to 119.0)
Gestational diabetes mellitus 255 50.0 (–46.0 to 146.0)
Antepartum haemorrhage 254 100.9 (–3.8 to 205.6)
Postpartum haemorrhage 254 49.2 (–0.8 to 99.2)
Admission to HDU or ICU 256 31.6 (–49.5 to 112.7)
Feeding 253
Breast Reference group
Mixed 33.3 (–25.7 to 92.3)
Bottle 38.8 (–4.6 to 82.1)
CS, caesarean section; HDU, high-dependency unit; ICU, intensive care unit.
DOI: 10.3310/hta22230 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 23
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Thangaratinam et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of
Southampton Science Park, Southampton SO16 7NS, UK.
53
TABLE 20 Maternal adverse effects of AED exposure: levetiracetam alone
Outcome Number of mothers
Mean levetiracetam
exposure in mg (SD)
Measure
Effect of increasing
exposure (95% CI)No outcome Outcome
LAEP score 88 N/A N/A IRR 1.0 (1.0 to 1.0)
Gestational age at delivery 126 N/A N/A MD 0.0 (0.0 to 0.0)
CS or instrumental delivery 124 1740 (987) 1548 (641) OR 1.0 (1.0 to 1.0)
Pre-term labour 96 1634 (864) 1888 (639) OR 1.0 (1.0 to 1.0)
Induction of labour 125 1620 (868) 1694 (834) OR 1.0 (1.0 to 1.0)
Pre-eclampsia 51 1645 (859) 1825 (459) OR 1.0 (1.0 to 1.0)
Gestational diabetes mellitus 124 1627 (807) 1471 (611) OR 1.0 (0.998 to 1.0)
Antepartum haemorrhage 70 1639 (859) 2033 (454) OR 1.0 (1.0 to 1.0)
Postpartum haemorrhage 127 1684 (890) 1396 (470) OR 1.0 (1.0 to 1.0)
Admission to HDU or ICU 125 1662 (858) 1314 (715) OR 1.0 (1.0 to 1.0)
Feeding 125 OR 1.000 (1.0 to 1.0)
Breast 1599 (897)
Mixed 1928 (1022)
Bottle 1611 (592)
CS, caesarean section; HDU, high-dependency unit; ICU, intensive care unit; IRR, incidence rate ratio; N/A, not applicable;
OR, odds ratio.
Note
Clustering of multiple fetuses by mother ignored as a result of convergence issues.
TABLE 21 Mean difference AED exposure by occurrence of maternal adverse events: levetiracetam alone
Adverse events Number of mothers MD in levetiracetam exposure (95% CI)
CS or instrumental delivery 126 –226.4 (–536.3 to 83.5)
Pre-term labour 127 23.6 (–644.4 to 691.5)
Induction of labour 127 7.7 (–307.4 to 322.8)
Pre-eclampsia 127 358.0 (–823.6 to 1539.5)
Gestational diabetes mellitus 126 –109.5 (–815.6 to 596.6)
Antepartum haemorrhage 127 507.2 (–459.5 to 1473.9)
Postpartum haemorrhage 127 –365.5 (–817.5 to 86.6)
Admission to HDU or ICU 127 –431.7 (–1184.8 to 321.5)
Breastfeeding
126 (128) 125 Reference group
97 (98) 246.5 (–153.4 to 646.5)
50 (51) –28.5 (–382.0 to 325.0)
CS, caesarean section; HDU, high-dependency unit; ICU, intensive care unit.
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TABLE 22 Maternal adverse effects of AED exposure: carbamazepine alone
Outcome Number of mothers
Mean carbamazepine
exposure in mg (SD)
Measure
Effect of increasing
exposure (95% CI)No outcome Outcome
LAEP score 60 N/Aa N/A IRR 1.0 (1.0 to 1.0)
Gestational age at delivery 86 N/A N/A MD –0.01 (–0.02 to 0.0)
CS or instrumental delivery 86 632 (317) 711 (290) OR 1.0 (1.0 to 1.0)
Pre-term labour 82 647 (295) 842 (315) OR 1.0 (1.0 to 1.0)
Induction of labour 82 631 (274) 747 (340) OR 1.0 (0.1 to 1.0)
Pre-eclampsia 81 676 (305) 604 (303) OR 1.0 (0.1 to 1.0)
Gestational diabetes mellitus 63 665 (305) 831 (249) OR 1.0 (1.0 to 1.0)
Antepartum haemorrhage 63 671 (305) 800 (283) OR 1.0 (0.98 to 1.06)
Postpartum haemorrhage 82 664 (297) 764 (363) OR 1.0 (1.0 to 1.0)
Admission to HDU or ICU 63 676 (308) 623 (167) OR 1.0 (0.99 to 1.01)
Feeding 85 OR 1.0 (1.0 to 1.0)
Breast 689 (336)
Mixed 634 (275)
Bottle 665 (174)
CS, caesarean section; HDU, high-dependency unit; ICU, intensive care unit; IRR, incidence rate ratio; N/A, not applicable;
OR, odds ratio.
a Not applicable as outcome and exposure variable are continuous.
Note
Clustering of multiple fetuses by mother ignored as a result of convergence issues.
TABLE 23 Mean difference AED exposure by occurrence of maternal adverse events: carbamazepine alone
Adverse events Number of mothers MD in carbamazepine exposure (95% CI)
CS or instrumental delivery 86 18.2 (–111.7 to 148.0)
Pre-term labour 86 179.0 (4.3 to 353.8)
Induction of labour 86 76.0 (–52.9 to 204.9)
Pre-eclampsia 85 –46.6 (–273.4 to 180.1)
Gestational diabetes mellitus 86 70.6 (–197.1 to 338.4)
Antepartum haemorrhage 86 254.7 (–152.0 to 661.5)
Postpartum haemorrhage 86 85.8 (–111.4 to 283.0)
Admission to HDU or ICU 86 16.4 (–316.4 to 349.2)
Feeding 85
Breast Reference group
Mixed –80.6 (–276.7 to 115.6)
Bottle –2.2 (–168.4 to 163.9)
CS, caesarean section; HDU, high-dependency unit; ICU, intensive care unit.
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TABLE 24 Maternal adverse effects of AED exposure: lamotrigine and levetiracetam
Outcome
Number of
mothers Measure
Mean lamotrigine exposure in
mg (SD)
Effect of increasing
exposure (95% CI)
Mean levetiracetam exposure in
mg (SD)
Effect of increasing
exposure (95% CI)No outcome Outcome No outcome Outcome
LAEP score 22 IRR N/A N/A 1.0 (1.000 to 1.001) N/A N/A 1.0 (1.0 to 1.0)
Gestational age at delivery 36 MD N/A N/A –0.01 (–0.050 to 0.030) N/A N/A 0.0 (–0.01 to 0.00)
CS or instrumental delivery 35 OR 376 (169) 451 (177) 1.0 (1.000 to 1.025) 1867 (913) 2060 (1028) 1.0 (1.0 to 1.0)
Pre-term labour 35 OR 421 (175) 424 (190) 1.0 (0.995 to 1.008) 1880 (873) 2508 (1364) 1.0 (1.0 to 1.0)
Induction of labour 35 OR 420 (205) 423 (129) 0.9991.0 (0.99 to 1.0 2053 (1137) 1889 (720) 1.0 (1.0 to 1.0)
Pre-eclampsia 23 OR 401 (169) 518 (34) Perfect prediction 2038 (961) 1743 (1316) Perfect prediction
Gestational diabetes mellitus – OR 410 (167) 450 Perfect prediction 1941 (891) 4462 Perfect prediction
Antepartum haemorrhage – OR 422 (178) 400 Perfect prediction 2013 (976) 1000 Perfect prediction
Postpartum haemorrhage 24 OR 387 (161) 566 (169) 1.0 (0.99 to 1.0) 1967 (963) 2060 (1106) 1.0 (1.0 to 1.0)
Admission to HDU or ICU – OR 423 (180) 400 (0) Perfect prediction 2028 (986) 1250 (354) Perfect prediction
Feeding 36 OR
Breast 446 (186) 0.99 (0.99 to 1.0) 2180 (969) 1.0 (1.0 to 1.0)
Mixed 523 2000
Bottle 404 (174) 1882 (1008)
CS, caesarean section; HDU, high-dependency unit; ICU, intensive care unit; IRR, incidence rate ratio; N/A, not applicable; OR, odds ratio.
Note
Clustering of multiple fetuses by mother ignored as a result of convergence issues.
A
PPEN
D
IX
2
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
56
TABLE 25 Mean difference AED exposure by occurrence of maternal adverse events: lamotrigine and levetiracetam
Adverse events Number of mothers
MD in lamotrigine exposure
(95% CI)
MD in levetiracetam
exposure (95% CI)
CS or instrumental delivery 36 87.3 (–46.8 to 221.5) 30.5 (–771.0 to 832.0)
Pre-term labour 36 15.3 (–146.4 to 177.0) 557.0 (–355.7 to 1469.7)
Induction of labour 36 –23.1 (–173.1 to 126.9) 87.0 (–783.1 to 957.2)
Pre-eclampsia 35 124.0 (–84.2 to 332.3) –5.1 (–1337.0 to 1326.8)
Gestational diabetes mellitus 35 –89.4 (–460.1 to 281.4) 2205.7 (56.8 to 4354.7)
Antepartum haemorrhage 36 79.1 (–340.6 to 498.8) –919.0 (–3331.4 to 1493.4)
Postpartum haemorrhage 36 142.8 (–11.6 to 297.2) –253.6 (–1198.7 to 691.5)
Admission to HDU or ICU 36 48.8 (–247.2 to 344.9) –593.1 (–2296.9 to 1110.8)
Feeding 36
Breast Reference group Reference group
Mixed –29.7 (–428.8 to 369.3) –332.227 (–2680.7 to 2016.2)
Bottle –74.0 (–209.9 to 61.9) –250.6 (–1050.4 to 549.3)
CS, caesarean section; HDU, high-dependency unit; ICU, intensive care unit.
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Appendix 3 Fetal outcomes
TABLE 26 Fetal adverse effects of AED exposure: lamotrigine alone
Outcome
Number of mothers
(number of babies)
Mean lamotrigine
exposure in mg (SD)
Measure
Effect of increasing exposure
(95% CI)
No
outcome Outcome
Cord blood levels,
lamotrigine (mg/l)
186 (188) N/A N/A MD 0.01 (0.01 to 0.01)
Major congenital
malformations
247 (254) 276 (156) 302 (116) ORa 1.0 (1.0 to 1.01)
Baby’s admission to
neonatal unit
254 (247) 279 (153) 273 (162) OR 1.0 (1.0 to 1.0)
Apgar score at 1 minute 247 (252) N/A N/A MD –1 × 10–4 (–0.001 to 0.001)
Apgar score at 5 minutes 249 (254) N/A N/A MD 3 × 10–4 (–0.001 to 0.001)
Birthweight (kg) 254 (261) N/A N/A MD 4 × 10–4 (–2 × 10–4 to 0.001)
Birthweight < 10th centile 254 (261) 279 (152) 268 (170) OR 1.0 (1.0 to 1.0)
Head circumference (cm) 202 (206) N/A N/A MD –1 × 10–4 (–0.001 to 0.002)
Cord pH A 103 (104) N/A N/A MD –2 × 10–4 (–3 × 10–4 to 7 × 10–4)
Cord pH V 109 (110) N/A N/A MDa –2 × 10–4 (–3 × 10–4 to –3 × 10–5)
A, arterial; N/A, not applicable; OR, odds ratio; V, venous.
a Clustering of multiple fetuses by mother ignored as a result of convergence issues.
TABLE 27 Mean difference AED exposure by occurrence of fetal adverse events: lamotrigine alone
Adverse events
Number of mothers
(number of babies)
MD in lamotrigine
exposure (95% CI)
Major congenital malformations 247 (254) 39.0 (–31.6 to 109.6)
Baby’s admission to neonatal unit 254 (247) 4.2 (–53.5 to 61.8)
Apgar score at 1 minute (< 7a) 247 (252) 9.0 (–73.5 to 91.5)
Apgar score at 5 minutes (< 7a) 249 (254) 90.9 (–40.5 to 222.3)
Birthweight < 10th centile 254 (261) –33.4 (–94.5 to 27.7)
Cord pH A (< 7a) 103 (104) –144.9 (–356.6 to 66.8)
Cord pH V (< 7a) 109 (110) –77.2 (–388.1 to 233.7)
A, arterial; V, venous.
a Number of babies with Apgar score of < 7.
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TABLE 28 Fetal adverse effects of AED exposure: levetiracetam alone
Outcome
Number of mothers
(number of babies)
Mean levetiracetam
exposure in mg (SD)
Measure
Effect of increasing
exposure (95% CI)
No
outcome Outcome
Cord blood levels,
levetiracetam (mg/l)
94 (95) N/A N/A MDa 0.01 (0.01 to 0.01)
Major congenital
malformations
126 (128) 1646 (858) 1859 (593) OR 1.0 (1.0 to 1.01)
Baby’s admission to
neonatal unit
124 (126) 1626 (789) 2063 (1415) OR 1.0 (1.0,1.0)
Apgar score at 1 minute 123 (125) N/A N/A MDa –8 × 10–6 (–3 × 10–4 to 3 × 10–4)
Apgar score at 5 minutes 123(125) N/A N/A MDa –4 × 10–5 (–2 × 10–4 to 1 × 10–4)
Birthweight (kg) 126 (128) N/A N/A MD 6 × 10–5 (–3 × 10–5 to 2 × 10–4)
Birthweight < 10th
centile
126 (128) 1609 (804) 1928 (1041) OR 1.0 (1.0 to 1.0)
Head circumference (cm) 97 (98) N/A N/A MDa 3 × 10–4 (–7 × 10–5 to 0.001)
Cord pH A 50 (51) N/A N/A MDa –0.005 (–0.01 to 0.00)
Cord pH V 59 (61) N/A N/A MD –0.003 (–0.01 to 0.00)
A, arterial; N/A, not applicable; OR, odds ratio; V, venous.
a Clustering of multiple fetuses by mother ignored as a result of convergence issues.
Note
Bold text denotes statistically significant results at the 5% level.
TABLE 29 Mean difference AED exposure by occurrence of fetal adverse events: levetiracetam alone
Adverse events Number of mothers (number of babies)
MD in levetiracetam
exposure (95% CI)
Major congenital malformations 126 (128) 149.3 (–572.1 to 870.6)
Baby’s admission to neonatal unit 124 (126) 362.2 (–206.5 to 930.9)
Apgar score at 1 minute (< 7a) 123 (125) –47.5 (–638.2 to 543.2)
Apgar score at 5 minutes (< 7a) 123 (125) Perfect prediction
Birthweight centile < 10th centile 126 (128) 225.4 (–216.0 to 666.8)
Cord pH A (< 7a) 50 (51) Perfect prediction
Cord pH V (< 7a) 59 (61) Perfect prediction
A, arterial; V, venous.
a Number of babies with Apgar score of < 7.
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TABLE 30 Fetal adverse effects of AED exposure: carbamazepine alone
Outcome
Number of mothers
(number of babies)
Mean carbamazepine
exposure in mg (SD)
Measure
Effect of increasing
exposure (95% CI)
No
outcome Outcome
Cord blood levels,
carbamazepine (mg/l)
62 (64) N/A N/A MDa 0.00 (0.00 to 0.00)
Major congenital
malformations
85 (88) 670 (285) 688 (398) OR 1.0 (1.0 to 1.0)
Baby’s admission to
neonatal unit
85 (88) 677 (290) 644 (358) OR 1.0 (0.99 to 1.0)
Apgar score at 1 minute 84 (87) N/A N/A MD 0.00 (0.00 to 0.00)
Apgar score at 5 minutes 84 (87) N/A N/A MDa –9 × 10–5 (–0.001 to 0.001)
Birthweight (kg) 85 (88) N/A N/A MD 0.00 (0.00 to 0.00)
Birthweight centile
< 10th centile
85 (88) 640 (299) 777 (281) OR 1.0 (1.0 to 1.0)
Head circumference (cm) 63 (66) N/A N/A MD 0.00 (0.00 to 0.00)
Cord pH A 35 (36) N/A N/A MD 1 × 10–5 (–1 × 10–4 to 1 × 10–4)
Cord pH V 40 (40) N/A N/A MDa 1 × 10–5 (–1 × 10–4 to 1 × 10–4)
A, arterial; N/A, not applicable; OR, odds ratio; V, venous.
a Clustering of multiple fetuses by mother ignored as a result of convergence issues.
TABLE 31 Mean difference AED exposure by occurence of fetal adverse events: carbamazepine alone
Adverse events Number of mothers (number of babies)
MD in carbamazepine
exposure (95% CI)
Major congenital malformations 85 (88) –14.1 (–198.9 to 170.8)
Baby’s admission to neonatal unit 85 (88) –58.8 (–231.4 to 113.7)
Apgar score at 1 minute (< 7a) 84 (87) –110.7 (–308.7 to 87.4)
Apgar score at 5 minutes (< 7a) 84 (87) 7.7 (–284.7 to 300.2)
Birthweight < 10th centile 85 (88) 132.1 (–5.7 to 269.9)
Cord pH A (< 7a) 35 (36) Perfect prediction
Cord pH V (< 7a) 40 (40) 32.8 (–624.2 to 689.9)
A, arterial; V, venous.
a Number of babies with Apgar score of < 7.
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TABLE 32 Fetal adverse effects of AED exposure: lamotrigine and levetiracetam
Outcome
Number of mothers
(number of babies) Measure
Mean lamotrigine
exposure in mg (SD)
Effect of increasing
exposure (95% CI)
Mean levetiracetam
exposure in mg (SD)
Effect of increasing
exposure (95% CI)
No
outcome Outcome
No
outcome Outcome
Cord blood levels,
lamotrigine (mg/l)
27 MD N/A N/A 0.009 (0.004 to 0.013) N/A N/A –2 × 10–4 (–0.001 to 0.001)
Cord blood levels,
levetiracetam (mg/l)
0.008 (–0.026 to 0.041) 0.008 (0.002 to 0.013)
Major congenital
malformations
22 (24) OR 429
(179)
391 (13) Perfect prediction 2011 (989) 1750 (354) Perfect prediction
Baby’s admission to
neonatal unit
36 (38) OR 421
(171)
440 (188) 1.005 (0.989 to 1.021) 1841 (767) 2297 (1244) 1.002 (0.998 to 1.006)
Apgar score at 1 minute 35 (37) MDa N/A N/A 3 × 10–4 (–0.004 to 0.005) N/A N/A 0.000 (0.000 to 0.001)
Apgar score at 5 minutes 35 (37) MDa N/A N/A 0.001 (–0.002 to 0.003) N/A N/A 0.000 (0.000 to 0.001)
Birthweight (kg) 35 (37) MD N/A N/A –0.001 (–0.002 to 0.000) N/A N/A 0.000 (0.000 to 0.000)
Birthweight < 10th centile 15 (17) OR 420
(185)
473 (115) Perfect prediction 1898 (947) 2218 (685) Perfect prediction
Head circumference (cm) 27 (28) MD N/A N/A –0.001 (–0.005 to 0.002) N/A N/A 0.001 (–2 × 10–4 to 0.001)
Cord pH A 13 (14) MDa N/A N/A 2 × 10–4 (–3 × 10–4 to 0.001) N/A N/A 6 × 10–5 (–1 × 10–4 to 2 × 10–4)
Cord pH V 14 (16) MD N/A N/A 2 × 10–4 (5 × 10–5 to 3 × 10–4) N/A N/A –3 × 10–5 (–9 × 10–5 to 2 × 10–5)
A, arterial; N/A, not applicable; OR, odds ratio; V, venous.
a Clustering of multiple fetuses by mother ignored as a result of convergence issues.
Note
Bold text denotes statistically significant results at the 5% level.
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TABLE 33 Mean difference AED exposure by occurrence of fetal adverse events: lamotrigine and levetiracetam
Adverse events
Number of mothers
(number of babies)
MD in lamotrigine
exposure (95% CI)
MD in levetiracetam
exposure (95% CI)
Major congenital malformations 22 (24) –11.5 (–288.6 to 265.7) –317.8 (–1920.0 to 1284.6)
Baby’s admission to neonatal unit 36 (38) 46.2 (–87.5 to 179.9) 522.5 (–233.5 to 1278.4)
Apgar score at 1 minute (< 7a) 35 (37) –42.1 (–239.8 to 155.5) 964.7 (–53.5 to 1982.9)
Apgar score at 5 minutes (< 7a) 35 (37) –128.2 (–551.8 to 295.4) 951.9 (–1351.1 to 3254.9)
Birthweight < 10th centile 15 (17) 161.3 (–15.4 to 338.0) 289.6 (–729.1 to 1308.2)
Cord pH A (< 7a) 13 (14) Perfect prediction Perfect prediction
Cord pH V (< 7a) 14 (16) Perfect prediction Perfect prediction
A, arterial; V, venous.
a Number of babies with Apgar score of < 7.
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Appendix 4 Qualitative interview guide
Antenatal Interview 
Interviewee Name:  ________________________  Date: ______________________ 
Prior to interview: Told Others of Interview Local & Time ___, Extra Batteries ___, Pen & 
Pad ___, Epilepsy Nurse/ Support Contact Numbers___  
Pre Interview Checklist X 
Understands qualitative study  
Received and read the PIS  
Answer participant’s questions  
Consented to take part obtained   
If not participating in trial: Interview consent signed  
Consented to record  
 
Field Notes (Details of where interviewed, who present, etc.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographic Info 
Age: ___________ 
# of children: ___________ 
Stage in pregnancy: ___________ 
Due Date: ___________ 
Ethnicity (self-identified): ___________ 
Religion: ___________ 
Occupation: ___________ 
Marital Status: ______________ 
Years had epilepsy: _____________ 
Type of Epilepsy (self-defined): 
_________________________   
Mailing Address:  ___________________ 
__________________________________ 
Email: ____________________________ 
Trial Number:  ___________________ 
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RECORDER ON 
1. Managing Epilepsy Outside of Pregnancy  
What would you like to call your condition? Is this how you usually refer to it?  
Take me back to when you first had __[reflect language back]__. Please tell me 
the story of when this first occurred. 
- Prompts: What happened, who was there… 
  - What do you call these events (i.e. seizures/episodes/fits)?  
- Please describe what these [participant’s term] are like. 
- How did you receive your diagnosis? When did your receive it? 
- How did you feel about the diagnosis? 
 
How does ____[participant’s term]___ fit into your day to day life? Tell me 
about what your normal day-to-day life is like.   
- Who have you told? Who do you talk to about this?  
- Who do you get support from? How do they support you? 
- Does [participant’s term] interfere with your day to day life? How?   
 
What drugs you have taken in the past? And now? 
Epilepsy is often thought of as a stigmatising condition.  How do you feel about 
that?  Is that true for you? 
 
2. Preconception Experience 
*First-time pregnancy:  
Before becoming pregnant- thinking about your __[epilepsy/participant’s 
term]___ -how did you feel about pregnancy? 
- Did you have any concerns/hopes?   
                   - What did you think about your medication and becoming pregnant?  
 
*Those with previous pregnancies: 
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Tell me about what your past pregnancy/ies where like.   
- Did this influence how you planned for this pregnancy? 
- Did you have any concerns/hopes for this second/third/fourth… pregnancy? 
Tell me about your labour experience 
* All participants 
How did you learn you were pregnant?  
-  How did you feel?  
- How did others (partners, family, etc.) feel? 
How did you find information about pregnancy while having [epilepsy/ 
participant’s term] ?  
 
  - Prompts: From where? Who?  
 
  - What did you think of this information? Was it helpful?  
 
3. Experience of Pregnancy 
How do you feel about being pregnant and having epilepsy? 
-Has the way you manage your [participant’s term] changed? How? Can you 
give an example? 
-How have you changed your life in relation to [participant’s term] since 
becoming pregnant? 
As you know you are receiving additional ante-natal care because of your 
epilepsy, which means that you are in a category of high risk. Has anyone 
mentioned that to you?  How do you feel about being categorised as high risk? 
 
Why did (or didn’t*) you decide to take part in this trial? 
*If opted out- can I ask why you chose not to participate?  
-How do you feel about the: drug regime, blood tests, hospital visits, and 
monitoring by the clinic? 
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4. Weighing Up Risks vs. Benefits 
How do you weigh up the risks vs the benefits of having baby while living with [epilepsy 
/participants’ term]? 
Cover the following areas through conversation: 
• Risks of [epilepsy/participant’s term] on your baby?  
• Risks to yourself? 
 
• Benefits of [epilepsy/participant’s term] on your baby? 
• Benefits to yourself? 
 
• Risks of epilepsy management/medication on your baby? 
• Risks to yourself? 
 
• Benefits of epilepsy management/medication on your baby? 
• Benefits to yourself?   
 
• Risks of seizures on your baby? 
• Risks to yourself? 
 
If participant sees seizures as positive:  
• How do you weigh up the benefits of seizures on your baby? 
• And the benefits to yourself? 
 
 
Who do you talk to about managing your [epilepsy/participant’s terms] during 
your pregnancy? 
What influences how you make decisions regarding managing epilepsy during 
your pregnancy?  
- Who influences these decisions?  
 - Who supports you? How do they support you? 
 
5. Tell me about your experience (of care/at the clinic) 
• How have your interactions with the doctors/nurses been? Expand/tell me more/give 
an example 
• Your concerns about (what stated in previous questions), have you raised them with 
nurses/doctors?  How did you feel about the information/advice they gave you? 
• Do you feel you get all your questions answered? 
• Do you have enough time with nurses/doctors? 
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6. Concerns and Hopes for the Future  
• What are your main concerns about the rest of your pregnancy? 
• What are your hopes for the rest of the pregnancy? 
 
• Do you have concerns about the labour?  
• What are hopes for the labour? 
 
• After the labour, and your baby is born, what are your hopes for your baby?   
• Do you have any concerns for your baby? 
 
• Do you have any concerns for yourself after the baby arrives? 
• What are your hopes for yourself after the baby arrives?  
 
7. Concluding Questions 
 
Is there anything else we didn’t discuss that you would like to talk about?  
Do you have questions for me? 
 
RECORDER OFF 
 
Post Interview Checklist X 
Ask participant if could contact us if she has a seizure 
during pregnancy
Give or mail voucher  
Type field notes and reflections  
Transcribe demographic details in reporter’s notebook  
Save recorded interview in computer and hard drive   
Destroy this form and any written notes  
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Postnatal Interview 
Interviewee Name:  ________________________  Date: ______________________ 
Prior to interview: Told Others of Interview Local & Time ___, Extra Batteries ___, Pen & Pad ___, 
Epilepsy Nurse/ Support Contact Numbers___,  
REVIEW PREVIOUS INTERVIEW(S)___ 
Make list of previous responses about management of epilepsy and pregnancy, and risks vs. 
benefits ___ 
Note participant’s term for epilepsy ___ 
Pre Interview Checklist X 
Answer participant’s questions  
Consent for continued participation obtained (verbal)  
Consented to record  
 
Field Notes (Details of where interviewed, who present, etc.) 
 
 
 
 
 
 
 
 
 
 
 
RECORDER ON 
1. Tell me how you have been since we last spoke 
-How was the rest of the pregnancy 
-Tell me about the labour 
-How have you and the baby been since the labour 
 
2. Thinking back, how do you feel about taking your medication while being 
pregnant?  
[refer to their response in previous interview(s)] 
 
3. Is there anything you feel could have been done differently/ better? 
 
4. [If have NOT yet talked about high risk pregnancies before] As you know you 
received additional ante-natal care because of your epilepsy, which means that 
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your pregnancy was categorised as high risk. Had anyone mentioned that to 
you?  How do you feel about your pregnancy being categorised as high risk? 
 
[If have ALREADY talked about high risk pregnancies before] We talked about 
your being in a high risk category before. In hindsight, how do you feel about 
your pregnancy being categorised as high risk?  
 
5. Are you managing your (epilepsy/participants’ own term) any differently now? 
If so, how? If not  [probe more] 
 
- Medication/dosage 
 
6. Thinking back to our conversation about the risks and benefits for your baby – 
[remind them of their previous answers]  - how do you feel now about those 
concerns after your baby has been born?  
 
7. Does your (epilepsy/participant’s own term) influence how you care for your 
child?  How? Are you taking extra precautions (in regards to below)? 
- Can you an example/tell me about X 
- Feeding Child (Breast, bottle, and where) 
- Bathing Child 
- Rest, Sleep for baby/you, and sleeping arrangements? 
- Going outside with your baby? 
- Supports from friends, family?  
- Supports from health visitors/midwives?  
o Visits in home? 
o Questions answered?  
o Enough time? 
o Quality of information? 
 
8. If you did not have (epilepsy/participant’s own term) do you think the way you 
care for your baby day to day would be different?  
- If yes, how?  
- If no, why not? 
 
9. Tell me about your experience of being in the Trial 
- Can you give an example/ tell me more about X  
 
10. Tell me about your experience of care during the pregnancy 
- had questions answered 
- enough time with doctors/nurses 
- quality of information, responses, diagnosis 
- Can you give me an example/tell me more about X 
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11. Concluding Questions: 
Is there anything else we didn’t discuss that you would like to talk about?  
 
Do you have questions for me? 
  
 
RECORDER OFF 
Post Interview Checklist X 
Check if received voucher, or verify is coming  
Type field notes and reflections  
Save recorded interview in computer and hard drive   
Destroy this form and any written notes  
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Appendix 5 Definition of the primary outcome
TABLE 34 Definition of the primary outcome
Outcome Definition
Time from randomisation to
first TCS
l Time between a 25% reduction in serum AED levels and the first TCS. A TCS (or
grand mal seizure) is a common generalised seizure, meaning that it affects both
sides of the brain. It involves strong muscular contractions, convulsions and a loss
of consciousness
Time from randomisation to any
other seizure
l Time between a 25% reduction in serum AED levels and the first seizure that is not
a TCS. Seizures are categorised as generalised (affecting the entire brain) or focal
(affecting one area of the brain)
l Other generalised seizures are absences (or petit mal seizures), which involve a brief
loss of consciousness, and myoclonic seizures, which typically involve muscle jerks
and can occur in clusters
l Focal seizures include complex partial seizures, in which consciousness is affected
and involuntary movements (automatisms), such as lip smacking, occur. During a
simple partial seizure, the person is aware and alert, and symptoms vary depending
on the area of the brain affected
TCS, tonic–clonic seizure.
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Appendix 6 List of core outcomes for studies on
pregnant women with epilepsy (Delphi)
TABLE 35 Core outcomes for studies on pregnant women with epilepsy (Delphi)
Outcomes
Neurological Fetal and neonatal Obstetric
l AED toxicitya
l Compliance with AEDa
l Drowning
l Maternal death
l Postnatal depression
l Seizure control (post partum and
in pregnancy)
l QoL
l Status epilepticus
l Sudden unexpected death
in epilepsy
l Admission to neonatal intensive
care unit
l Autism spectrum disorder
l Anthropometric measurements
including birthweight
l Fetal anticonvulsant syndromea
l Congenital abnormalities (major
and minor)
l Neonatal haemorrhagic diseasea
l Neurodevelopmenta
l Neonatal withdrawal symptomsa
l Neonatal clinical complicationsb
l Stillbirth
l Admission to high-dependency or
intensive care unit
l Breastfeeding ratea
l Hypertensive disorder (pre-eclampsia,
eclampsia)
l Pregnancy outcome (live birth rate,
ectopic pregnancy, miscarriage,
termination of pregnancy)
l Mode of delivery
l Pre-term birth
a Outcomes applicable only in studies on pregnant women on antiepileptic agents.
b Acute respiratory distress syndrome, anaemia hypoglycaemia, hyperglycaemia, hypocalcaemia, hypotonia, feeding
problems, sedation syndrome, icterus/convulsions, cephalhaematoma and Apgar scores.
Some content from Al Wattar et al.52
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Appendix 7 List of collaborators
The EMPiRE trial collaborative network:
l Dr Shanika Samarasekera – Queen Elizabeth Hospital, Birmingham
l Professor Rajat Gupta – Birmingham Children’s Hospital, Birmingham
l Dr Naghme Adab – University Hospital of Coventry and Warwickshire
l Professor Ismail Khaled – Keele University Medical School and University of North Staffordshire
l Mr Lee Middleton – Birmingham University, Birmingham
l Miss Manjo Doug – Birmingham Women’s NHS Foundation Trust, Birmingham
l Professor Tracy Baker – Birmingham
l Dr Salwa El-Taher – Arrowe Park Hospital, Wirral
l Dr Catharina Schram – Royal Blackburn Hospital, Lancashire; Burnley General Hospital, Lancashire
l Dr Virginia Beckett – Bradford Royal Infirmary, Bradford
l Dr Jim Morrow – Royal Victoria Hospital, Belfast
l Mr Alexander Pirie – Birmingham Women’s Hospital, Birmingham
l Dr Neil Shah – Birmingham City Hospital, Birmingham
l Dr Fadi Alfhaily – Colchester Hospital, Colchester
l Ms Sadia Malick – University Hospitals Coventry and Warwickshire, Coventry
l Dr Mark Johnson – Chelsea and Westminster Hospital, London
l Miss Sasha Rajendran – The Royal Derby Hospital, Derby
l Dr Alastair Campbell – Edinburgh Royal Infirmary, Edinburgh
l Dr John O’Dwyer – Frimley Park Hospital, London
l Miss Maggie Armstrong – Glan Clwyd Hospital, Rhyl
l Dr Charlotte Lawthorn – Royal Gwent Hospital, Newport
l Dr Janet Brennand – Southern General Hospital, Glasgow
l Dr Isaac Babarinsa – Gloucester Royal Hospital, Gloucestershire
l Dr Avideah Nejad – Royal Hampshire County Hospital, Hampshire
l Dr Gary Dennis – Royal Hallamshire Hospital, Sheffield
l Dr Jacqueline Tay – Leeds General Infirmary, Leeds
l Dr Manjiri Khare – University Hospitals of Leicester, Leicester
l Dr Feroza Dawood – Liverpool Women’s Hospital, Liverpool
l Dr Charlotte Lawthorn – Neville Hall Hospital, Abergavenny
l Dr Tadala Saukila – University Hospital of Durham, Newcastle upon Tyne
l Mr Wesley McCullough – Northampton General Hospital, Northamptonshire
l Dr Alpa Shah – Newham Hospital, London
l Dr Fidelma O’Mahoney – University Hospital of North Staffordshire, Staffordshire
l Miss Abha Govind – North Middlesex University Hospital, London
l Dr Oier Aeka and Dr Lucy Mackillop – John Radcliffe Hospital, Oxford
l Dr Karen Brackley – Princess Anne Hospital, Southampton
l Dr Mukta Bhattacharya – Queen Alexandra Hospital, Portsmouth
l Dr Leye Thompson – Queen’s Hospital, Romford
l Dr Sophia Stone – St Richard’s Hospital, Chichester
l Dr Philippa Marsden – Royal Victoria Infirmary, Newcastle upon Tyne
l Dr Rehan Khan – The Royal London Hospital, London
l Miss Heather Brown – Royal Sussex County Hospital, Brighton
l Mr Narayanaswamy Raman – Southend Hospital, Westcliff on Sea
l Dr Hanah Cock – St George’s Hospital, London
l Dr Robert Powell – Singleton Hospital, Swansea
l Dr Teresa Kelly – St Mary’s Hospital, Manchester
l Dr Aarti Ullal – Sunderland Royal Hospital, Sunderland
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l Mr Phil Tittensor – Stafford General Hospital, Stafford
l Dr Adam Gornall – Royal Shrewsbury Hospital, Shrewsbury
l Dr Aylur Rajasri – Royal Cornwall Hospital (Treliske), Truro
l Professor Catherine Nelson-Piercy – St Thomas’ Hospital, London
l Dr Khalid Hamandi – University Hospital of Wales, Cardiff
l Dr Rita Arya – Warrington Hospital, Warrington
l Dr Lakshmi Thirumalaikumar – Worcestershire Royal Hospital, Worcester
l Dr Sophia Stone – Worthing Hospital, Western Sussex
l Dr Sujatha Thamban – Whipps Cross Hospital, London.
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Appendix 8 Recruitment at each site
TABLE 36 Breakdown of recruitment by site
Site
Trial group, n
Total (N= 557), n
Randomised
Non-randomised
(N= 294)TDM (N= 130) CFM (N= 133)
Arrowe Park Hospital 0 1 1 2
Royal Blackburn Hospital 1 4 6 11
Bradford General Hospital 2 2 2 6
Royal Victoria Hospital 2 5 5 12
Birmingham Women’s Hospital 12 10 27 49
Burnley General Hospital 0 3 5 8
Birmingham City Hospital 5 0 3 8
Colchester General Hospital 3 2 6 11
University Hospital Coventry 3 0 4 7
Chelsea & Westminster Hospital 3 3 4 10
Royal Derby Hospital 2 3 4 9
Royal Edinburgh Infirmary 1 3 1 5
Frimley Park Hospital 3 0 5 8
Glan Clwyd Hospital 5 5 7 17
Royal Gwent Hospital 2 1 5 8
Southern General Hospital 2 5 6 13
Gloucester Royal Hospital 1 0 2 3
Royal Hampshire County Hospital 1 2 5 8
Jessop Hospital 5 3 14 22
Leeds General Infirmary 3 2 6 11
Leicester Royal Infirmary 1 1 7 9
Liverpool Women’s Hospital 3 4 15 22
Nevill Hall Hospital 1 0 2 3
University Hospital of North Durham 1 2 5 8
Northampton General Hospital 0 2 1 3
Newham University Hospital 1 1 4 6
North Staffordshire Hospital 4 1 6 11
North Middlesex University Hospital 0 1 1 2
John Radcliffe Hospital 2 3 6 11
Southampton General Hospital 3 1 7 11
continued
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TABLE 36 Breakdown of recruitment by site (continued )
Site
Trial group, n
Total (N= 557), n
Randomised
Non-randomised
(N= 294)TDM (N= 130) CFM (N= 133)
Queen Alexandra Hospital 2 0 3 5
Queen’s Hospital 7 7 13 27
St Richard’s Hospital 3 6 9 18
Royal Victoria Infirmary 7 5 10 22
Royal London Hospital 2 1 5 8
Royal Sussex County Hospital 1 0 5 6
Southend University Hospital 2 6 2 10
St George’s Hospital 4 3 10 17
Singleton Hospital 5 4 7 16
Salford Royal 1 2 5 8
Sunderland Royal Hospital 6 3 2 11
Stafford Hospital 7 6 4 17
Royal Shrewsbury Hospital 3 1 5 9
Royal Cornwall Hospital 2 2 2 6
St Thomas’ Hospital 1 7 19 27
University Hospital of Wales 0 2 5 7
Warrington Hospital 0 2 4 6
Worcestershire Royal Hospital 4 3 6 13
Worthing Hospital 1 1 4 6
Whipps Cross University Hospital 0 2 2 4
CFM, clinical features monitoring; TDM, therapeutic drug monitoring.
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Appendix 9 Case report form
Baseline booklet
BASELINE BOOKLET 
Patient UTIN:   __ __/__ __ __ 
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BASELINE 
BOOKLET 
Visit checklist 1 Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
CHECKLIST (Completed Y/N) ACTION 
Have you advised the 
trial ofice that the 
participant has been 
recruited to EMPIRE 
by faxing Recruitment 
form: Parts 1 & 2? 
Yes      File completed Recruitment Form: parts 1 & 2  
No     
Send Recruitment Form: parts 1 & 2 AND EMPIRE Trial blood request 
form to the trial ofice. Proceed according to SOP no. 3 Blood collection 
and processing 
Has a blood sample 
been taken? Yes      
Centrifuge and package sample according to SOP no. 3 Blood collection 
and processing 
No     
Please take blood sample and package according to SOP no. 3 Blood 
collection and processing 
Or  
Document reason why blood sample was not taken  
Please state here: 
 
Have you provided the 
participant with the 
EMPIRE diary? 
Yes      Explain how diary is to be completed. 
No     
Please provide participant with diary and explain how it is to be 
completed. 
Or  
Document reason why diary not given 
Please state here: 
 
Have you completed 
Baseline Booklet? 
Yes      File Baseline Booklet in participant’s CRF ile. 
No     Complete Baseline Booklet and ile in participant’s CRF ile. 
Has the participant 
completed: 
Patient’s 
questionnaire (EQ-5d, 
LAEP& cost 
questionnaire) 
Yes      Return completed Patient’s questionnaire to participant’s CRF ile. 
No     
Ask participant to complete Patient’s questionnaire and ile in 
participant’s CRF ile. 
OR 
Document reason why not completed. 
Please state here: 
 
To be continued on the next page 
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BASELINE 
BOOKLET 
Visit checklist 2 Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
CHECKLIST (Completed Y/N) ACTION 
Has the participant 
completed: 
QOLIE 31 
questionnaire? 
Yes      Return completed QOLIE 31 questionnaire to participant’s CRF ile.  
No     
Ask participant to complete QOLIE 31 questionnaire and ile in 
participant’s CRF ile.  
OR 
Document reason why not completed. 
Please state here: 
 
 
Has the participant 
completed: 
NDDI-E screening tool? 
Yes      
Return completed NDDI-E to participant’s CRF ile. Score above 15 may 
imply existence of depression. If the case, please refer accordingly to 
your usual clinical practice. 
No     
Ask participant to complete NDDI-E screening tool and ile in 
participant’s CRF ile.  
OR 
Document reason why not completed. 
Please state here: 
 
Have you completed 
Purple Alert and 
Adverse Events 
Forms? 
Yes      File is in participant’s CRF ile. 
No     Complete if necessary and ile in participant’s CRF ile. 
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BASELINE 
BOOKLET 
Recruitment form  
Part 1 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
IMPORTANT: Part 1 & 2 of this form MUST be completed and sent to the Trial Co-ordinator along with 
the EMPIRE blood request form on the day of the participant’s recruitment 
 
 
PRE-TRIAL SERUM AED LEVEL (PRE-PREGNANCY OR EARLY PREGNANCY) 
As the treating clinician you have the choice of setting a pre-pregnancy serum AED level (PPSL) OR the Early 
Pregnancy serum AED level (taken in pregnancy prior to trial baseline visit) (EPSL) as the ‘target’ level. If a pre-
pregnancy level is to be used it should be taken within the last 12 months. You should be conident that when 
this level was taken the participant was adherent to treatment, on the same current daily dosage and ideally the 
time interval between the oral dosage and serum level will be similar to those taken throughout the pregnancy. 
PRE-PREGNANCY SERUM AED LEVEL (PPSL) 
As the treating clinician are you conident that: 
The participant’s serum level has been taken pre-pregnancy and recorded in 
the last 12 months? 
Yes       No   
You know the timing of the serum level and the last dose taken? Yes       No   
Do you think the serum level of AED in pre-pregnancy takes into account the 
time of the day of intake? 
Yes       No   
If you have answered yes to all the above are you happy for the pre-pregnancy 
serum AED level to be the target level for the trial? 
Yes       No   
If yes, please set pre-pregnancy serum AED level as the target AED level for the trial. 
EARLY PREGNANCY SERUM AED LEVEL (EPSL)  
(TAKEN IN PREGNANCY PRIOR TO TRIAL BASELINE VISIT)  
As the treating clinician are you conident that: 
The participant’s serum level has been taken in this pregnancy? Yes       No   
You know the timing of the serum level and the last dose taken? Yes       No   
Do you think the serum level of AED in this pregnancy takes into account the 
time of the day of intake? 
Yes       No   
If you have answered yes to all the above are you happy for the pre-trial 
serum AED level to be the target level for the trial? 
Yes       No   
If yes, please set pregnancy serum AED level as the target AED level for the trial. 
Do that ONLY if pre-pregnancy level is not set as a target. 
  
  
  
  
  
  
  
  
Please, state the date when  
the patient consent was obtained  
DD / MMM / YYYY 
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
84
BASELINE 
BOOKLET 
Recruitment form 
Part 2 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
Please present all available data regarding pre-trial AED serum levels i.e. pre-pregnancy AED 
serum levels (PPSL), early pregnancy serum levels (EPSL) or both. 
Current AED   
Please use Brand name, if prescribed 
Total 
daily dose 
(mg) 
AED serum 
level known 
SERUM LEVEL   Date  
AED level taken 
Use as the 
EMPIRE 
serum 
target level 
Value Unit 
carbamazepine  
(generic) 
Yes    No  
 
PPSL         
μmol/l  
mg/l      
DD / MMM / YYYY 
Yes  
No 
 
 
Tegretol  
(brand) 
Yes    No  EPSL   
μmol/l  
mg/l      
DD / MMM / YYYY 
Yes  
No 
 
 
Tegretol Retard 
(brand)  
Yes    No  Neither    
lamotrigine 
(generic)  Yes    No  
 
PPSL         
μmol/l  
mg/l      
DD / MMM / YYYY 
Yes  
No 
 
 
EPSL   
μmol/l  
mg/l      
DD / MMM / YYYY 
Yes  
No 
 
 Lamictal  
(brand) 
Yes    No  
Neither    
levetiracetam  
(generic) Yes    No  
 
PPSL         
μmol/l  
mg/l      
DD / MMM / YYYY 
Yes  
No 
 
 
EPSL   
μmol/l  
mg/l      
DD / MMM / YYYY 
Yes  
No 
 
 Keppra  
(brand) 
Yes    No  
Neither    
phenytoin 
(generic) Yes    No  
 
PPSL         
μmol/l  
mg/l      
DD / MMM / YYYY 
Yes  
No 
 
 
EPSL   
μmol/l  
mg/l      
DD / MMM / YYYY 
Yes  
No 
 
 Epanutin 
(brand) 
Yes    No  
Neither    
      
Gestational age 
_____________ weeks _______________days 
Did the participant experience seizures (any type) during the 3 months prior to her pregnancy? Yes     No   
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BASELINE 
BOOKLET 
Baseline form 
AED Medication 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
AED MEDICATION 
This part is to be used to document all dose changes for all AED medication taken 6 months prior to the 
start of the trial up until this visit.  
Medication 
Total  
daily dose 
(mg)
Start date Ongoing? End date 
 
 DD / MMM / YYYY Yes     No   DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
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BASELINE 
BOOKLET 
Baseline form 
Non-AED Medication 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
NON-AED MEDICATION 
This part is to be used to document all dose changes for all non AED medication taken 6 months prior to 
the start of the trial up until the inal post natal visit.  
Medication 
Total  
daily dose 
(mg)
Start date Ongoing? End date 
Folic Acid 
 DD / MMM / YYYY Yes     No   DD / MMM / YYYY 
Vitamin K 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
Methyldopa 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
Nifedipine 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
Insulin 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
Metformin 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
Labetelol 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
Ferrous sulphate 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
Aspirin 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
If any other medication is being used, please specify medication name and ill in following gaps.  
If not applicable please cross the section. 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
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BASELINE 
BOOKLET 
Baseline Form 
Surgical & Obstetric History 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
SURGICAL HISTORY 
Has the participant had any intracranial surgery prior to the study visit? Yes       No     
If yes, please specify  
 
Date DD / MMM / YYYY 
VAGAL NERVE STIMULATION (VNS) 
Does the patient have a VNS 
device itted? Yes       No   
If yes, current status of 
the VNS device On       Off   
GRAVIDA & PARITY 
Gravida 
(Number of pregnancies including this one) 
 Parity 
(Number of previous births at 24 weeks or 
more gestation) 
 
PREVIOUS PREGNANCY COMPLICATIONS 
Has the participant had any terminations or miscarriages? Yes       No   
If yes, please specify below:  
Total number of terminations 
 
Total number of miscarriages  
Number of 1st  
trimester miscarriages 
 Number of 2nd 
trimester miscarriages 
 
 
Previous maternal history  
Pre-eclampsia 
Yes     No  
Eclampsia 
Yes     No  
Gestational 
diabetes Yes     No  
Antepartum 
haemorrhage Yes     No  
Abruption 
Yes     No  
Caesarean 
section Yes     No  
Postpartum 
haemorrhage Yes     No  
Infection 
Yes     No  
Other Yes     No  
If Other, please specify  
Admission to hospital due to seizures in previous pregnancies Yes     No  
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BASELINE 
BOOKLET 
Baseline Form 
Medical History  
(excluding epilepsy) 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
MEDICAL HISTORY 
Is there a history of: Patient Family history 
1. Congenital abnormalities Yes       No     Yes       No     
2. Learning dificulties Yes       No     Yes       No     
3. Diabetes Yes       No     Yes       No     
4. Chronic Hypertension Yes       No     Yes       No     
5. Renal disease Yes       No     Yes       No     
6. Immunological problems  Yes       No     Yes       No     
If yes, please specify:                                 a) Systemic Lupus Yes       No     Yes       No     
b) Erythematosis Yes       No     Yes       No     
c) Rheumatoid arthritis Yes       No     Yes       No     
d) If other, please specify here   
7. Cardiac disease 
If yes, please specify here 
Yes       No     
 
Yes       No     
 
8. Haematological disorders Yes       No     Yes       No     
If yes, please specify:                        a) Deep vein thrombosis Yes       No     Yes       No     
b) Pulmonary embolism Yes       No     Yes       No     
c) Thrombocytopenia Yes       No     Yes       No     
d) If other, please specify here   
9. HIV Yes       No     Yes       No     
10. Tuberculosis Yes       No     Yes       No     
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11. Any genetically inherited disorders 
If yes, please specify here 
Yes       No     Yes       No     
12. Mental illness Yes       No     Yes       No     
If yes, please specify:                               a) Majo r depression Yes       No     Yes       No     
  b) Puerperal psychosis Yes       No     Yes       No     
c) Bipolar disorder Yes       No     Yes       No     
d) Schizophrenia Yes       No     Yes       No     
e) If other, please specify here   
13. Any other    
If yes, please specify here 
Yes       No     
 
Yes       No     
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BASELINE 
BOOKLET 
Baseline Form 
Epilepsy History 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
DIAGNOSIS OF EPILEPSY
  
Age at irst seizure  
(excluding febrile) 
years Date of irst seizure 
(excluding febrile) DD / MMM / YYYY 
AETIOLOGY OF EPILEPSY 
Idiopathic, assumed genetic   
Structural (if yes, please specify)  
Trauma    Stroke    
Space occupying 
lesions    
SLE    
Vascular 
malformation    
Other  
(if yes please specify below)    
  
Cryptogenic   
Infection (if yes, please specify)  Encephalitis    HIV  
Metabolic  (if yes, please specify)  Alcohol    Drug  
EPILEPSY SYNDROME 
Syndrome Please tick one 
Partial Epilepsy Symptomatic or cryptogenic partial epilepsy  
Temporal lobe  
Frontal lobe  
Parietal lobe  
Occipital lobe  
Localisation unknown  
Generalised 
 
Juvenile myoclonic epilepsy  
Tonic clonic seizures on wakening  
Childhood absence epilepsy  
Juvenile absence epilepsy  
Unclassiied Epilepsy/Other syndromic diagnosis  
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BASELINE 
BOOKLET 
Baseline Form  
Seizure types 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
SEIZURE CLASSIFICATION & FREQUENCY 
Seizure description (s) 
Has the participant ever 
experienced any of the 
following: 
Yes/No 
Number of seizures 
in the 3 months prior 
to pregnancy (if exact 
number not known, 
please give best 
estimate) 
Number of seizures 
since becoming 
pregnant (if exact 
number not known, 
please give best 
estimate) 
Generalized 
 
Tonic clonic 
(including 
secondary 
generalized 
seizures) 
Yes      No    
 
Absence Yes      No     
Myoclonus Yes      No     
Partial Simple  Yes      No     
Complex Yes      No     
Unclassiied/Other Yes      No     
CLUSTERS 
Has the patient had a 
seizure cluster? Yes       No   
Date of last seizure 
cluster DD / MMM / YYYY 
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BASELINE 
BOOKLET 
Baseline Form 
EEG/MRI 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
EEG INTERPRETATION (IF AVAILABLE) 
Has an EEG been performed at any 
time? Yes    No   
Date 
DD / MMM / YYYY 
Result known  
If yes, please specify outcome below: Yes    No   
 
Is EEG normal? Yes    No   
 
If abnormal, is it clinically signiicant? Yes    No   
If clinically signiicant  
please specify 
Focal epileptiform  
discharges  
If yes, please specify: 
Generalised epileptiform  
discharges  
If yes, please specify: 
Other  If yes, please specify: 
 
MRI/CT INTERPRETATION (IF AVAILABLE) 
Has an MRI been performed at any 
time? Yes       No   
Date 
DD / MMM / YYYY 
Result known Yes       No   
If yes, please specify outcome: 
Has the MRI demonstrated aetiology of 
epilepsy? 
If yes, please specify below 
Yes       No    
Tumour Yes       No   
Vascular 
malformation Yes       No   
Previous trauma Yes       No   
Hippocampal 
sclerosis Yes       No   
Previous stroke Yes       No   Cortical dysplasia Yes       No   
Other ( if yes please specify) Yes       No    
Has a CT been performed? Yes       No   Date 
DD / MMM / YYYY 
Result known Yes       No   
If yes, please specify outcome: 
Has the CT demonstrated aetiology of 
epilepsy? If yes, please specify: Yes       No   
 
Tumour Yes       No   Previous stroke Yes       No   
Previous trauma Yes       No   
Vascular 
malformation Yes       No   
Other, if yes please specify  Yes       No    
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 BASELINE 
BOOKLET 
Baseline Form 
Demographics Part 1 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
DEMOGRAPHICS 
 
MOTHER’S  
ETHNIC GROUP 
Please tick only one 
White Black or Black British 
British  African  
Irish  Caribbean  
White other  Black other  
Asian or Asian British Mixed Other ethnic group 
Bangladeshi  Mixed – White/Black African  Other ethnic group  
Indian  
Mixed – White/Black 
Caribbean 
   
Pakistani  Mixed – White/Asian  Not given  
Chinese  Mixed – White/Chinese    
Asian other  Mixed other    
 
 
HEIGHT AND WEIGHT  
Height  cm Weight  kg 
 
PATIENT’S AGE 
Years  Months  
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BASELINE 
BOOKLET 
Baseline Form 
Demographics Part 2 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
EMPLOYMENT & DRIVING STATUS 
Employed – Full-time 
 
Holds a valid driving licence Yes    No  
Employed – Part-time 
 
Self – employed 
 
Medically it to drive Yes    No  
Unemployed 
 
EDUCATIONAL DETAILS 
Highest qualiication 
 
 
 
 
Degree Level  
A Level  
GCSE Level  
Below GCSE Level  
School leaving age __________ yrs  
NICOTINE & ALCOHOL CONSUMPTION DURING PREGNANCY 
 
Average number of alcohol 
units per week 
 
 
Examples 
Units Example 
1 unit 
Half pint of ordinary strength beer, lager, or cider (3-4% alcohol by volume) or a small pub 
measure (25 ml) of spirits (40% alcohol by volume) 
2 units Medium glass of 12.5% wine (175ml) or can of 4.5% beer (440ml) 
3 units Large glass of 12.5% wine (250ml)  or pint of 6% cider 
   
 
   
 
 
 
 
 
Smoker  
If yes, specify  
number of cigarettes per day 
 
Ex-smoker  
If yes, specify  
how long ago patient stopped smoking  
0 – 3 
months 
 
3+  
months 
 
Non-smoker   
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BASELINE 
BOOKLET 
Baseline Form 
Previous children 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
CHILDREN 
Please use the following sheets to document information about all of the participant’s previous 
births/children. Please begin with the most recent birth/child. One sheet should be used per child. 
If not applicable, please cross all irrelevant sections.   
Child number  Gender Male   Female   DOB DD / MMM / YYYY 
Gestational age at delivery wks Birth weight kg 
Neonatal death Yes     No       Still birth Yes     No   
Delivery mode Spontaneous Vaginal   Forceps   Ventouse   Caesarean section  
AED Exposure        
If yes, please specify AEDs taken when pregnant with this child: 
Yes     No     
lamotrigine                Yes      No    levetiracetam Yes      No       
carbamazepine 
 
Yes      No    sodium valproate      Yes      No       
phenytoin 
 
Yes      No    Other, if yes please specify 
 
Yes      No       
Congenital malformations (if yes, please specify below)  Yes     No     
Spina biida      Yes      No    Hydrocephalus Yes      No    
Diaphragmatic hernia                Yes      No    Anencephaly Yes      No    
Cleft lip      Yes      No    Congenital heart disease Yes      No    
Cleft palate Yes      No    Tumours Yes      No    
Gastroschisis Yes      No    Limb abnormalities Yes      No    
Duodenal atresia Yes      No    
External genital 
abnormalities Yes      No    
Congenital Cystic Adenomatoid 
Malformation 
Yes      No    
Other, if yes please specify 
 
Yes      No    
Epilepsy in childhood Yes     No   
  
    
    
  
    
    
    
  
    
    
    
    
    
    
    
  
Regular follow-up for neuro-developmental concerns Yes     No   
Statement of special educational needs?   Yes     No   
ADHD  
Attention deicit 
hyperactivity disorder 
Yes     No   
Aspergers 
syndrome Yes     No   
Autism Yes     No   
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BASELINE 
BOOKLET 
Baseline Form 
Previous children 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
CHILDREN 
Please use the following sheets to document information about all of the participant’s previous 
births/children. Please begin with the most recent birth/child. One sheet should be used per child. 
If not applicable, please cross all irrelevant sections.   
Child number  Gender Male   Female   DOB DD / MMM / YYYY 
Gestational age at delivery wks Birth weight kg 
Neonatal death  
(below 28 days) Yes     No       
Still birth Yes     No   
Delivery mode Spontaneous Vaginal   Forceps   Ventouse   Caesarean section  
AED Exposure        
If yes, please specify AEDs taken when pregnant with this child: 
Yes     No     
lamotrigine                Yes      No    levetiracetam Yes      No       
carbamazepine 
 
Yes      No    sodium valproate      Yes      No       
phenytoin 
 
Yes      No    Other, if yes please specify 
 
Yes      No       
Congenital malformations (if yes, please specify below)  Yes     No     
Spina biida      Yes      No    Hydrocephalus Yes      No    
Diaphragmatic hernia                Yes      No    Anencephaly Yes      No    
Cleft lip      Yes      No    Congenital heart disease Yes      No    
Cleft palate Yes      No    Tumours Yes      No    
  
    
    
  
    
    
    
  
    
    
    
    
Gastroschisis Yes      No    Limb abnormalities Yes      No    
Duodenal atresia Yes      No    
External genital 
abnormalities Yes      No    
Congenital Cystic Adenomatoid 
Malformation 
Yes      No    
Other, if yes please specify 
 
Yes      No    
Epilepsy in childhood Yes     No   
Regular follow-up for neuro-developmental concerns Yes     No   
Statement of special educational needs?   Yes     No   
ADHD  
Attention deicit 
hyperactivity disorder 
Yes     No   
Aspergers 
syndrome Yes     No   
Autism Yes     No   
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BASELINE 
BOOKLET 
Baseline Form 
Previous children 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
CHILDREN 
Please use the following sheets to document information about all of the participant’s previous 
births/children. Please begin with the most recent birth/child. One sheet should be used per child. 
If not applicable, please cross all irrelevant sections. 
Child number  Gender Male   Female   DOB DD / MMM / YYYY 
Gestational age at delivery wks Birth weight kg 
Neonatal death  
(below 28 days) Yes     No       
Still birth Yes     No   
Delivery mode Spontaneous Vaginal   Forceps   Ventouse   Caesarean section  
AED Exposure        
If yes, please specify AEDs taken when pregnant with this child: 
Yes     No     
lamotrigine                Yes      No    levetiracetam Yes      No       
carbamazepine 
 
Yes      No    sodium valproate      Yes      No       
phenytoin 
 
Yes      No    Other, if yes please specify 
 
Yes      No       
Congenital malformations (if yes, please specify below)  Yes     No     
Spina biida      Yes      No    Hydrocephalus Yes      No    
Diaphragmatic hernia                Yes      No    Anencephaly Yes      No    
Cleft lip      Yes      No    Congenital heart disease Yes      No    
Cleft palate Yes      No    Tumours Yes      No    
Gastroschisis Yes      No    Limb abnormalities Yes      No    
Duodenal atresia Yes      No    
External genital 
abnormalities Yes      No    
Congenital Cystic Adenomatoid 
Malformation 
Yes      No    
Other, if yes please specify 
 
Yes      No    
Epilepsy in childhood Yes     No   
  
    
    
  
    
    
    
  
    
    
    
    
    
    
    
  
Regular follow-up for neuro-developmental concerns Yes     No   
Statement of special educational needs?   Yes     No   
ADHD  
Attention deicit 
hyperactivity disorder 
Yes     No   
Aspergers 
syndrome Yes     No   
Autism Yes     No   
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BASELINE 
BOOKLET 
Baseline Form 
Previous children 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
CHILDREN 
Please use the following sheets to document information about all of the participant’s previous 
births/children. Please begin with the most recent birth/child. One sheet should be used per child. 
If not applicable, please cross all irrelevant sections.   
Child number  Gender Male   Female   DOB DD / MMM / YYYY 
Gestational age at delivery wks Birth weight kg 
Neonatal death  
(below 28 days) Yes     No       
Still birth Yes     No   
Delivery mode Spontaneous Vaginal   Forceps   Ventouse   Caesarean section  
AED Exposure        
If yes, please specify AEDs taken when pregnant with this child: 
Yes     No     
lamotrigine                Yes      No    levetiracetam Yes      No       
carbamazepine 
 
Yes      No    sodium valproate      Yes      No       
phenytoin 
 
Yes      No    Other, if yes please specify 
 
Yes      No       
Congenital malformations (if yes, please specify below)  Yes     No     
Spina biida      Yes      No    Hydrocephalus Yes      No    
Diaphragmatic hernia                Yes      No    Anencephaly Yes      No    
Cleft lip      Yes      No    Congenital heart disease Yes      No    
Cleft palate Yes      No    Tumours Yes      No    
Gastroschisis Yes      No    Limb abnormalities Yes      No    
Duodenal atresia Yes      No    
External genital 
abnormalities Yes      No    
Congenital Cystic Adenomatoid 
Malformation 
Yes      No    
Other, if yes please specify 
 
Yes      No    
Epilepsy in childhood Yes     No   
  
    
    
  
    
    
    
  
    
    
    
    
    
    
    
  
Regular follow-up for neuro-developmental concerns Yes     No   
Statement of special educational needs?   Yes     No   
ADHD  
Attention deicit 
hyperactivity disorder 
Yes     No   
Aspergers 
syndrome Yes     No   
Autism Yes     No   
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BASELINE 
BOOKLET 
Baseline Form 
Previous children 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
CHILDREN 
Please use the following sheets to document information about all of the participant’s previous 
births/children. Please begin with the most recent birth/child. One sheet should be used per child. 
If not applicable, please cross all irrelevant sections.    
Child number  Gender Male   Female   DOB DD / MMM / YYYY 
Gestational age at delivery wks Birth weight kg 
Neonatal death  
(below 28 days) Yes     No       
Still birth Yes     No   
Delivery mode Spontaneous Vaginal   Forceps   Ventouse   Caesarean section  
AED Exposure        
If yes, please specify AEDs taken when pregnant with this child: 
Yes     No     
lamotrigine                Yes      No    levetiracetam Yes      No       
carbamazepine 
 
Yes      No    sodium valproate      Yes      No       
phenytoin 
 
Yes      No    Other, if yes please specify 
 
Yes      No       
Congenital malformations (if yes, please specify below)  Yes     No     
Spina biida      Yes      No    Hydrocephalus Yes      No    
Diaphragmatic hernia                Yes      No    Anencephaly Yes      No    
Cleft lip      Yes      No    Congenital heart disease Yes      No    
Cleft palate Yes      No    Tumours Yes      No    
Gastroschisis Yes      No    Limb abnormalities Yes      No    
Duodenal atresia Yes      No    
External genital 
abnormalities Yes      No    
Congenital Cystic Adenomatoid 
Malformation 
Yes      No    
Other, if yes please specify 
 
Yes      No    
Epilepsy in childhood Yes     No   
  
  
    
    
  
    
    
    
  
    
    
    
    
    
    
    
  
Regular follow-up for neuro-developmental concerns Yes     No   
Statement of special educational needs?   Yes     No   
ADHD  
Attention deicit 
hyperactivity disorder 
Yes     No   
Aspergers 
syndrome Yes     No   
Autism Yes     No   
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Neurological Disorders Depression Inventory for Epilepsy
PATIENT’S 
QUESTIONAIRE 
Baseline visit 
NDDI-E SCREENING TOOL 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
EPILEPSY FOUNDATION NEUROLOGICAL DISORDER DEPRESSION INVENTORY FOR 
EPILEPSY (NDDI-E) SCREENING TOOL 
For each item listed below please circle the answer that best describes you (the mother) within the last 2 
weeks, including today. If a particular feelings occurred ‘always’ or ‘often’ circle 4.  
If it occurred sometimes circle 3 and so on. Please be sure to answer every item. 
 
 Always or often Sometimes Rarely Never 
1. Everything is a 
struggle 
 
4 
 
3 2 1 
2. Nothing I do is 
right 
 
4 
 
3 2 1 
3. Feel guilty 
 
4 
 
3 2 1 
4. I’d be better off 
dead 
 
4 
 
3 2 1 
5. Frustrated 
 
4 
 
3 2 1 
6. Dificulty inding 
pleasure 
 
4 
 
3 2 1 
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Patient questionnaire
PATIENT’S QUESTIONNAIRE 
Patient UTIN:   __ __/__ __ __ 
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Please note that the analogous scale was not used.
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PATIENT’S 
QUESTIONNAIRE 
Cost questionnaire  
Part 1  
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
QUESTIONAIRE FOR MEASURING COSTS TO PREGNANT MOTHERS WITH EPILEPSY ON 
ANTIEPILEPTIC MEDICATION  
The aim of the questionnaire: 
Health care programmes that treat conditions affect a large number of people. However, very little is 
known about the hidden costs of these treatments to the health service and to individuals taking part. 
An estimation of the costs would be incomplete if we did not consider the cost to the patients when 
attending for treatment. By doing this we can find out if the service we provide is valuable for each 
individual. The information we get from this questionnaire will help us to find out this valuable 
information, and will be part of the EMPIRE study. 
What you need to do: 
We would appreciate it if you would take time to ill in this short questionnaire. Please answer every 
question. We are interested in this particular visit for your pregnancy. If you are not sure or cannot 
remember the exact details, please give the best answer you can. You do not have to put your name on the 
questionnaire and therefore the information you provide is anonymous.  
For all visits after the irst one 
If your travel cost arrangements have not changed since you last illed in the questionnaire, please 
tick HERE.   
If they have changed, please can you complete the questionnaire below. 
Thank you for your participation in the EMPIRE study, your time and interest are very 
much appreciated 
Thinking about your most recent visit to the hospital clinic: 
1. What would have been your main activity if you had not attended the clinic? 
 
 Paid employment   
Looking after relatives   
Leisure activities   
Housework    
Studying at college   
Other       Please specify_________________ 
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PATIENT’S 
QUESTIONNAIRE 
Cost questionnaire  
Part 2 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
If you are in paid employment, please answer question 2, if not go to question 3. 
2. What arrangements did you make to take time off work? (Please tick one box) 
 
 Paid absence from work   
 Unpaid absence from work   
 Will make the time up               
 Came to clinic outside work time  
 Took holiday     
 Other arrangements     Please specify___________ 
 
3. How long did it take you to travel to the clinic? 
________ hours ________minutes 
4. Approximately what distance did you have to travel to get to the clinic (one-way)? 
            _______________miles 
5.a) How did you travel to the clinic? Please tick the main forms of transport. 
 Walking     
 Private car     
 Public transport - bus               
 Public transport - train              
 Taxi      
Other       Please specify _______________ 
 
b) If you travelled by private car, were you given a lift by someone else?   
  
Yes    No  
c) If you travelled by private car, how much was paid in car park fees? 
£_____p_____ 
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PATIENT’S 
QUESTIONNAIRE 
Cost questionnaire  
Part 3 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
d) If you travelled by public transport (bus or train), what was the cost of the one-way fare? If 
you were given a return fare, simply halve it. Put zero if you did not travel by public transport at 
all or you did not pay a fare. 
£_____p_____ 
e) If you travelled by  taxi what was the cos t of the (one-way) fare? Pu t ze ro if you did not 
travel by taxi at all or you did not pay a fare.       
       £_____p_____  
 
6. Did anyone accompany you to the clinic  
and wait for you while you received your care ? Yes  No   
If yes, did they take time off work ?  Yes  No  
7. If you have other dependants,  
Did you pay someone to look after them? 
Yes    No    Not Applicable  
If yes, how much did it cost?       £_____ p______ 
or 
Did someone take time off work to look after them?  Yes    No  
8. How long did you spend waiting at the clinic before your appointment? 
________ hours ________minutes 
If you have any comments about your costs for attending the clinic or anything else about this study 
please write them below. 
 
 
 
 
Thank you for taking the time to complete this questionnaire. 
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Quality Of Life In Epilepsy – 31-item questionnaire
 
QUALITY OF LIFE IN EPILEPSY QOLIE 31 
(Version 1.0 UK) 
Patient UTIN:   __ __/__ __ __ 
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QUALITY OF LIFE IN EPILEPSY QOLIE – 31 VERSION 1.0 
INSTRUCTIONS 
The QOLIE-31 is a survey of health related quality of life for adults (18 years or older) with epilepsy.  This 
questionnaire should be completed only by the person who has epilepsy (not a relative or a friend) because 
no one else knows how YOU feel. 
 
There are 31 questions about your health and daily activities.  Answer every question by circling the 
appropriate number (1, 2, 3….).  If you are unsure about how to answer a question, please give the best 
answer you can and write a comment or explanation on the side of the page.  These notes maybe useful if 
you discuss the QOLIE-31 with your doctor.  Completing the QOLIE-31 before and after treatment changes 
may help you and your doctor understand how the changes have affected your life. 
 
1. Overall, how would you rate your quality of life? 
(Please circle only one number on the scale below) 
 
      10         9            8           7           6             5           4            3            2            1         0 
 
PATIENT’S 
QUESTIONNAIRE 
QOLIE 31 Version 1.0 UK 
Part 1 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
Best Possible 
Quality of life 
Worst Possible 
Quality of life 
(as bad as or worse 
than being dead) 
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PATIENT’S 
QUESTIONNAIRE 
QOLIE 31 Version 1.0 UK 
Part 2 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
These questions are about how you FEEL and how things have been for you during the past 4 weeks.  For 
each question, please indicate the one answer that comes closest to the way you have been feeling.  
How much time during the past 4 weeks…….         (Circle one number on each line) 
 All of 
the 
time 
Most of 
the 
time 
A good 
bit of 
the 
time 
Some of 
the 
time 
A little 
bit of 
the 
time 
None of 
the 
time 
2.   Did you feel full of life? 1 2 3 4 5 6 
3. Have you been a very 
nervous person? 
1 2 3 4 5 6 
4. Have you felt so down in 
the dumps that nothing 
could cheer you up? 
1 2 3 4 5 6 
5. Have you felt calm and 
peaceful? 
1 2 3 4 5 6 
6. Did you have a lot of 
energy? 
1 2 3 4 5 6 
7. Have you felt 
downhearted and low? 
1 2 3 4 5 6 
8.  Did you feel worn out? 1 2 3 4 5 6 
9. Have you been a happy 
person? 
1 2 3 4 5 6 
10. Did you feel tired? 1 2 3 4 5 6 
11. Have you worried about 
having another it? 
1 2 3 4 5 6 
12. Did you have dificulty 
reasoning and solving 
problems (such as 
making plans, making 
decisions, learning new 
things)? 
1 2 3 4 5 6 
13. Has your health limited 
your social activities 
(such as visiting friends 
or close relatives)? 
1 2 3 4 5 6 
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PATIENT’S 
QUESTIONNAIRE 
QOLIE 31 Version 1.0 UK 
Part 3 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
14. How has your QUALITY OF LIFE been during the past 4 weeks (that is, how have things 
been going for you)? 
(Circle one number) 
Very good 
could hardly 
have been 
better 
Pretty good 
Good & bad 
parts about 
equal 
Pretty bad 
Very bad: could 
hardly have 
been worse 
1 2 3 4 5 
 
The following question is about MEMORY. 
 (Circle one number) 
 Yes, a lot 
Yes, 
somewhat 
Only a 
little 
No, not at 
all 
15. In the past 4 weeks, have 
you had any trouble with 
your memory? 
1 2 3 4 
The following question is about how often during the past 4 weeks you have had trouble 
remembering or how often this memory problem has interfered with your normal work or living 
                  (Circle one number only for question 16) 
 
All of 
the time 
Most of 
the 
time 
A good 
bit of 
the 
time 
Some of 
the 
time 
A little 
of the 
time 
None 
of the 
time 
16. Trouble 
remembering things 
people told you  
1 2 3 4 5 6 
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PATIENT’S 
QUESTIONNAIRE 
QOLIE – 31 Version 1.0 UK 
Part 4 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
The following questions are about CONCENTRATION problems you may have. During the 
past 4 weeks, how often have you had trouble concentrating or how often have these 
problems interfered with your normal work or living?          (Circle one number on 
each line) 
 
All of the 
time 
Most of 
the 
time 
A good 
bit of 
the 
time 
Some 
of the 
time 
A little 
of the 
time 
None of 
the time 
17. Trouble concentrating 
on reading 
1 2 3 4 5 6 
18. Trouble concentrating 
on one thing at a time 
1 2 3 4 5 6 
 
The following questions are about problems you may have with certain ACTIVITIES.  Circle one 
number for how much during the past 4 weeks your epilepsy or antiepileptic medication has 
caused you trouble with……              (Circle one number on each line) 
 
A great 
deal 
A lot 
Somewh
at 
Only a 
little 
No, not at 
all 
19. Leisure time (such as 
hobbies and going out) 
1 2 3 4 5 
20. Driving 1 2 3 4 5 
The following questions relate to how you FEEL about your its.   (Circle one number on each line) 
 
Very 
fearful 
Somewhat 
fearful 
Not very 
fearful 
Not fearful 
at all 
21. How afraid are you of having a fit 
during the next 4 weeks? 
1 2 3 4 
 
 Worry a lot Occasionally 
worry 
Don’t worry at 
all 
22. Do you worry about hurting 
yourself during a fit?  
1 2 3 
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PATIENT’S 
QUESTIONNAIRE 
QOLIE – 31 Version 1.0 UK 
Part 5 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
The following questions relate to how you FEEL about your its.   (Circle one number on each line) 
 Very 
worried 
Somewhat 
worried 
Not very 
worried 
Not at all 
worried  
23. How worried are you about 
embarrassment or other social 
problems due to a it during the 
next 4 weeks? 
1 2 3 4 
24. How worried are you that the 
drugs you are taking may be bad 
for you if you have to take them 
for a long time?  
1 2 3 4 
For each of these PROBLEMS circle one number for how much they bother you on a scale of 1 
to 5 where 1 = Not at all bothersome, and 5 = Extremely bothersome. 
 Not at all 
bothersome 
 Extremely 
bothersome 
25. Fits  1 2 3 4 5 
26. Memory dificulties 1 2 3 4 5 
27. Work limitations 1 2 3 4 5 
28. Social limitations 1 2 3 4 5 
29. Physical effects of 
antiepileptic drugs 
1 2 3 4 5 
30. Mental effects of 
antiepileptic drugs 
1 2 3 4 5 
31.  How good or bad do you think your health is?  On the thermometer scale below, the best 
imaginable state of health is 10 and the worst imaginable state is 0.  Please indicate how you feel 
about your health by circling one number on the scale. Please consider your epilepsy as part 
of your health when you answer this question. 
(Please circle only one number on the scale below) 
 10          9              8              7              6               5              4               3               2              1            0 
Best Imaginable Health State Worst Imaginable Health State 
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Antenatal follow-up booklet
ANTENATAL FOLLOW-UP 
 BOOKLET 
Patient UTIN:   __ __/__ __ __ 
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ANTENATAL 
FOLLOW-UP 
BOOKLET 
Visit checklist  
Part 1 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
Gestational age 
_____________ weeks _______________days 
 
CHECKLIST ACTION 
Have you received a 
PURPLE ALERT or 
requested any non 
trial serum AED 
levels? 
Yes      
Check that serum AED levels collected since the participant’s entry 
into the trial have been received from the trial ofice and have been 
recorded in Purple Alert Form (PAF). 
No     No action required 
Has a blood sample 
been taken? 
Yes      
Centrifuge and package sample according to SOP no.3 Blood 
collection and processing 
Send EMPIRE trial blood request form to trial ofice 
No     
Please take blood sample and package according to SOP no.3 Blood 
collection and processing 
Send EMPIRE trial blood request form to trial ofice 
Or  
Document reason why blood sample was not taken. 
Please state here: 
 
Has participant 
completed all 
relevant pages of the 
EMPIRE diary 
Yes      
Please ile diary in participant’s CRF ile and provide participant 
with a new diary 
Please enter next clinic visit date and time in participants diary. 
No     
Please ask participant to recall as much information since the last 
visit as possible and document in diary. 
Has the participant 
completed: 
Patient’s 
questionnaire? 
Yes      Return completed Patient’s questionnaire to participant’s CRF ile. 
No     
Ask participant to complete Patient’s questionnaire and ile in 
participant’s CRF ile. 
OR 
Document reason why not completed 
Please state here: 
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FOR PARTICIPANTS 
BETWEEN 32 - 36 
WEEKS GESTATION 
ONLY 
Has the participant 
completed: 
QOLIE 
questionnaire?  
Yes      Return completed Patient’s questionnaire to participant’s CRF ile. 
No     
Ask participant to complete Patient’s questionnaire and ile in 
participant’s CRF ile. 
OR 
Document reason why not completed 
Please state here: 
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ANTENATAL 
FOLLOW-UP 
BOOKLET 
Visit checklist  
Part 2 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
CHECKLIST ACTION 
Have there been any 
dose changes to AED 
or concomitant 
medication? 
Yes      Please, if so note all the changes in relevant part of this booklet. 
No     No further action 
Has participant 
experienced any 
adverse events? 
Yes      
Report in accordance with SOP no. 4. Adverse events and serious 
adverse events reporting. Update Adverse Events Form. 
No     No further action 
FOR PARTICIPANTS 
20 WEEKS 
GESTATION ONLY 
Has a routine 
ultrasound been 
conducted? 
Yes      
Please complete Ultrasound form for congenital abnormalities 
in midtrimester and ile in participant’s CRF ile. 
No     No further action. 
FOR PARTICIPANTS 
24 WEEKS & OVER 
ONLY 
Is an ultrasound scan 
for fetal growth 
required? 
Yes      
Please complete Ultrasound form for fetal growth and ile in 
participant’s CRF ile 
No     No further action 
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ANTENATAL 
FOLLOW-UP 
BOOKLET 
AED Medication 
Part 1 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
CURRENT TREATMENT 
Current AED.  
Please use Brand name, if prescribed 
Current daily 
dose (mg) 
Does the dose 
need to be 
changed today? 
New daily  
dose (mg) 
carbamazepine  
(generic) Yes   No  
 
Yes      
 No    
 
Tegretol  
(brand) Yes   No  
Tegretol Retard 
(brand)  Yes   No  
lamotrigine 
(generic)  Yes   No  
 
Yes      
 No    
 
Lamictal  
(brand) Yes   No  
levetiracetam  
(generic) Yes   No  
 
Yes      
 No    
 
Keppra  
(brand) Yes   No  
phenytoin  
(generic) Yes   No  
 
Yes      
 No    
 
Epanutin  
(brand) Yes   No  
sodium valproate  
(generic) Yes   No  
 
Yes      
      No    
 
Epilim 
(brand) Yes   No  
Have you adding any new AED medication today?  
If yes, please update specify drug name (brand) and dose below 
Yes       No     
Drug name: Daily dose (mg): 
If dose is being changed or a new drug added today, was this in response to? (please tick one) 
Purple alert               Clinical concerns      Patient concerns      
Has there been any change in the treatment between the last clinic visit and patient’s visit today? 
Yes       No     If yes, please update  ‘TREATMENT MODIFICATION’ in next section’ 
Since the last visit, has the team received a PURPLE ALERT for this patient? 
Yes      No     If yes, please ill the PURPLE ALERT section in the end of this booklet 
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ANTENATAL 
FOLLOW-UP 
BOOKLET 
AED Medication 
Part 2 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
TREATMENT MODIFICATION SINCE LAST CLINICAL VISIT 
CAUTION! Please record all changes in treatment in separate rows, alike if the change refers to dosage 
change, change of a drug’s brand, drug discontinuation or commencement. 
New drug or 
dosage change 
of already 
received one? 
AED name 
Daily dose 
before 
change* 
(mg) 
Date of change, drug 
introduction or 
discontinuation 
Daily dose after 
change or start 
dose in case of 
new drug 
(mg) 
If dose 
changed since 
last visit, who 
made the 
change? 
If dose changed 
since last visit, was 
this in response 
to? (please tick 
one)? 
New  drug          
     
Dose change     
 
Drug stopped 
 
  
DD / MMM /YYYY  
 
Clinical team   
 
Patient            
 
Purple alert               
 
Clinical concerns       
 
Patient concerns       
 
New  drug          
     
Dose change     
 
Drug stopped 
 
  
DD / MMM /YYYY 
 
Clinical team   
 
Patient            
 
Purple alert               
 
Clinical concerns      
 
Patient concerns      
 
New  drug          
     
Dose change     
 
Drug stopped 
 
  
DD / MMM /YYYY 
 
Clinical team   
 
Patient            
 
Purple alert               
 
Clinical concerns      
 
Patient concerns      
 
New  drug          
     
Dose change     
 
Drug stopped 
 
  
DD / MMM /YYYY 
 
Clinical team   
 
Patient            
 
Purple alert               
 
Clinical concerns      
 
Patient concerns      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
New drug or 
dosage change 
of already 
received one? 
AED name 
Daily dose 
before 
change* 
(mg) 
Date of change, drug 
introduction or 
discontinuation 
Daily dose after 
change or start 
dose in case of 
new drug 
(mg) 
If dose 
changed since 
last visit, who 
made the 
change? 
If dose changed 
since last visit, was 
this in response 
to? (please tick 
one)? 
New  drug          
     
Dose change     
 
Drug stopped 
 
 
 
DD / MMM /YYYY 
Clinical team   
 
Patient            
 
Purple alert               
 
Clinical concerns      
 
Patient concerns      
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ANTENATAL 
FOLLOW-UP 
BOOKLET 
Adherence checklist  
Part 1 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
TREATMENT ADHERENCE 
Has the patient taken the Trial AED(s) according to the clinician’s plan? 
Yes       No          
If no, please select one  
relevant reason: 
Concerned about effects to baby  
Concerned about side effects  
Forgotten to change dose  
Instructions not clear  
Has the AED serum level been checked by anyone outside the trial 
protocol? Yes       No     
If yes please specify by whom and record serum level(s) below: 
A & E  Obstetrician  Neurologist  Midwife  
Date of  
Blood Test 
AED Medication 
Test result for serum level  
Value Unit 
DD / MMM / YY 
  μmol/l  mg/l  
DD / MMM / YY 
  μmol/l  mg/l  
DD / MMM / YY 
  μmol/l  mg/l  
DD / MMM / YY 
  μmol/l  mg/l  
DD / MMM / YY 
  μmol/l  mg/l  
If yes, please report the unblinding to Trial Coordinator 
HOSPITAL ADMISSION 
Has the patient been admitted to hospital since her last visit? Yes       No     
Was it epilepsy 
related? 
Admission 1 Date & 
Time of 
admission DD / MMM / YY HH : MM 
Date & 
Time of 
discharge DD / MMM / YY HH : MM 
Yes     No   
Admission 2 Date & 
Time of 
admission DD / MMM / YY HH : MM 
Date & 
Time of 
discharge DD / MMM / YY HH : MM 
Yes     No   
  
 
 
 
 
  
    
  
  
  
  
  
  
  
  
Admission 3 Date & 
Time of 
admission DD / MMM / YY HH : MM 
Date & 
Time of 
discharge DD / MMM / YY HH : MM 
Yes     No   
Admission 4 Date & 
Time of 
admission DD / MMM / YY HH : MM 
Date & 
Time of 
discharge DD / MMM / YY HH : MM 
Yes     No   
Admission 5 Date & 
Time of 
admission DD / MMM / YY HH : MM 
Date & 
Time of 
discharge DD / MMM / YY HH : MM 
Yes     No   
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ANTENATAL 
FOLLOW-UP 
BOOKLET 
Non-AE medication Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
ADDITIONAL MEDICATION 
This part is to be used to document all dose changes for all non-AE medication taken from the start of the 
trial up until the visit. 
Medication 
Total daily 
dose (mg) 
Start date Ongoing? End date 
Folic Acid 
 DD / MMM / YYYY Yes     No   DD / MMM / YYYY 
Vitamin K 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
Methyldopa 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
Nifedipine 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
Insulin 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
Metformin 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
Labetelol 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
Ferrous sulphate 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
Aspirin 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
Diazepam or clobazam 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
If any OTHER  non-AED medication (other than listed above) is being used, please specify medication’s 
name and ill in following gaps: 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
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ANTENATAL 
FOLLOW-UP 
BOOKLET 
Ultrasound form for 
congenital abnormalities  
in midtrimester 
Participant UTIN Date 
__ __/__ __ __ DD / MMM / YYYY 
 
Was an ultrasound performed? Yes       No        If yes, please complete the following: 
Is the pregnancy multiple? Yes       No                  
If yes, please specify 
 Twins  Triplets  More 
Fetus (no.)  Gestational Age _________weeks __________days 
Congenital malformations  Yes     No    If yes, please specify below 
Spina biida      Yes     No     Hydrocephalus Yes     No     
Diaphragmatic hernia                Yes     No     Anencephaly Yes     No     
Cleft lip      Yes     No     Congenital heart disease Yes     No     
Cleft palate Yes     No     Tumours Yes     No     
Gastroschisis Yes     No     Limb abnormalities Yes     No     
Duodenal atresia Yes     No     External genital abnormalities Yes     No     
Congenital Cystic  
Adenomatoid Malformation 
Yes     No     
Other, please specify: 
 
Yes     No   
Was a fetal echo performed?  Yes         No       Not done              
If yes, please specify if fetal echo was:          If abnormal, please specify abnormality: 
Normal                 Abnormal    
Fetus (no.)  Gestational Age _________weeks __________days 
Congenital malformations  Yes     No    If yes, please specify below 
Spina biida      Yes     No     Hydrocephalus Yes     No     
Diaphragmatic hernia                Yes     No     Anencephaly Yes     No     
Cleft lip      Yes     No     Congenital heart disease Yes     No     
Cleft palate Yes     No     Tumours Yes     No     
Gastroschisis Yes     No     Limb abnormalities Yes     No     
  
  
   
  
    
    
    
    
    
    
  
  
   
  
  
    
    
    
    
    
Duodenal atresia Yes     No     External genital abnormalities Yes     No     
Congenital Cystic  
Adenomatoid Malformation 
Yes     No     
Other, please specify: 
 
Yes     No   
Was a fetal echo performed?  Yes         No       Not done              
If yes, please specify if fetal echo was:          If abnormal, please specify abnormality: 
Normal                 Abnormal    
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 ANTENATAL 
FOLLOW-UP 
BOOKLET 
Ultrasound form  
for fetal growth 
Participant UTIN Date 
__ __/__ __ __ DD / MMM / YYYY 
 
Was fetal growth 
measured? Yes       No                 If yes, please complete the following 
Date of scan DD / MMM / YYYY 
Is the pregnancy 
multiple? Yes       No                 
If yes, please specify 
 Twins  Triplets  More 
Fetus 
number 
 Gestational Age _________weeks __________days 
Small for 
Gestational Age 
(deined as birth 
weight less than 
10th centile) 
Yes       No          
Customised  
centile used 
Yes       No          
Umbilical artery 
Doppler 
Normal  
Absent end diastolic low (EDF)  
Reversed end diastolic low  (EDF)  
Raised pulsatility index  
Liquor volume Normal  
Reduced  
Excess  
Fetus 
number 
 Gestational Age _________weeks __________days 
  
  
   
    
 
 
 
 
 
 
 
Small for 
Gestational Age 
(deined as birth 
weight less than 
10th centile) 
Yes       No          
Customised  
centile used 
Yes       No          
Umbilical artery 
Doppler 
Normal  
Absent end diastolic low (EDF)  
Reversed end diastolic low  (EDF)  
Raised pulsatility index  
Liquor volume Normal  
Reduced  
Excess  
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ANTENATAL 
FOLLOW-UP 
BOOKLET 
Purple alert record Participant UTIN Date 
__ __/__ __ __ DD / MMM / YYYY 
Please, ill this section only if you received a PURPLE ALERT for this patient since the last 
clinical visit. 
If you received PURPLE ALERT for this patient,  
did you inform the patient about it?    Yes       No                   
If you did not inform the patient, please give reason below: 
 
 
 
 
What action was taken as a result of the PURPLE alert? 
a. Offer to patient to increase AED dose Yes       No     
If yes, did patient accept increase in dose?  Yes       No     
If you did not offer an increase in dose, please give reason below: 
 
 
 
b. Follow-up visit brought forward Yes       No     
c. Other action taken Yes       No     
If yes, please specify: 
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Delivery booklet
DELIVERY BOOKLET 
Patient UTIN:   __ __/__ __ __ 
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DELIVERY 
BOOKLET 
Visit checklist Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
 
CHECKLIST ACTION 
Has a blood sample 
been taken? Yes      
Centrifuge and package sample according to Blood Processing SOP no.3  
Send EMPIRE trial blood request form to trial ofice  
No     
Please take blood sample and package according to Blood Processing SOP 
no.3 
Send EMPIRE trial blood request form to trial ofice 
Or  
Document reason why blood sample was not taken  
Please state here: 
 
Has the cord blood 
sample been taken? Yes      
Centrifuge and package sample according to Blood Processing SOP no.3 
Send EMPIRE trial blood request form to trial ofice  
No     
Please take cord blood sample and package according to Blood Processing 
SOP no.3 Send EMPIRE trial blood request form to trial ofice 
Or  
Document reason why the sample was not taken  
Please state here: 
 
 
Has cord pH sample 
been taken? 
Yes      Documented result in CRF. 
No     
Take cord pH according to routine practice at site and document the result 
in CRF. 
Or  
Document reason why the sample was not taken  
Please state here: 
 
Have the delivery 
booklet been 
completed? 
Yes      File Delivery Booklet is in participant’s CRF ile. 
No     Complete Delivery Booklet and ile in participant’s CRF ile 
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DELIVERY 
BOOKLET 
Delivery details Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
DELIVERY DETAILS 
Gestational age  
at delivery _____________ weeks _______________days 
Delivery 
mode Spontaneous Vaginal  Forceps  Ventouse  Caesarean Section  
MATERNAL COMPLICATIONS 
Pre-clampsia Yes    No  
Gestation 
Diabetes Mellitus Yes    No  
Blood 
transfusion Yes   No  
Preterm delivery (<37 weeks) Yes      No   If yes,               Spontaneous     Induced     
Post partum haemorrhage Yes      No   If yes,        Atonic      Trauma      Both    
Ante partum haemorrhage Yes      No  
Preterm rupture of 
membranes (<37 weeks) 
Yes    No  
Induction of labour 
(If yes, please specify reasons for 
induction) 
Yes      No  Seizure deterioration Yes    No  
Post dates Yes    No  
Pre-eclampsia Yes    No  
Maternal request Yes    No  
Spontaneous rupture of the 
membranes 
Yes    No  
Admission to HDU/ITU Yes      No   If yes, was it seizure related? Yes    No  
Infection 
(if yes, please specify) 
Yes      No  Genital Yes    No  
Urinary Yes    No  
Chorioamnionitis Yes    No  
Wound Yes    No  
Respiratory Yes    No  
Other  
(if yes, please specify below) 
 
Yes    No  
Any other maternal 
complications Yes      No  
If yes, please specify 
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HOSPITAL ADMISSION 
Date & Time of 
admission DD / MMM / YY HH : MM 
Date & Time of 
discharge DD / MMM / YY HH : MM 
BREASTFEEDING INTENTION 
Sole breast feeding  Mixed breast & bottle  Bottle only     
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DELIVERY 
BOOKLET 
Baby details Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
BABY DETAILS 
Please use the following sheets to document information about all of the participant’s 
births/children. One sheet should be used per child. Please specify child number between booklet 
name and participant UTIN.  
Birth 
Weight 
kg Baby’s sex Female         Male          
Birth weight in customised centiles _________ centiles Head Circumference cm 
Apgar 
score          
1’  Cord pH  
                    
A  
5’  V  
 
Stillbirth Yes   No   Neo-natal death Yes   No   
Small for gestational age 
(deined as weight less than 
10th centile) 
Yes   No   Admission to neonatal unit Yes   No   
 
CONGENITAL MALFORMATIONS 
Diaphragmatic 
hernia 
Yes     
 
No      
 
Gastroschisis 
Yes     
 
No      
 
Hydrocephalus 
Yes     
 
No    
 
Spina biida 
Yes     
 
No      
 
Duodenal atresia 
Yes     
 
No      
 
Cleft lip 
Yes     
 
No    
 
Cleft palate 
Yes     
 
No      
 
Congenital Cystic 
Adenomatoid 
Malformation 
Yes     
 
No      
 
Anencephaly 
Yes     
 
No    
 
Congenital 
heart disease 
Yes     
 
No      
 
If yes, please specify 
Tumours 
Yes     
 
No      
 
If yes, please specify 
Limb 
abnormalities 
Yes     
 
No      
 
If yes, please specify 
External 
genital 
abnormities 
Yes     
 
No      
 
If yes, please specify 
Any other 
malformation  
Yes     
 
No      
 
If yes, please specify 
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DELIVERY 
BOOKLET 
Baby details Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
BABY DETAILS 
Please use the following sheets to document information about all of the participant’s 
births/children. One sheet should be used per child. Please specify child number between booklet 
name and participant UTIN.  
Birth 
Weight 
kg Baby’s gender Female         Male          
Birth weight in customised centiles _________ centiles Head Circumference cm 
Apgar 
score          
1’  Cord pH  
                    
A  
5’  V  
 
Stillbirth Yes   No   Neo-natal death Yes   No   
Small for gestational age 
(deined as weight less than 
10th centile) 
Yes   No   Admission to neonatal unit Yes   No   
 
CONGENITAL MALFORMATIONS 
Diaphragmatic 
hernia 
Yes     
 
No      
 
Gastroschisis 
Yes     
 
No      
 
Hydrocephalus 
Yes     
 
No    
 
Spina biida 
Yes     
 
No      
 
Duodenal atresia 
Yes     
 
No      
 
Cleft lip 
Yes     
 
No    
 
Cleft palate 
Yes     
 
No      
 
Congenital Cystic 
Adenomatoid 
Malformation 
Yes     
 
No      
 
Anencephaly 
Yes     
 
No    
 
Congenital 
heart disease 
Yes     
 
No      
 
If yes, please specify 
Tumours 
Yes     
 
No      
 
If yes, please specify 
Limb 
abnormalities 
Yes     
 
No      
 
If yes, please specify 
External 
genital 
abnormities 
Yes     
 
No      
 
If yes, please specify 
Any other 
malformation  
Yes     
 
No      
 
If yes, please specify 
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DELIVERY 
BOOKLET 
Baby details Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
BABY DETAILS 
Please use the following sheets to document information about all of the participant’s 
births/children. One sheet should be used per child. Please specify child number between booklet 
name and participant UTIN.  
Birth 
Weight 
kg Baby’s gender Female         Male          
Birth weight in customised centiles _________ centiles Head Circumference cm 
Apgar 
score          
1’  Cord pH  
                    
A  
5’  V  
 
Stillbirth Yes   No   Neo-natal death Yes   No   
Small for gestational age 
(deined as weight less than 
10th centile) 
Yes   No   Admission to neonatal unit Yes   No   
 
CONGENITAL MALFORMATIONS 
Diaphragmatic 
hernia 
Yes     
 
No      
 
Gastroschisis 
Yes     
 
No      
 
Hydrocephalus 
Yes     
 
No    
 
Spina biida 
Yes     
 
No      
 
Duodenal atresia 
Yes     
 
No      
 
Cleft lip 
Yes     
 
No    
 
Cleft palate 
Yes     
 
No      
 
Congenital Cystic 
Adenomatoid 
Malformation 
Yes     
 
No      
 
Anencephaly 
Yes     
 
No    
 
Congenital 
heart disease 
Yes     
 
No      
 
If yes, please specify 
Tumours 
Yes     
 
No      
 
If yes, please specify 
Limb 
abnormalities 
Yes     
 
No      
 
If yes, please specify 
External 
genital 
abnormities 
Yes     
 
No      
 
If yes, please specify 
Any other 
malformation  
Yes     
 
No      
 
If yes, please specify 
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Postnatal follow-up booklet
POSTNATAL FOLLOW-UP 
BOOKLET 
Patient UTIN:   __ __/__ __ __ 
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POSTNATAL 
FOLLOW-UP 
BOOKLET 
Visit checklist 
 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
CHECKLIST ACTION 
Has a blood sample 
been taken? 
Yes   
   
Send EMPIRE trial blood request form to trial ofice 
Centrifuge and package sample according to SOP no.3 Blood 
collection and processing  
No    
 
Centrifuge and package sample according to SOP no.3 Blood 
collection and processing 
Send EMPIRE trial blood request form to trial ofice 
Or  
Document reason why blood sample was not taken. 
Please state here: 
 
 
 
Has the participant 
completed: 
Patient’s 
questionnaire? 
Yes   
   
Return completed Patient’s questionnaire to participant’s CRF ile. 
No    
 
Ask participant to complete Patient’s questionnaire and ile in 
participant’s CRF ile. 
OR 
Document reason why not completed 
Please state here: 
 
 
 
Have there been any 
dose changes to AED 
or concomitant 
medication? 
Yes   
   
Please, if so note all the changes in relevant part of this booklet. 
No    
 
No further action 
 
 
 
 
 
 
Has participant 
experienced any 
adverse events? 
Yes   
   
Report in accordance with SOP no. 4. Adverse events and serious 
adverse events reporting. Update Adverse Events Form. 
No    
 
No further action 
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POSTNATAL 
FOLLOW-UP 
BOOKLET 
Post Natal Form 
 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
Please use the following sheets to document information about all of the participant’s 
births/children. One sheet should be used per child. Please specify child number between booklet 
name and participant UTIN.  
NEONATAL DEATH 
Neonatal death Yes      No        
Date of neonatal death DD / MMM / YYYY 
Reasons for 
neonatal death 
(please tick all relevant 
reasons) 
Congenital abnormalities  
Infection  
Birth trauma  
Extreme prematurity  
Other  If other, please specify:  
 
 
 
BABY DETAILS 
Age (n/52)  Weight kg 
Head 
Circumference 
cm 
Any maternal concerns 
Yes      No    If yes, please specify below: 
 
Admission to neonatal 
unit after discharge 
Yes      No    If yes, please specify below: 
 
Baby has been in 
neonatal unit since birth Yes      No    
Baby has congenital 
abnormalities Yes      No    
BREASTFEEDING  
Current feeding method Duration of sole breastfeeding 
Sole breast feeding   
Mixed breast & bottle  Weeks_________ Days____________ 
  
 
 
 
 
 
  
  
    
 
 
Bottle only  Weeks_________ Days____________ 
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 POSTNATAL 
FOLLOW-UP 
BOOKLET 
Post Natal Form 
 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
Please use the following sheets to document information about all of the participant’s 
births/children. One sheet should be used per child. Please specify child number between booklet 
name and participant UTIN.  
NEONATAL DEATH 
Neonatal death Yes      No        
Date of neonatal death DD / MMM / YYYY 
Reasons for 
neonatal death 
(please tick all relevant 
reasons) 
Congenital abnormalities  
Infection  
Birth trauma  
Extreme prematurity  
Other  Please specify:  
 
 
 
BABY DETAILS 
Age (n/52)  Weight 
kg 
Head 
Circumference cm 
Any maternal concerns 
Yes      No    If yes, please specify 
 
Admission to neonatal 
unit after discharge 
Yes      No    If yes, please specify  
 
Baby has been in 
neonatal unit since birth Yes      No    
Baby has congenital 
abnormalities Yes      No    
BREASTFEEDING  
Current feeding method Duration of sole breastfeeding 
Sole breast feeding   
  
 
 
 
 
 
  
  
  
  
 
Mixed breast & 
bottle  Weeks_________ Days____________ 
Bottle only  Weeks_________ Days____________ 
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POSTNATAL 
FOLLOW-UP 
BOOKLET 
Post Natal Form 
 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
Please use the following sheets to document information about all of the participant’s 
births/children. One sheet should be used per child. Please specify child number between booklet 
name and participant UTIN. 
NEONATAL DEATH 
Neonatal death Yes      No        
Date of neonatal death DD / MMM / YYYY 
Reasons for 
neonatal death 
(please tick all relevant 
reasons) 
Congenital abnormalities  
Infection  
Birth trauma  
Extreme prematurity  
Other  Please specify:  
 
 
 
BABY DETAILS 
Age (n/52)  Weight kg 
Head 
Circumference 
cm 
Any maternal concerns 
Yes      No    If yes, please specify 
 
Admission to neonatal 
unit after discharge 
Yes      No    If yes, please specify  
 
Baby has been in 
neonatal unit since birth Yes      No    
Baby has congenital 
abnormalities Yes      No    
BREASTFEEDING  
Current feeding method Duration of sole breastfeeding 
Sole breast feeding   
  
 
 
 
 
 
  
  
  
  
 
Mixed breast & 
bottle  Weeks_________ Days____________ 
Bottle only  Weeks_________ Days____________ 
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POSTNATAL 
FOLLOW-UP 
BOOKLET 
Adherence checklist 
Part 1 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
CURRENT AED 
Current AED  
Please use Brand name, if prescribed 
Current daily dose 
(mg) 
Date of any dose 
change after 
delivery 
carbamazepine (generic) Yes   No   DD / MMM / YY 
Tegretol Yes   No   DD / MMM / YY 
Tegretol Retard Yes   No   DD / MMM / YY 
lamotrigine (generic) Yes   No   DD / MMM / YY 
Lamictal (brand) Yes   No   DD / MMM / YY 
levetiracetam (generic) Yes   No   DD / MMM / YY 
Keppra (brand) Yes   No   DD / MMM / YY 
phenytoin (generic) Yes   No   DD / MMM / YY 
Epanutin (brand) Yes   No   DD / MMM / YY 
sodium valproate (generic) Yes   No   DD / MMM / YY 
Epilim (brand) Yes   No   DD / MMM / YY 
 
Has there been an AED dose change since delivery? Yes       No          
If the dose has been changed since delivery: 
1) Who was responsible for the change: Clinician   Patient   
2) Was it in response to: 
(please tick all relevant reasons) 
Routine clinical plan      
Patient concerns     
Clinician concerns     
 
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
Has the patient taken the AED postnatally according clinician’s plan?   
If no, please select one relevant reason: 
Yes       No     
Concerned about worsening of seizures  
Forgotten to change dose  
Instructions not clear  
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POSTNATAL 
FOLLOW-UP 
BOOKLET 
Adherence checklist 
Part 2 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
AED LEVELS 
Has the AED level been checked postnatally by anyone outside the EMPIRE 
Trial team? If yes, please specify below: Yes       No     
A & E  Obstetrician  Neurologist  Midwife  
Has the result been revealed to the local research team? Yes          No    
Date of  
Blood Test 
AED Medication 
Test result for serum level  
Value Unit 
DD / MMM / YY 
  μmol/l  mg/l  
DD / MMM / YY 
  μmol/l  mg/l  
DD / MMM / YY 
  μmol/l  mg/l  
DD / MMM / YY 
  μmol/l  mg/l  
DD / MMM / YY 
  μmol/l  mg/l  
If yes, please report the unblinding to Trial Coordinator 
ANY ADDITIONAL MEDICATION 
Medication 
Total daily 
dose (mg) 
Start date Ongoing? End date 
Diazepam or 
clobazam  DD / MMM / YYYY Yes     No   DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
  
    
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
 
 DD / MMM / YYYY 
Yes     No   
DD / MMM / YYYY 
  
  
DOI: 10.3310/hta22230 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 23
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Thangaratinam et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of
Southampton Science Park, Southampton SO16 7NS, UK.
139
 POSTNATAL 
FOLLOW-UP 
BOOKLET 
Adherence checklist 
Part 3 
Participant UTIN Visit date 
__ __/__ __ __ DD / MMM / YYYY 
HOSPITAL ADMISSION 
Has the patient been admitted to hospital since delivery? Yes       No     
Was it 
epilepsy 
related? 
Admission 
1 
Date & 
Time of 
admission DD / MMM / YY HH : MM 
Date & 
Time of 
discharge DD / MMM / YY HH : MM 
Yes   
     
No     
 
Admission 
2 
Date & 
Time of 
admission DD / MMM / YY HH : MM 
Date & 
Time of 
discharge DD / MMM / YY HH : MM 
Yes   
     
No     
 
Admission 
3 
Date & 
Time of 
admission DD / MMM / YY HH : MM 
Date & 
Time of 
discharge DD / MMM / YY HH : MM 
Yes   
     
No     
 
Admission 
4 
Date & 
Time of 
admission DD / MMM / YY HH : MM 
Date & 
Time of 
discharge DD / MMM / YY HH : MM 
Yes   
     
No     
 
TOXICITY 
Did AED toxicity occur at any point during 6 weeks 
post delivery? Yes     No  
Did any of the following symptoms occur? 
dizziness Yes     No  
unsteadiness Yes     No  
nausea Yes     No  
headache Yes     No  
vomiting Yes     No  
  
  
  
  
  
  
  
  
  
  
  
Did toxicity result in medical intervention? 
Yes          No             If yes, please specify: 
 Admission to ward  Change in medication 
 Out-patient or GP appointment  Seen and discharged at A&E 
 Admission to ICU  Telephone advice 
 Other (if yes, please specify)  
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Purple alert form
PURPLE ALERT FORM  (PAF) Participant UTIN Date 
__ __/__ __ __ DD / MMM / YYYY 
If you receive a purple alert for this participant please complete serum AED levels below: 
If you are using a pre-trial serum level (PTSL) for this participant at baseline please ensure 
you document this as the irst serum level on this form.  
Pre-trial Serum 
AED Level as trial 
target level 
(please tick one)  
Date of blood test Current AED 
Total 
daily dose  
(mg) 
Serum Level 
Value Unit 
PPSL       
EPSL          
Neither   
 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
IN TRIAL SERUM AED LEVELS  
Date of blood test 
Most recent serum AED level (if available) 
Current AED 
Total 
daily dose  
(mg) 
Serum Level  
Value Unit 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
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DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
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PURPLE ALERT FORM  (PAF) Participant UTIN Date 
__ __/__ __ __ DD / MMM / YYYY 
If you receive a purple alert for this participant please complete serum AED levels below: 
If you are using a pre-trial serum level (PTSL) for this participant at baseline please ensure 
you document this as the irst serum level on this form. 
Pre-trial Serum 
AED Level as trial 
target level 
(please tick one)  
Date of blood test Current AED 
Total 
daily dose  
(mg) 
Serum Level 
Value Unit 
PPSL       
EPSL          
Neither   
 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
IN TRIAL SERUM AED LEVELS  
Date of blood test 
Most recent serum AED level (if available) 
Current AED 
Total 
daily dose  
(mg) 
Serum Level  
Value Unit 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
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DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
 
 
DD / MMM / YYYY 
   μmol/l 
mg/l 
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Adverse events form
ADVERSE EVENTS* FORM 
Participant UTIN 
__ __/__ __ __ 
*Refer to SOP no. 4 (AE and Serious AE Reporting) for further actions required if participant experiences an AE. 
Adverse event (AE)  Date reported 
DD / MMM / YYYY 
AE timeframe AE onset date 
DD / MMM / YYYY 
AE end date 
DD / MMM / YYYY 
Intensity 
  Mild 
  Moderate 
  Severe 
Serious AE 
  Serious  
  Non serious 
Is the AE likely to be due to the 
intervention? 
  Yes 
  No 
Is the AE expected?  
Expected reactions will be found in SmPC 
(http://emc.medicines.org.uk/) and/or 
protocol.   
  Yes 
  No 
Outcome of AE  Resolved          Resolved with sequelae (If yes, specify) 
 Improved                   Persisting                      Worsened         
 Fatal (if yes, specify date of death  DD / MMM / YYYY)  Unknown  
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Appendix 10 Seizure diary
Next clinic appointment DD/MMM/YYYY HH:MM 
 
Trials Office: Women's Health Research Unit, Centre for Primary Care and Public Health, 
Blizard Institute, Barts and The London School of Medicine and Dentistry 
Yvonne Carter Building, 58 Turner Street, London, E1 2AB. Tel: XXXX  
Fax:  XXXX  
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Clonic seizures - Some people have convulsive seizures but their body does not go stiff at 
the start. These are called clonic seizures.
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